<!DOCTYPE html>
<html>
<head>

      <meta http-equiv="Content-Type" content="text/html; charset=utf-8">

        <script> var url = encodeURIComponent('https://www.science.org/doi/10.1126/science.abj5508');</script>

        <script> var body_html = '<body > <div > <div > <div > <div > <div > <div > <div > <div > <div > <div > <span >Advertisement</span> </div> </div> </div> </div> </div> </div> </div> <header > <div ><div ><div ><div ><div ><div ><div ><a ><div >science</div></a></div></div><div ><div ><a ><div >science advances</div></a></div></div><div ><div ><a ><div >science immunology</div></a></div></div><div ><div ><a ><div >science robotics</div></a></div></div><div ><div ><a ><div >science signaling</div></a></div></div><div ><div ><a ><div >science translational medicine</div></a></div></div><div ><div ><a ><div >science partner journals</div></a></div></div></div></div></div></div></div> <div > <div > <div > <div > <div ><div ><div ><label >Searching:</label><div ><div ><div ><a >Anywhere</a><a >Science</a><a >Science Advances</a><a >Science Immunology</a><a >Science Robotics</a><a >Science Signaling</a><a >Science Translational Medicine</a></div></div></div></div><div > <a ><u>Advanced Search</u></a> </div></div></div> </div> </div> </div> <div > <div > <div > <h6 >Trending Terms:</h6> <ul > <li > <a >covid-19</a> </li> <li > <a >climate</a> </li> <li > <a >science policy</a> </li> <li > <a >genome editing</a> </li> <li > <a >batteries</a> </li> </ul> </div> </div> </div> </div> </header><div ><div ><div > <div > <div > <ul > <li > <a >Current Issue</a> </li> <li > <a >First release papers</a> </li> <li > <a >Archive</a> </li> <li > <div > <a >About</a> <div > <a >About Science</a> <a >Mission Scope</a> <a >Editors Advisory Boards</a> <a >Editorial Policies</a> <a >Information for Authors</a> <a >Information for Reviewers</a> <a >Journal Metrics</a> <a >Staff</a> <a >Contact Us</a> </div> </div> </li> </ul> </div> <div > <ul > <li > <a >Submit manuscript</a> </li> <li > <div > <a >More</a> </div> </li> </ul> </div> </div> <a >GET OUR E-ALERTS</a> </div></div></div> <main > <div ><div ><div ><div ><div > <div ><a >Home</a><a >Science</a><a >First Release</a>4′-Fluorouridine is an oral antiviral that blocks respiratory syncytial virus and SARS-CoV-2 replication</div><div >Back To First Release</div> </div> <article ><section ><header><div ><div ><div ><div >OPEN ACCESS</div><div >Research Article</div></div><div ><div > <div >Share on</div> </div></div></div><h1 >4′-Fluorouridine is an oral antiviral that blocks respiratory syncytial virus and SARS-CoV-2 replication</h1><div >Julien Sourimant https://orcid.org/0000-0002-1660-1666, Carolin M. Lieber, Megha Aggarwal, Robert M. Cox, Josef D. Wolf https://orcid.org/0000-0003-2507-6944, Jeong-Joong Yoon https://orcid.org/0000-0001-9379-0416, Mart Toots, … Show All … , Chengin Ye https://orcid.org/0000-0002-1934-9494, Zachary Sticher https://orcid.org/0000-0002-7022-1410, Alexander A. Kolykhalov, Luis Martinez-Sobrido https://orcid.org/0000-0001-7084-0804, Gregory R. Bluemling https://orcid.org/0000-0001-9138-7578, Michael G. Natchus, George R. Painter https://orcid.org/0000-0002-9803-8095, and Richard K. Plemper https://orcid.org/0000-0003-2034-2107 [email protected] Show Fewer</div><div >Science • 2 Dec 2021 • First Release • DOI: 10.1126/science.abj5508</div><div ><div > <div > <a ><div ><div ><h6>PREVIOUS ARTICLE</h6><div>Impact of community masking on COVID-19: A cluster-randomized trial in Bangladesh</div></div></div>Previous</a><a ><div ><div ><h6>NEXT ARTICLE</h6><div>Structural basis for continued antibody evasion by the SARS-CoV-2 receptor binding domain</div></div></div>Next</a> </div> </div></div></div></header><div ><div ><section ><h2 >Abstract</h2><div >The COVID-19 pandemic has underscored the critical need for broad-spectrum therapeutics against respiratory viruses. Respiratory syncytial virus (RSV) is a major threat to pediatric patients and the elderly. We describe 4′-fluorouridine (4′-FlU, EIDD-2749), a ribonucleoside analog that inhibits RSV, related RNA viruses, and SARS-CoV-2 with high selectivity index in cells and human airway epithelia organoids. Polymerase inhibition within in vitro RdRP assays established for RSV and SARS-CoV-2 revealed transcriptional stalling after incorporation. Once-daily oral treatment was highly efficacious at 5 mg/kg in RSV-infected mice or 20 mg/kg in ferrets infected with different SARS-CoV-2 variants-of-concern, initiated 24 or 12 hours after infection, respectively. These properties define 4′-FlU as a broad-spectrum candidate for the treatment of RSV, SARS-CoV-2, and related RNA virus infections.</div></section></div></div></section><section ><div ><div >The COVID-19 experience has highlighted the need for orally-bioavailable broad-spectrum antivirals that could be quickly deployed against newly emerging viral pathogens. Remdesivir—a direct-acting broad-spectrum antiviral—is still the only small molecule therapeutic approved for use against SARS-CoV-2 infection in the United States, but it requires intravenous administration. The ensuing restriction to hospitalized patients compromises its clinical effect as treatment is initiated too late in the infection cycle (<a ><i>1</i></a>). We have demonstrated efficacy of orally available EIDD-2801 (molnupiravir) against influenza viruses in human organoid models and ferrets (<a ><i>2</i></a>), and subsequent animal and human data showed that antiviral efficacy of molnupiravir extends to SARS-CoV-2 in vivo (<a ><i>3</i></a>, <a ><i>4</i></a>). Molnupiravir acts by inducing lethal viral mutagenesis after incorporation into viral genomic RNA of influenza viruses (<a ><i>2</i></a>) and betacoronaviruses (<a ><i>5</i></a>). The drug was recently approved in the United Kingdom and is currently considered for emergency use authorization against COVID-19 in the United States. However, even with this accelerated development timeline, molnupiravir only became available to patients nearly two years into the pandemic. To have a substantial effect on a mounting pandemic, an antiviral must be approved for human use before a new pathogen emerges, making the case for the development of broad-spectrum antivirals.</div><div >We have identified RSV disease as a viable primary indication for a candidate broad-spectrum antiviral, on the basis of the unmet major health threat imposed by RSV and well-established protocols for clinical trials of anti-RSV therapeutics. RSV infections are responsible for over 58,000 hospitalizations of children below 5 years of age in the United States annually, and approximately 177,000 hospitalizations of adults above the age of 65 (<a ><i>6</i></a>–<a ><i>9</i></a>). Despite this major health and economic burden, no therapeutics have been licensed specifically for treatment of RSV disease (<a ><i>10</i></a>). Anti-RSV drug discovery efforts have increasingly focused on inhibiting the viral RNA-dependent RNA polymerase (RdRP) complex (<a ><i>11</i></a>). The core polymerase machinery comprises the large (L) polymerase protein, its obligatory cofactor, the phosphoprotein (P), and the encapsidated negative-sense RNA genome (<a ><i>11</i></a>). Allosteric inhibitors of RSV L have potent activity as seen, for instance, with the experimental drug candidates AVG-233 (<a ><i>12</i></a>) and inhaled PC786 (<a ><i>13</i></a>).</div><div >In search of a drug that is active against RSV and SARS-CoV-2, is orally available, and acts through a distinct mechanism of activity (MOA) from molnupiravir, we explored 4′-fluorine substitutions in a series of analogs of the molnupiravir parent molecule <i>N</i><sup>4</sup>-hydroxycytidine (NHC) (<a ><i>14</i></a>). The focus on 4′-fluorine ribose substitutions was motivated by the small atomic radius and strong stereo-electronic effect of fluorine that can influence backbone conformation flexibility, which may lead to improved selectivity indices, increased lipophilicity, and greater metabolic stability (<a ><i>15</i></a>). A synthetic intermediate in the approach to 4′-fluoro-<i>N</i><sup>4</sup>-hydroxycytidine (compound 5 in fig. S1) was deprotected to provide 4′-FIU (<a >Fig. 1A</a>), which emerged as broadly active antiviral when biotested.</div><section ><h2>4′-FlU is a broad-spectrum mononegavirus inhibitor with high SI</h2><div >Following the approach of using RSV disease as a primary indication to advance a novel candidate broad-spectrum antiviral, we first assessed activity of 4′-FlU against a recombinant RSV A2-line19F (recRSV A2-L19F) (<a ><i>16</i></a>) and clinical RSV isolates on immortalized HEp-2 cells. The compound showed potent dose-dependent activity against all RSV strains tested, returning half-maximal effective concentrations (EC<sub>50</sub> values) ranging from 0.61 to 1.2 μM (<a >Fig. 1B</a> and table S1). This cell culture potency was on par with the previously reported anti-RSV activity of NHC (fig. S2). Global metabolic activity of established human and animal cell lines (HEp-2, MDCK, BHK-T7, and BEAS-2B) exposed to up to 500 μM of 4′-FlU remained unaltered, indicating that the antiviral effect is as a result of cytotoxicity (<a >Fig. 1C</a> and table S2). When glucose was replaced with galactose as a carbohydrate source to link cell metabolic activity strictly to mitochondrial oxidation (<a ><i>17</i></a>), we determined a half-maximal cytotoxic concentration (CC<sub>50</sub>) of 4′-FlU of 250 μM (<a >Fig. 1C</a> and table S2).</div><div >When tested on disease-relevant primary human airway epithelial cells (HAE) derived from two different donors (<a >Fig. 1D</a>), 4′-FlU showed ≥17-fold increased anti-RSV potency relative to that on HEp-2 cells, but unchanged low cytotoxicity (CC<sub>50</sub> 169 μM) (<a >Fig. 1E</a>), resulting in a high selectivity index (SI = EC<sub>50</sub>/CC<sub>50</sub>) of ≥1877. Consistent with these findings, quantitative immunocytochemistry on HAE cells confirmed that 4′-FlU reduced steady-state levels of nuclear-(SDH-A; IC<sub>50</sub> 272.8 μM) and mitochondrial-(COX-I; IC<sub>50</sub> 146.8 μM) encoded proteins only at high concentrations (fig. S3).</div><div >We next explored the 4′-FlU indication spectrum. We assessed a panel of negative-sense RNA viruses of the paramyxovirus and rhabdovirus families, including measles virus (MeV), human parainfluenza virus type 3 (HPIV3), Sendai virus (SeV), vesicular stomatitis virus (VSV), and rabies virus (RabV) that, like RSV, belong to the mononegavirus order, and found that the compound demonstrated submicromolar active concentrations (<a >Fig. 1F</a> and table S1). Testing a representative of phylogenetically distant positive-sense RNA viruses, the betacoronavirus SARS-CoV-2 was also sensitive to 4′-FlU, with EC<sub>50</sub> values ranging from 0.2 to 0.6 μM against isolates of different lineages (<a >Fig. 1G</a> and table S1).</div><div >At initial mechanistic characterization, 4′-FlU inhibited RSV and paramyxovirus RdRP complex activity in cell-based minireplicon systems (<a >Fig. 1H</a> and table S1). The RdRP activity of Nipah virus (NiV)—a highly pathogenic zoonotic paramyxovirus with pandemic potential (<a ><i>18</i></a>)—was also efficiently inhibited by 4′-FlU in an NiV minireplicon reporter assay. The antiviral effect of 4′-FlU was dose-dependently reversed by addition of an excess of exogenous pyrimidines (cytidine and uridine) but not purines to the cultured cells, which is consistent with competitive inhibition of RdRP activity (<a ><i>2</i></a>, <a ><i>19</i></a>) (<a >Fig. 1I</a>).</div></section><section ><h2>Incorporation of 4′-FlU by RSV and SARS-CoV-2 RdRP causes sequence-modulated transcriptional stalling</h2><div >To characterize the molecular MOA of 4′-FlU, we purified recombinant RSV L and P proteins expressed in insect cells (<a >Fig. 2A</a>) and determined performance of the bioactive 5′-triphosphate form of 4′-FlU (4′-FlU-TP) within in vitro primer extension assays (<a ><i>20</i></a>) (<a >Fig. 2B</a>). In the presence of radio-labeled ATP and an increasing amount of UTP, RSV RdRP complexes elongated the primer until reaching a G in third position on the template strand, and continued further upon addition of CTP (<a >Fig. 2C</a>) (fig. S4 and data S1). Replacing UTP with 4′-FlU-TP resulted in efficient primer extension up to the third nucleotide, confirming that RSV RdRP recognizes and incorporates 4′-FlU in place of UTP (<a >Fig. 2C</a>). Incorporation kinetics (<a ><i>21</i></a>) showed only a moderate reduction in substrate affinity for 4′-FlU-TP compared with UTP (<a >Fig. 2D</a>). Further addition of CTP to the reaction mix resulted in limited elongation rather than the expected full-length product, which suggested delayed polymerase stalling by incorporated 4′-FlU (fig. S4 and data S1). Direct side-by-side comparison with GS-443902—the active metabolite of remdesivir and a “delayed polymerase stalling” inhibitor well-characterized for SARS-CoV-2—along with RSV and other RNA viruses (<a ><i>21</i></a>, <a ><i>22</i></a>), corroborated this antiviral effect of 4′FlU-TP (<a >Fig. 2E</a> and data S1).</div><div >When a modified template coded for incorporation of only a single UTP (<a >Fig. 2F</a> and data S1), primers elongated preferentially to position <i>i</i>+3 after 4′-FlU-TP, whereas the efficiency of full elongation was strongly reduced compared with extension in the presence of UTP. However, repositioning the incorporation site further downstream in the template triggered immediate polymerase stalling at position <i>i</i> (fig. S5), indicating template sequence dependence of the inhibitory effect. Transcription stalling at <i>i</i> or <i>i</i>+3 were also observed after multiple 4′-FlU incorporations: an AxAxxx template (<a >Fig. 2G</a>) and direct tandem incorporations through an AAxxAx template (fig. S5) caused stalling at position <i>i</i>, whereas increasing spacer length between the incorporated uridines shifted preferential stalling to <i>i</i>+3 (fig. S5). This variable delayed polymerase stalling within one to four nucleotides of the incorporation site was equally prominent when we examined de novo initiation of RNA synthesis at the promoter with a synthetic native RSV promoter sequence rather than extension of primer-template pairs (fig. S6).</div><div >Purification of a core SARS-CoV-2 polymerase complex [nonstructural proteins (nsp) 7, 8, and 12] from bacterial cell lysates (<a ><i>23</i></a>, <a ><i>24</i></a>) (<a >Fig. 2H</a>) and assessment of RdRP bioactivity in equivalent primer-extension in vitro polymerase assays (<a >Fig. 2I</a>) again demonstrated incorporation of 4′-FlU-TP in place of UTP by the coronavirus RdRP (<a >Fig. 2J</a>), but no sign of immediate polymerase stalling. However, SARS-CoV-2 polymerase stalling was triggered by multiple incorporations of 4′-FlU-TP, and was particularly prominent when a second incorporation of 4′-FlU-TP occurred at the <i>i</i>+4 position (<a >Fig. 2K</a> and fig. S7). Primer extension was blocked when the nsp12 subunit was omitted or an nsp12 variant carrying mutations in the catalytic site was used, confirming specificity of the reaction (fig. S7 and data S1).</div></section><section ><h2>4′-FlU is rapidly anabolized, metabolically stable, and potently antiviral in disease-relevant well-differentiated HAE cultures</h2><div >Quantitation of 4′-FlU and its anabolites in primary HAE cells (<a >Fig. 3A</a>) demonstrated rapid intracellular accumulation of 4′-FlU, reaching a level of 3.42 nmol/million cells in the first hour of exposure (<a >Fig. 3B</a>). Anabolism to bioactive 4′-FlU-TP was efficient, resulting in concentrations of 10.38 nmol/million cells at peak (4 hours after exposure start) and 1.31 nmol/million cells at plateau (24 hours). The anabolite was metabolically stable, remaining present in sustained concentrations of approximately 1 nmol/million cells over a 6-hour monitoring period, corresponding to an extrapolated half-life of 9.7 hours (<a >Fig. 3C</a>).</div><div >To explore efficacy in a disease-relevant human tissue model, we cultured the HAEs at the air-liquid interface, inducing the formation of a well-differentiated 3D airway epithelium that included ciliated and mucus-producing cells (<a ><i>25</i></a>) (<a >Fig. 3D</a>). Adding 4′-FlU to the basolateral chamber of the transwells after apical infection of the epithelium with RSV potently reduced apical virus shedding with an EC<sub>50</sub> of 55 nM (<a >Fig. 3E</a>). Overall titer reduction spanned nearly four orders of magnitude, ranging from 3.86×10<sup>4</sup> TCID<sub>50</sub> in control cells to 78.18 TCID<sub>50</sub> at 5 μM basolateral 4′-FlU, approaching the level of detection.</div><div >Confocal microscopy validated formation of a pseudostratified organization of the epithelium with tight junctions in the airway epithelium tissue model (<a >Fig. 3F</a>), visualized efficient RSV replication in vehicle-treated tissue models (<a >Fig. 3G</a>), and confirmed near-sterilizing antiviral efficacy in the presence of 50 μM basolateral 4′-FlU (<a >Fig. 3H</a> and figs. S8 and S9). Under the latter conditions, positive staining for RSV antigen was rarely detected.</div></section><section ><h2>4′-FlU is orally efficacious in a therapeutic dosing regimen in a small-animal model of RSV infection</h2><div >To test 4′-FlU efficacy in vivo, we employed the mouse model of RSV infection (supplementary text), challenging animals with recRSV-A2-L19F, which efficiently replicates in mice (<a ><i>16</i></a>). In a dose-to-failure study, we infected BALB/cJ mice intranasally and initiated once-daily oral treatment two hours after infection at 0.2, 1, or 5 mg 4′-FlU/kg body weight. Treatment at all dose levels resulted in a statistically significant reduction in lung virus load compared with vehicle-treated animals (<a >Fig. 4A</a>). The antiviral effect was dose dependent and approached nearly two orders of magnitude at the 5 mg/kg dose. Consistent with high metabolic stability in HAEs, a twice-daily dosing regimen did not significantly enhance efficacy (fig. S10). Becuase animal appearance, body weight, temperature (fig. S11), and relative lymphocyte and platelet counts (<a >Fig. 4B</a> and fig. S12) were unchanged in the 5 mg/kg group compared with vehicle-treated animals, we selected this dose for further studies.</div><div >For a longitudinal assessment of therapeutic benefit, we employed an in vivo imaging system (IVIS) with a red-shifted luciferase (<a ><i>26</i></a>) expressing a RSV reporter virus generated for this study. This assay allows a noninvasive spatial appreciation of intrahost viral dissemination. Daily imaging (<a >Fig. 4C</a> and fig. S13) revealed considerable reduction of bioluminescence intensity in lungs of 4′-FlU-treated animals at day 5 post-infection, corresponding to peak viral replication, independent of whether treatment was initiated 24 hours before or 1 hour after infection (<a >Fig. 4D</a>). This IVIS profile is consistent with reduced viral replication and ameliorated viral pneumonia in treated animals.</div><div >To probe the therapeutic window of 4′-FlU, we initiated treatment at 2, 12, 24, 36, and 48 hours after infection. All treatment groups showed a statistically significant reduction of lung virus burden compared with vehicle-treated animals, but effect size was dependent on the time of treatment initiation (<a >Fig. 4E</a> and fig. S14). On the basis of our experience with therapeutic intervention with related respiratory RNA viruses that cause lethal disease (<a ><i>25</i></a>), we require a reduction of lung virus load of at least one order of magnitude. With this constraint, the therapeutic window of 4′-FlU extended to 24 hours after infection in mice.</div></section><section ><h2>4′-FlU is effective against SARS-CoV-2 in HAE and the ferret model</h2><div >To test activity against SARS-CoV-2 in the human airway organoids, we first confirmed that the WA1 isolate replicated efficiently in HAEs of all donors tested (<a >Fig. 5, A to C</a>, and fig. S15). Treatment of infected organoids with basolateral 4′-FlU dose-dependently reduced apical virus shedding, albeit with a limited maximal effect size of approximately two orders of magnitude at 50 μM (<a >Fig. 5D</a>). Confocal microscopy revealed that the epithelium was largely devoid of SARS-CoV-2 nucleocapsid protein under these conditions (<a >Fig. 5E</a>), with only sporadic staining detectable in a small subset of ciliated cells (<a >Fig. 5F</a> and fig. S15).</div><div >To probe for a corresponding antiviral effect in vivo, we determined efficacy of oral 4′-FlU against an early pandemic isolate (WA1) and VoC alpha, gamma, and delta in the ferret model (<a ><i>27</i></a>), which recapitulates hallmarks of uncomplicated human infection (<a ><i>3</i></a>). For dose level selection in ferrets, we determined single oral dose ferret pharmacokinetic (PK) profiles of 4′-FlU. When administered at 15 or 50 mg/kg, peak plasma concentrations (C<sub>max</sub>) of 4′-FlU reached 34.8 and 63.3 μM, respectively, and overall exposure was 154 ± 27.6 and 413.1 ± 78.1 hours×nmol/ml, respectively, revealing good oral dose-proportionality (<a >Fig. 6A</a> and table S3). On the basis of this PK performance, we selected once-daily dosing at 20 mg/kg body weight for efficacy tests (<a >Fig. 6B</a>).</div><div >Intranasal infection of ferrets with 1×10<sup>5</sup> PFU of each isolate resulted in rapid viral shedding into the upper respiratory tract, which plateaued in vehicle-treated animals 48 to 60 hours after infection (<a >Fig. 6C</a>). Therapeutic treatment with 4′-FlU initiated 12 hours after infection reduced virus burden in nasal lavages by approximately three orders of magnitude (WA1) to &lt;50 PFU/ml within 12 hours of treatment onset. All three VoC were highly sensitive to 4′-FlU, remaining below the level of detection 36 to 48 hours after onset of oral treatment. Viral titers in nasal turbinate tissue extracted 4 days after infection (<a >Fig. 6D</a>) and associated viral RNA copy numbers (fig. S16) correlated with this reduction in shed virus load. Shedding of infectious particles ceased completely in all animals after 2.5 days of treatment (3 days post-infection).</div></section><section ><h2>Conclusions</h2><div >This study identifies and characterizes the ribonucleoside analog 4′-FlU, which potently inhibits pathogens of different clinically-relevant negative and positive-sense RNA virus families. The compound causes delayed stalling of RSV and SARS-CoV-2 polymerases within in vitro RdRP assays, reminiscent of the antiviral effect of remdesivir (<a ><i>28</i></a>, <a ><i>29</i></a>). However, 4′-FlU can also trigger immediate RdRP stalling depending on sequence context, suggesting steric hindrance of polymerase advance or of accommodating the next incoming nucleotide as the underlying MOA. We cannot exclude that additional effects further enhance the antiviral effect in cellula as proposed for other nucleoside analogs (<a ><i>30</i></a>). Slightly lower sensitivity of SARS-CoV-2 to 4′-FlU compared with RSV could be a result of the exonuclease activity of the coronavirus polymerase, which can eliminate ribonucleoside analogs (<a ><i>31</i></a>, <a ><i>32</i></a>). Alternatively, coronavirus RdRP may have a greater capacity to tolerate the compound, because SARS-CoV-2 RdRP showed a higher tendency than RSV polymerase to advance after 4′-FlU-TP incorporation in the RdRP assays, which do not contain exonuclease functionality.</div><div >Once-daily oral administration to mice and ferrets significantly reduced the burden of RSV and SARS-CoV-2, respectively, when treatment was initiated up to 24 (RSV) or 12 (SARS-CoV-2) hours after infection. Because RSV (<a ><i>33</i></a>) and SARS-CoV-2 (<a ><i>34</i></a>) host invasion is slower in humans, these data outline a viable therapeutic window for human treatment. Equally potent activity against SARS-CoV-2 VoC alpha, gamma, and delta demonstrated broad anti-coronavirus efficacy of 4′-FlU, building confidence that the compound will remain active against future VoC that may be increasingly less responsive to spike-targeting vaccines or antibody therapeutics. Formal tolerability studies are pending, but 4′-FlU was well tolerated by the human organoid models and efficacious in murids and mustelids. Blood analysis of treated mice uncovered no antiproliferative effect of 4′-FlU on the hematopoietic system. These results establish 4′-FlU as a broad-spectrum orally efficacious inhibitor of major RNA viruses, making it a promising therapeutic option for RSV disease and COVID-19, and a much-needed contributor to improving pandemic preparedness.</div></section><section ><h2>Acknowledgments</h2><div >We thank C. F. Basler for providing Calu-3 cells, D. Waugh for plasmid pRK792 encoding TEV protease (Addgene plasmid #8830), the Georgia State University High Containment Core and the Department for Animal Research for support, and A. L. Hammond for critical reading of the manuscript. <b>Funding: </b>This work was supported, in part, by Public Health Service grants AI153400, AI071002, and AI141222 (to R.K.P.), from the NIH/NIAID. The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication. <b>Author contributions:</b> Conceptualization: M.G.N., G.R.P., and R.K.P. Investigation: J.S., R.M.C., M.T., J.Y., C.M.L., M.A., J.D.W., Z.S., and R.K.P. Resources: G.R.B., A.A.K., L.M.S., and R.K.P. Visualization: G.R.B. and J.S. Validation: J.S. and R.K.P. Funding acquisition: R.K.P. Project administration: M.G.N. and R.K.P. Supervision: G.R.P. and R.K.P. Writing – original draft: J.S. and R.K.P. Writing – review and editing: J.S. and R.K.P. <b>Competing interests:</b> G.R.B. and G.R.P. are coinventors on patent WO 2019/1736002 covering composition of matter and use of EIDD-2749 and its analogs as an antiviral treatment. This study could affect their personal financial status. All other authors declare that they have no competing interests. <b>Data and materials availability:</b> All data are available in the main text or the supplementary materials. Materials and methods are available as supplementary materials at the Science website. Transfer of EIDD-2749 material to other institutions for research purposes is covered by MTAs from Emory University. This work is licensed under a Creative Commons Attribution 4.0 International (CC BY 4.0) license, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. To view a copy of this license, visit <a >https://creativecommons.org/licenses/by/4.0/</a>. This license does not apply to figures/photos/artwork or other content included in the article that is credited to a third party; obtain authorization from the rights holder before using such material.</div></section> </div></section><section ><div ><section ><h2>Supplementary Material</h2><section><h3>Summary</h3><div ><a >science.org/doi/10.1126/science.abj5508</a></div><div >Materials and Methods</div><div >Supplementary Text</div><div >Figs. S1 to S18</div><div >Tables S1 to S3 </div><div >References (<a ><i>35</i></a>, <a ><i>36</i></a>)</div><div >MDAR Reproducibility Checklist</div><div >Data S1 and S2</div></section><section><h3>Resources</h3><div ><div ><div >File (science.abj5508-sm.pdf)</div><div >Download</div></div><div ><div >File (science.abj5508_data_s1_and_s2.zip)</div><div >Download</div></div><div ><div >File (science.abj5508_mdar_reproducibility_checklist.pdf)</div><div >Download</div></div></div></section></section><section ><h2>References and Notes</h2><div ><div >1</div><div ><div ><div >J. H. Beigel, K. M. Tomashek, L. E. Dodd, A. K. Mehta, B. S. Zingman, A. C. Kalil, E. Hohmann, H. Y. Chu, A. Luetkemeyer, S. Kline, D. Lopez de Castilla, R. W. Finberg, K. Dierberg, V. Tapson, L. Hsieh, T. F. Patterson, R. Paredes, D. A. Sweeney, W. R. Short, G. Touloumi, D. C. Lye, N. Ohmagari, M. D. Oh, G. M. Ruiz-Palacios, T. Benfield, G. Fätkenheuer, M. G. Kortepeter, R. L. Atmar, C. B. Creech, J. Lundgren, A. G. Babiker, S. Pett, J. D. Neaton, T. H. Burgess, T. Bonnett, M. Green, M. Makowski, A. Osinusi, S. Nayak, H. C. Lane; ACTT-1 Study Group Members, Remdesivir for the Treatment of Covid-19 - Final Report. N. Engl. J. Med. <b>383</b>, 1813–1826 (2020).</div><div ><div>Crossref</div><div><a >PubMed</a></div><div><a >Google Scholar</a></div></div></div></div></div><div ><div >2</div><div ><div ><div >M. Toots, J.-J. Yoon, R. M. Cox, M. Hart, Z. M. Sticher, N. Makhsous, R. Plesker, A. H. Barrena, P. G. Reddy, D. G. Mitchell, R. C. Shean, G. R. Bluemling, A. A. Kolykhalov, A. L. Greninger, M. G. Natchus, G. R. Painter, R. K. Plemper, Characterization of orally efficacious influenza drug with high resistance barrier in ferrets and human airway epithelia. Sci. Transl. Med. <b>11</b>, eaax5866 (2019).</div><div ><div><a >Crossref</a></div><div><a >PubMed</a></div><div><a >Google Scholar</a></div></div></div></div></div><div ><div >3</div><div ><div ><div >R. M. Cox, J. D. Wolf, R. K. Plemper, Therapeutically administered ribonucleoside analogue MK-4482/EIDD-2801 blocks SARS-CoV-2 transmission in ferrets. Nat. Microbiol. <b>6</b>, 11–18 (2021).</div><div ><div><a >Crossref</a></div><div><a >PubMed</a></div><div><a >Google Scholar</a></div></div></div></div></div><div ><div >4</div><div ><div ><div >G. R. Painter, R. A. Bowen, G. R. Bluemling, J. DeBergh, V. Edpuganti, P. R. Gruddanti, D. B. Guthrie, M. Hager, D. L. Kuiper, M. A. Lockwood, D. G. Mitchell, M. G. Natchus, Z. M. Sticher, A. A. Kolykhalov, The prophylactic and therapeutic activity of a broadly active ribonucleoside analog in a murine model of intranasal venezuelan equine encephalitis virus infection. Antiviral Res. <b>171</b>, 104597 (2019).</div><div ><div><a >Crossref</a></div><div><a >PubMed</a></div><div><a >Google Scholar</a></div></div></div></div></div><div ><div >5</div><div ><div ><div >T. P. Sheahan, A. C. Sims, S. Zhou, R. L. Graham, A. J. Pruijssers, M. L. Agostini, S. R. Leist, A. Schäfer, K. H. Dinnon 3rd, L. J. Stevens, J. D. Chappell, X. Lu, T. M. Hughes, A. S. George, C. S. Hill, S. A. Montgomery, A. J. Brown, G. R. Bluemling, M. G. Natchus, M. Saindane, A. A. Kolykhalov, G. Painter, J. Harcourt, A. Tamin, N. J. Thornburg, R. Swanstrom, M. R. Denison, R. S. Baric, An orally bioavailable broad-spectrum antiviral inhibits SARS-CoV-2 in human airway epithelial cell cultures and multiple coronaviruses in mice. Sci. Transl. Med. <b>12</b>, eabb5883 (2020).</div><div ><div><a >Crossref</a></div><div><a >PubMed</a></div><div><a >Google Scholar</a></div></div></div></div></div><div ><div >6</div><div ><div ><div >A. R. Falsey, P. A. Hennessey, M. A. Formica, C. Cox, E. E. Walsh, Respiratory syncytial virus infection in elderly and high-risk adults. N. Engl. J. Med. <b>352</b>, 1749–1759 (2005).</div><div ><div><a >Crossref</a></div><div><a >PubMed</a></div><div><a >Google Scholar</a></div></div></div></div></div><div ><div >7</div><div ><div ><div >B. Rha, A. T. Curns, J. Y. Lively, A. P. Campbell, J. A. Englund, J. A. Boom, P. H. Azimi, G. A. Weinberg, M. A. Staat, R. Selvarangan, N. B. Halasa, M. M. McNeal, E. J. Klein, C. J. Harrison, J. V. Williams, P. G. Szilagyi, M. N. Singer, L. C. Sahni, D. Figueroa-Downing, D. McDaniel, M. M. Prill, B. L. Whitaker, L. S. Stewart, J. E. Schuster, B. A. Pahud, G. Weddle, V. Avadhanula, F. M. Munoz, P. A. Piedra, D. C. Payne, G. Langley, S. I. Gerber, Respiratory Syncytial Virus-Associated Hospitalizations Among Young Children: 2015-2016. Pediatrics <b>146</b>, e20193611 (2020).</div><div ><div><a >Crossref</a></div><div><a >PubMed</a></div><div><a >Google Scholar</a></div></div></div></div></div><div ><div >8</div><div ><div ><div >T. Shi, A. Denouel, A. K. Tietjen, I. Campbell, E. Moran, X. Li, H. Campbell, C. Demont, B. O. Nyawanda, H. Y. Chu, S. K. Stoszek, A. Krishnan, P. Openshaw, A. R. Falsey, H. Nair, H. Nair, H. Campbell, T. Shi, S. Zhang, Y. Li, P. Openshaw, J. Wedzicha, A. Falsey, M. Miller, P. Beutels, L. Bont, A. Pollard, E. Molero, F. Martinon-Torres, T. Heikkinen, A. Meijer, T. K. Fischer, M. van den Berge, C. Giaquinto, R. Mikolajczyk, J. Hackett, B. Cai, C. Knirsch, A. Leach, S. K. Stoszek, S. Gallichan, A. Kieffer, C. Demont, A. Denouel, A. Cheret, S. Gavart, J. Aerssens, R. Fuentes, B. Rosen, H. Nair, H. Campbell, T. Shi, S. Zhang, Y. Li, P. Openshaw, J. Wedzicha, A. Falsey, M. Miller, P. Beutels, L. Bont, A. Pollard, E. Molero, F. Martinon-Torres, T. Heikkinen, A. Meijer, T. K. Fischer, M. van den Berge, C. Giaquinto, R. Mikolajczyk, J. Hackett, B. Cai, C. Knirsch, A. Leach, S. K. Stoszek, S. Gallichan, A. Kieffer, C. Demont, A. Denouel, A. Cheret, S. Gavart, J. Aerssens, R. Fuentes, B. Rosen; RESCEU Investigators, Global Disease Burden Estimates of Respiratory Syncytial Virus-Associated Acute Respiratory Infection in Older Adults in 2015: A Systematic Review and Meta-Analysis. J. Infect. Dis. <b>222</b> (Suppl 7), S577–S583 (2020).</div><div ><div><a >Crossref</a></div><div><a >PubMed</a></div><div><a >Google Scholar</a></div></div></div></div></div><div ><div >9</div><div ><div ><div >T. Shi, D. A. McAllister, K. L. O’Brien, E. A. F. Simoes, S. A. Madhi, B. D. Gessner, F. P. Polack, E. Balsells, S. Acacio, C. Aguayo, I. Alassani, A. Ali, M. Antonio, S. Awasthi, J. O. Awori, E. Azziz-Baumgartner, H. C. Baggett, V. L. Baillie, A. Balmaseda, A. Barahona, S. Basnet, Q. Bassat, W. Basualdo, G. Bigogo, L. Bont, R. F. Breiman, W. A. Brooks, S. Broor, N. Bruce, D. Bruden, P. Buchy, S. Campbell, P. Carosone-Link, M. Chadha, J. Chipeta, M. Chou, W. Clara, C. Cohen, E. de Cuellar, D.-A. Dang, B. Dash-Yandag, M. Deloria-Knoll, M. Dherani, T. Eap, B. E. Ebruke, M. Echavarria, C. C. de Freitas Lázaro Emediato, R. A. Fasce, D. R. Feikin, L. Feng, A. Gentile, A. Gordon, D. Goswami, S. Goyet, M. Groome, N. Halasa, S. Hirve, N. Homaira, S. R. C. Howie, J. Jara, I. Jroundi, C. B. Kartasasmita, N. Khuri-Bulos, K. L. Kotloff, A. Krishnan, R. Libster, O. Lopez, M. G. Lucero, F. Lucion, S. P. Lupisan, D. N. Marcone, J. P. McCracken, M. Mejia, J. C. Moisi, J. M. Montgomery, D. P. Moore, C. Moraleda, J. Moyes, P. Munywoki, K. Mutyara, M. P. Nicol, D. J. Nokes, P. Nymadawa, M. T. da Costa Oliveira, H. Oshitani, N. Pandey, G. Paranhos-Baccalà, L. N. Phillips, V. S. Picot, M. Rahman, M. Rakoto-Andrianarivelo, Z. A. Rasmussen, B. A. Rath, A. Robinson, C. Romero, G. Russomando, V. Salimi, P. Sawatwong, N. Scheltema, B. Schweiger, J. A. G. Scott, P. Seidenberg, K. Shen, R. Singleton, V. Sotomayor, T. A. Strand, A. Sutanto, M. Sylla, M. D. Tapia, S. Thamthitiwat, E. D. Thomas, R. Tokarz, C. Turner, M. Venter, S. Waicharoen, J. Wang, W. Watthanaworawit, L.-M. Yoshida, H. Yu, H. J. Zar, H. Campbell, H. Nair; RSV Global Epidemiology Network, Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in young children in 2015: A systematic review and modelling study. Lancet <b>390</b>, 946–958 (2017).</div><div ><div><a >Crossref</a></div><div><a >PubMed</a></div><div><a >Google Scholar</a></div></div></div></div></div><div ><div >10</div><div ><div ><div >G. S. Cockerill, J. A. D. Good, N. Mathews, State of the Art in Respiratory Syncytial Virus Drug Discovery and Development. J. Med. Chem. <b>62</b>, 3206–3227 (2019).</div><div ><div><a >Crossref</a></div><div><a >PubMed</a></div><div><a >Google Scholar</a></div></div></div></div></div><div ><div >11</div><div ><div ><div >R. Fearns, R. K. Plemper, Polymerases of paramyxoviruses and pneumoviruses. Virus Res. <b>234</b>, 87–102 (2017).</div><div ><div><a >Crossref</a></div><div><a >PubMed</a></div><div><a >Google Scholar</a></div></div></div></div></div><div ><div >12</div><div ><div ><div >R. M. Cox, M. Toots, J.-J. Yoon, J. Sourimant, B. Ludeke, R. Fearns, E. Bourque, J. Patti, E. Lee, J. Vernachio, R. K. Plemper, Development of an allosteric inhibitor class blocking RNA elongation by the respiratory syncytial virus polymerase complex. J. Biol. Chem. <b>293</b>, 16761–16777 (2018).</div><div ><div><a >Crossref</a></div><div><a >PubMed</a></div><div><a >Google Scholar</a></div></div></div></div></div><div ><div >13</div><div ><div ><div >J. DeVincenzo, L. Cass, A. Murray, K. Woodward, E. Meals, M. Coates, L. Daly, V. Wheeler, J. Mori, C. Brindley, A. Davis, M. McCurdy, K. Ito, B. Murray, P. Strong, G. Rapeport, Safety and Anti-viral Effects of Nebulized PC786 in a Respiratory Syncytial Virus Challenge Study. J. Infect. Dis. jiaa716 (2020).</div><div ><div><a >Crossref</a></div><div><a >PubMed</a></div><div><a >Google Scholar</a></div></div></div></div></div><div ><div >14</div><div ><div ><div >J. J. Yoon, M. Toots, S. Lee, M.-E. Lee, B. Ludeke, J. M. Luczo, K. Ganti, R. M. Cox, Z. M. Sticher, V. Edpuganti, D. G. Mitchell, M. A. Lockwood, A. A. Kolykhalov, A. L. Greninger, M. L. Moore, G. R. Painter, A. C. Lowen, S. M. Tompkins, R. Fearns, M. G. Natchus, R. K. Plemper, Orally Efficacious Broad-Spectrum Ribonucleoside Analog Inhibitor of Influenza and Respiratory Syncytial Viruses. Antimicrob. Agents Chemother. <b>62</b>, ••• (2018).</div><div ><div><a >Crossref</a></div><div><a >PubMed</a></div><div><a >Google Scholar</a></div></div></div></div></div><div ><div >15</div><div ><div ><div >P. Richardson, Applications of fluorine to the construction of bioisosteric elements for the purposes of novel drug discovery. Expert Opin. Drug Discov. <b>16</b>, 1261–1286 (2021).</div><div ><div><a >Crossref</a></div><div><a >PubMed</a></div><div><a >Google Scholar</a></div></div></div></div></div><div ><div >16</div><div ><div ><div >M. L. Moore, M. H. Chi, C. Luongo, N. W. Lukacs, V. V. Polosukhin, M. M. Huckabee, D. C. Newcomb, U. J. Buchholz, J. E. Crowe Jr., K. Goleniewska, J. V. Williams, P. L. Collins, R. S. Peebles Jr., A chimeric A2 strain of respiratory syncytial virus (RSV) with the fusion protein of RSV strain line 19 exhibits enhanced viral load, mucus, and airway dysfunction. J. Virol. <b>83</b>, 4185–4194 (2009).</div><div ><div><a >Crossref</a></div><div><a >PubMed</a></div><div><a >Google Scholar</a></div></div></div></div></div><div ><div >17</div><div ><div ><div >L. D. Marroquin, J. Hynes, J. A. Dykens, J. D. Jamieson, Y. Will, Circumventing the Crabtree effect: Replacing media glucose with galactose increases susceptibility of HepG2 cells to mitochondrial toxicants. Toxicol. Sci. <b>97</b>, 539–547 (2007).</div><div ><div><a >Crossref</a></div><div><a >PubMed</a></div><div><a >Google Scholar</a></div></div></div></div></div><div ><div >18</div><div ><div ><div >S. P. Luby, The pandemic potential of Nipah virus. Antiviral Res. <b>100</b>, 38–43 (2013).</div><div ><div><a >Crossref</a></div><div><a >PubMed</a></div><div><a >Google Scholar</a></div></div></div></div></div><div ><div >19</div><div ><div ><div >Note: Based on the current knowledge of the pyrimidine salvage pathway, it must be assumed that the large excess of extracellular cytidine leads to conversion of CTP to UTP via cytidine deaminase (CDA), competing with 4′-FlU.</div></div></div></div><div ><div >20</div><div ><div ><div >B. Ludeke, R. Fearns, The respiratory syncytial virus polymerase can perform RNA synthesis with modified primers and nucleotide analogs. Virology <b>540</b>, 66–74 (2020).</div><div ><div><a >Crossref</a></div><div><a >PubMed</a></div><div><a >Google Scholar</a></div></div></div></div></div><div ><div >21</div><div ><div ><div >E. P. Tchesnokov, J. Y. Feng, D. P. Porter, M. Götte, Mechanism of Inhibition of Ebola Virus RNA-Dependent RNA Polymerase by Remdesivir. Viruses <b>11</b>, 326 (2019).</div><div ><div><a >Crossref</a></div><div><a >PubMed</a></div><div><a >Google Scholar</a></div></div></div></div></div><div ><div >22</div><div ><div ><div >C. J. Gordon, E. P. Tchesnokov, E. Woolner, J. K. Perry, J. Y. Feng, D. P. Porter, M. Götte, Remdesivir is a direct-acting antiviral that inhibits RNA-dependent RNA polymerase from severe acute respiratory syndrome coronavirus 2 with high potency. J. Biol. Chem. <b>295</b>, 6785–6797 (2020).</div><div ><div><a >Crossref</a></div><div><a >PubMed</a></div><div><a >Google Scholar</a></div></div></div></div></div><div ><div >23</div><div ><div ><div >T. L. Dangerfield, N. Z. Huang, K. A. Johnson, Expression and purification of tag-free SARS-CoV-2 RNA-dependent RNA polymerase in <i>Escherichia coli</i>. STAR Protoc <b>2</b>, 100357 (2021).</div><div ><div><a >Crossref</a></div><div><a >PubMed</a></div><div><a >Google Scholar</a></div></div></div></div></div><div ><div >24</div><div ><div ><div >Note: Our nsp12 preparations contain a mixture of ‘GroEL’ and ‘tf’, and nsp12 as described before, the latter representing 19% and 18% of the protein content of the preparations containing catalytically active and inactive nsp12, respectively.</div></div></div></div><div ><div >25</div><div ><div ><div >M. Toots, J.-J. Yoon, M. Hart, M. G. Natchus, G. R. Painter, R. K. Plemper, Quantitative efficacy paradigms of the influenza clinical drug candidate EIDD-2801 in the ferret model. Transl. Res. <b>218</b>, 16–28 (2020).</div><div ><div><a >Crossref</a></div><div><a >PubMed</a></div><div><a >Google Scholar</a></div></div></div></div></div><div ><div >26</div><div ><div ><div >S. M. Coleman, A. McGregor, A bright future for bioluminescent imaging in viral research. Future Virol. <b>10</b>, 169–183 (2015).</div><div ><div><a >Crossref</a></div><div><a >PubMed</a></div><div><a >Google Scholar</a></div></div></div></div></div><div ><div >27</div><div ><div ><div >Note: Male ferrets were not included in this study for practical reasons as they are territorial and available ABSL3 space cannot accommodate the number of cages that this study would require to achieve meaningful statistical power.</div></div></div></div><div ><div >28</div><div ><div ><div >G. Kokic, H. S. Hillen, D. Tegunov, C. Dienemann, F. Seitz, J. Schmitzova, L. Farnung, A. Siewert, C. Höbartner, P. Cramer, Mechanism of SARS-CoV-2 polymerase stalling by remdesivir. Nat. Commun. <b>12</b>, 279 (2021).</div><div ><div><a >Crossref</a></div><div><a >PubMed</a></div><div><a >Google Scholar</a></div></div></div></div></div><div ><div >29</div><div ><div ><div >E. P. Tchesnokov, C. J. Gordon, E. Woolner, D. Kocinkova, J. K. Perry, J. Y. Feng, D. P. Porter, M. Götte, Template-dependent inhibition of coronavirus RNA-dependent RNA polymerase by remdesivir reveals a second mechanism of action. J. Biol. Chem. <b>295</b>, 16156–16165 (2020).</div><div ><div><a >Crossref</a></div><div><a >PubMed</a></div><div><a >Google Scholar</a></div></div></div></div></div><div ><div >30</div><div ><div ><div >J. J. Feld, J. H. Hoofnagle, Mechanism of action of interferon and ribavirin in treatment of hepatitis C. Nature <b>436</b>, 967–972 (2005).</div><div ><div><a >Crossref</a></div><div><a >PubMed</a></div><div><a >Google Scholar</a></div></div></div></div></div><div ><div >31</div><div ><div ><div >E. C. Smith, H. Blanc, M. C. Surdel, M. Vignuzzi, M. R. Denison, Coronaviruses lacking exoribonuclease activity are susceptible to lethal mutagenesis: Evidence for proofreading and potential therapeutics. PLOS Pathog. <b>9</b>, e1003565 (2013).</div><div ><div><a >Crossref</a></div><div><a >PubMed</a></div><div><a >Google Scholar</a></div></div></div></div></div><div ><div >32</div><div ><div ><div >E. Minskaia, T. Hertzig, A. E. Gorbalenya, V. Campanacci, C. Cambillau, B. Canard, J. Ziebuhr, Discovery of an RNA virus 3′-&gt;5′ exoribonuclease that is critically involved in coronavirus RNA synthesis. Proc. Natl. Acad. Sci. U.S.A. <b>103</b>, 5108–5113 (2006).</div><div ><div><a >Crossref</a></div><div><a >PubMed</a></div><div><a >Google Scholar</a></div></div></div></div></div><div ><div >33</div><div ><div ><div >C. M. El Saleeby, A. J. Bush, L. M. Harrison, J. A. Aitken, J. P. Devincenzo, Respiratory syncytial virus load, viral dynamics, and disease severity in previously healthy naturally infected children. J. Infect. Dis. <b>204</b>, 996–1002 (2011).</div><div ><div><a >Crossref</a></div><div><a >PubMed</a></div><div><a >Google Scholar</a></div></div></div></div></div><div ><div >34</div><div ><div ><div >B. Oberfeld, A. Achanta, K. Carpenter, P. Chen, N. M. Gilette, P. Langat, J. T. Said, A. E. Schiff, A. S. Zhou, A. K. Barczak, S. Pillai, SnapShot: COVID-19. Cell <b>181</b>, 954–954.e1 (2020).</div><div ><div><a >Crossref</a></div><div><a >PubMed</a></div><div><a >Google Scholar</a></div></div></div></div></div><div ><div >35</div><div ><div ><div >C. Ye, K. Chiem, J.-G. Park, J. A. Silvas, D. Morales Vasquez, J. Sourimant, M. J. Lin, A. L. Greninger, R. K. Plemper, J. B. Torrelles, J. J. Kobie, M. R. Walter, J. C. de la Torre, L. Martinez-Sobrido, Analysis of SARS-CoV-2 infection dynamic in vivo using reporter-expressing viruses. Proc. Natl. Acad. Sci. U.S.A. <b>118</b>, e2111593118 (2021).</div><div ><div><a >Crossref</a></div><div><a >PubMed</a></div><div><a >Google Scholar</a></div></div></div></div></div><div ><div >36</div><div ><div ><div >M. A. Rameix-Welti, R. Le Goffic, P.-L. Hervé, J. Sourimant, A. Rémot, S. Riffault, Q. Yu, M. Galloux, E. Gault, J.-F. Eléouët, Visualizing the replication of respiratory syncytial virus in cells and in living mice. Nat. Commun. <b>5</b>, 5104 (2014).</div><div ><div><a >Crossref</a></div><div><a >PubMed</a></div><div><a >Google Scholar</a></div></div></div></div></div></section></div></section><div ><div ><header><h2>Information Authors</h2></header><section ><h3>Information</h3><section ><h4>Published In</h4><div > <div ><div >Science</div><div >First Release</div></div></div></section><section ><h4>Copyright</h4><div > Copyright © 2021 The Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. No claim to original U.S. Government Works. Distributed under a Creative Commons Attribution License 4.0 (CC BY).</div><div >https://creativecommons.org/licenses/by/4.0/</div><div >This is an open-access article distributed under the terms of the <a >Creative Commons Attribution license</a>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</div></section><section ><h4>Submission history</h4><div><b >Received</b>: 19 May 2021</div><div><b >Accepted</b>: 29 November 2021</div></section><section ><h4>Permissions</h4><div>Request permissions for this article.</div><div><a >Request Permissions</a></div></section><section ><h4>Acknowledgments</h4><div >We thank C. F. Basler for providing Calu-3 cells, D. Waugh for plasmid pRK792 encoding TEV protease (Addgene plasmid #8830), the Georgia State University High Containment Core and the Department for Animal Research for support, and A. L. Hammond for critical reading of the manuscript. <b>Funding: </b>This work was supported, in part, by Public Health Service grants AI153400, AI071002, and AI141222 (to R.K.P.), from the NIH/NIAID. The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication. <b>Author contributions:</b> Conceptualization: M.G.N., G.R.P., and R.K.P. Investigation: J.S., R.M.C., M.T., J.Y., C.M.L., M.A., J.D.W., Z.S., and R.K.P. Resources: G.R.B., A.A.K., L.M.S., and R.K.P. Visualization: G.R.B. and J.S. Validation: J.S. and R.K.P. Funding acquisition: R.K.P. Project administration: M.G.N. and R.K.P. Supervision: G.R.P. and R.K.P. Writing – original draft: J.S. and R.K.P. Writing – review and editing: J.S. and R.K.P. <b>Competing interests:</b> G.R.B. and G.R.P. are coinventors on patent WO 2019/1736002 covering composition of matter and use of EIDD-2749 and its analogs as an antiviral treatment. This study could affect their personal financial status. All other authors declare that they have no competing interests. <b>Data and materials availability:</b> All data are available in the main text or the supplementary materials. Materials and methods are available as supplementary materials at the Science website. Transfer of EIDD-2749 material to other institutions for research purposes is covered by MTAs from Emory University. This work is licensed under a Creative Commons Attribution 4.0 International (CC BY 4.0) license, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. To view a copy of this license, visit <a >https://creativecommons.org/licenses/by/4.0/</a>. This license does not apply to figures/photos/artwork or other content included in the article that is credited to a third party; obtain authorization from the rights holder before using such material.</div></section></section><section ><h3>Authors</h3><section ><h4>Affiliations</h4><div ><div >Julien Sourimant https://orcid.org/0000-0002-1660-1666</div><div ><div ><div >Center for Translational Antiviral Research, Georgia State University, Atlanta, GA 30303, USA.</div></div><div >View all articles by this author</div></div></div><div ><div >Carolin M. Lieber</div><div ><div ><div >Center for Translational Antiviral Research, Georgia State University, Atlanta, GA 30303, USA.</div></div><div >View all articles by this author</div></div></div><div ><div >Megha Aggarwal</div><div ><div ><div >Center for Translational Antiviral Research, Georgia State University, Atlanta, GA 30303, USA.</div></div><div >View all articles by this author</div></div></div><div ><div >Robert M. Cox</div><div ><div ><div >Center for Translational Antiviral Research, Georgia State University, Atlanta, GA 30303, USA.</div></div><div >View all articles by this author</div></div></div><div ><div >Josef D. Wolf https://orcid.org/0000-0003-2507-6944</div><div ><div ><div >Center for Translational Antiviral Research, Georgia State University, Atlanta, GA 30303, USA.</div></div><div >View all articles by this author</div></div></div><div ><div >Jeong-Joong Yoon https://orcid.org/0000-0001-9379-0416</div><div ><div ><div >Center for Translational Antiviral Research, Georgia State University, Atlanta, GA 30303, USA.</div></div><div >View all articles by this author</div></div></div><div ><div >Mart Toots</div><div ><div ><div >Center for Translational Antiviral Research, Georgia State University, Atlanta, GA 30303, USA.</div></div><div >View all articles by this author</div></div></div><div ><div >Chengin Ye https://orcid.org/0000-0002-1934-9494</div><div ><div ><div >Texas Biomedical Research Institute, San Antonio, TX 78227, USA.</div></div><div >View all articles by this author</div></div></div><div ><div >Zachary Sticher https://orcid.org/0000-0002-7022-1410</div><div ><div ><div >Emory Institute for Drug Development, Emory University, Atlanta, GA 30322, USA.</div></div><div >View all articles by this author</div></div></div><div ><div >Alexander A. Kolykhalov</div><div ><div ><div >Emory Institute for Drug Development, Emory University, Atlanta, GA 30322, USA.</div><div >Drug Innovation Ventures at Emory (DRIVE), Atlanta, GA 30322, USA.</div></div><div >View all articles by this author</div></div></div><div ><div >Luis Martinez-Sobrido https://orcid.org/0000-0001-7084-0804</div><div ><div ><div >Texas Biomedical Research Institute, San Antonio, TX 78227, USA.</div></div><div >View all articles by this author</div></div></div><div ><div >Gregory R. Bluemling https://orcid.org/0000-0001-9138-7578</div><div ><div ><div >Emory Institute for Drug Development, Emory University, Atlanta, GA 30322, USA.</div><div >Drug Innovation Ventures at Emory (DRIVE), Atlanta, GA 30322, USA.</div></div><div >View all articles by this author</div></div></div><div ><div >Michael G. Natchus</div><div ><div ><div >Emory Institute for Drug Development, Emory University, Atlanta, GA 30322, USA.</div></div><div >View all articles by this author</div></div></div><div ><div >George R. Painter https://orcid.org/0000-0002-9803-8095</div><div ><div ><div >Emory Institute for Drug Development, Emory University, Atlanta, GA 30322, USA.</div><div >Drug Innovation Ventures at Emory (DRIVE), Atlanta, GA 30322, USA.</div><div >Department of Pharmacology, Emory University School of Medicine, Atlanta, GA 30322, USA.</div></div><div >View all articles by this author</div></div></div><div ><div >Richard K. Plemper<sup >*</sup> https://orcid.org/0000-0003-2034-2107 [email protected]</div><div ><div ><div >Center for Translational Antiviral Research, Georgia State University, Atlanta, GA 30303, USA.</div><div >Department of Pediatrics, Emory University School of Medicine, Atlanta, GA 30322, USA.</div></div><div >View all articles by this author</div></div></div></section><section ><h4>Funding Information</h4><div >National Institute of Allergy and Infectious Diseases: AI153400</div><div >National Institute of Allergy and Infectious Diseases: AI071002</div><div ><a >National Institute of Allergy and Infectious Diseases</a>: AI141222</div></section><section ><h4>Notes</h4><div >*Corresponding author. Email: <a >[email protected]</a></div></section></section></div><div ><header><h2>Metrics Citations</h2></header><section ><h3>Metrics</h3><section > <h5 > Article Usage </h5> </section><section > <h5 > Altmetrics </h5> </section></section><section ><h3>Citations</h3><section > <div > <h5 >Export citation</h5> <p>Select the format you want to export the citation of this publication.</p> </div> </section></section></div><div ><header><h2>View Options</h2></header><div ><h3>View options</h3><section ><h4>PDF format</h4><p>Download this article as a PDF file</p><a >Download PDF</a></section></div><div ><h3>Get Access</h3><section > <div ><h5>Log in to view the full text</h5> <p><a >AAAS Log in</a></p> <p>AAAS login provides access to Science for AAAS members, and access to other journals in the Science family to users who have purchased individual subscriptions.</p> <ul > <li >Become a AAAS Member</li> <li ><a >Activate your Account</a></li> <li ><a >Purchase Access to Other Journals in the Science Family</a></li> <li><a >Account Help</a></li> </ul> <div > <div >Log in via OpenAthens. <div ><a >via OpenAthens</a></div> </div> <div >Log in via Shibboleth. <div ><a >via Shibboleth</a></div> </div> </div> </div> <div ><h5>More options</h5><p><a >Purchase digital access to this article</a></p><p >Download and print this article for your personal scholarly, research, and educational use.</p><p><a >Purchase this issue in print</a></p><p>Buy a single issue of Science for just $15 USD.</p></div> </section></div></div><div ><header><h2>Media</h2></header><section ><h3>Figures</h3></section><section ><h3>Multimedia</h3></section></div><div ><header><h2>Tables</h2></header></div><div ><header><h2>Share</h2></header><h3>Share</h3><div ><section ><h4>Share article link</h4><div ><a >Copy Link</a><div ><p >Copied!</p><p >Copying failed.</p></div></div></section><section ><h4>Share on social media</h4><div >facebook<a >twitter</a><a >linkedin</a><a >email</a></div></section></div></div></div></article><section ><div ><div ><div ><div ><h3 >Submit a Response to This Article</h3></div></div></div></div> <div > <div > <h2 >(0)eLetters</h2> </div> <p >eLetters is an online forum for ongoing peer review. Submission of eLetters are open to all. eLetters are not edited, proofread, or indexed. Please read our Terms of Service before submitting your own eLetter.</p> <a >Log In to Submit a Response</a> <p >No eLetters have been published for this article yet.</p> </div> </section> <div ><a >View Full Text</a><a >Download PDF</a></div> </div></div></div></div><div ><div ><div ><div ><section><div ><h4 > Current Issue </h4><div ><div > <div ><div><article ><div ><div ><h3 ><a >Cell-by-cell dissection of phloem development links a maturation gradient to cell specialization</a></h3><ul ><li >By<ul > <li >Pawel Roszak</li> <li >Jung-ok Heo</li> <li >et al.</li> </ul> </li></ul></div></div></article><article ><div ><div ><h3 >The energetics of uniquely human subsistence strategies</h3><ul ><li >By<ul > <li >Thomas S. Kraft</li> <li >Vivek V. Venkataraman</li> <li >et al.</li> </ul> </li></ul></div></div></article><article ><div ><div ><h3 >Early giant reveals faster evolution of large body size in ichthyosaurs than in cetaceans</h3><ul ><li >By<ul > <li >P. Martin Sander</li> <li >Eva Maria Griebeler</li> <li >et al.</li> </ul> </li></ul></div></div></article></div><div ><a >Table of Contents</a></div></div> </div></div></div></section><section > <h4 >LATEST NEWS</h4> <div > <div ><div > <article > <div > <div > News<time >30 Dec 2021</time> </div> <div > Airborne DNA from plants could reveal invasive species, impact of climate change </div> </div> </article> <article > <div > <div > ScienceInsider<time >29 Dec 2021</time> </div> <div > Once a ‘crazy idea,’ patent-pooling nonprofit will help bring COVID-19 pills to world’s poor </div> </div> </article> <article > <div > <div > ScienceInsider<time >28 Dec 2021</time> </div> <div > The natural world loses two of its biggest advocates </div> </div> </article> <article > <div > <div > ScienceInsider<time >28 Dec 2021</time> </div> <div > <a > What the Charles Lieber verdict says about U.S. China Initiative </a> </div> </div> </article> <article > <div > <div > ScienceInsider<time >25 Dec 2021</time> </div> <div > NASA’s Webb telescope takes flight—a Christmas gift to astronomers everywhere </div> </div> </article> <article > <div > <div > News<time >23 Dec 2021</time> </div> <div > <a > More than a virus: Science’s areas to watch in 2022 </a> </div> </div> </article> </div></div> </div></section></div></div></div></div> </main> </div> </div> </div> </body>'</script>

      </head>
        <body class="valid" valid="valid" title="valid: True, node: 1, tag: body, level: 1" node_number="1"> <div class="valid" valid="valid" title="valid: True, node: 2, tag: div, level: 2" node_number="2"> <div class="valid" valid="valid" title="valid: True, node: 3, tag: div, level: 3" node_number="3"> <div class="valid" valid="valid" title="valid: True, node: 4, tag: div, level: 4" node_number="4"> <div class="valid" valid="valid" title="valid: True, node: 5, tag: div, level: 5" node_number="5"> <div class="valid" valid="valid" title="valid: True, node: 6, tag: div, level: 6" node_number="6"> <div class="valid" valid="valid" title="valid: True, node: 7, tag: div, level: 7" node_number="7"> <div class="valid" valid="valid" title="valid: True, node: 8, tag: div, level: 8" node_number="8"> <div class="valid" valid="valid" title="valid: True, node: 9, tag: div, level: 9" node_number="9"> <div class="valid" valid="valid" title="valid: True, node: 10, tag: div, level: 10" node_number="10"> <div class="valid" valid="valid" title="valid: True, node: 11, tag: div, level: 11" node_number="11"> <span class="valid" valid="valid" title="valid: True, node: 12, tag: span, level: 12" node_number="12">Advertisement</span> </div> </div> </div> </div> </div> </div> </div> <header class="valid" valid="valid" title="valid: True, node: 13, tag: header, level: 5" node_number="13"> <div class="valid" valid="valid" title="valid: True, node: 14, tag: div, level: 6" node_number="14"><div class="valid" valid="valid" title="valid: True, node: 15, tag: div, level: 7" node_number="15"><div class="valid" valid="valid" title="valid: True, node: 16, tag: div, level: 8" node_number="16"><div class="valid" valid="valid" title="valid: True, node: 17, tag: div, level: 9" node_number="17"><div class="valid" valid="valid" title="valid: True, node: 18, tag: div, level: 10" node_number="18"><div class="valid" valid="valid" title="valid: True, node: 19, tag: div, level: 11" node_number="19"><div class="valid" valid="valid" title="valid: True, node: 20, tag: div, level: 12" node_number="20"><a class="valid" valid="valid" title="valid: True, node: 21, tag: a, level: 13" node_number="21"><div class="valid" valid="valid" title="valid: True, node: 22, tag: div, level: 14" node_number="22">science</div></a></div></div><div class="valid" valid="valid" title="valid: True, node: 23, tag: div, level: 11" node_number="23"><div class="valid" valid="valid" title="valid: True, node: 24, tag: div, level: 12" node_number="24"><a class="valid" valid="valid" title="valid: True, node: 25, tag: a, level: 13" node_number="25"><div class="valid" valid="valid" title="valid: True, node: 26, tag: div, level: 14" node_number="26">science advances</div></a></div></div><div class="valid" valid="valid" title="valid: True, node: 27, tag: div, level: 11" node_number="27"><div class="valid" valid="valid" title="valid: True, node: 28, tag: div, level: 12" node_number="28"><a class="valid" valid="valid" title="valid: True, node: 29, tag: a, level: 13" node_number="29"><div class="valid" valid="valid" title="valid: True, node: 30, tag: div, level: 14" node_number="30">science immunology</div></a></div></div><div class="valid" valid="valid" title="valid: True, node: 31, tag: div, level: 11" node_number="31"><div class="valid" valid="valid" title="valid: True, node: 32, tag: div, level: 12" node_number="32"><a class="valid" valid="valid" title="valid: True, node: 33, tag: a, level: 13" node_number="33"><div class="valid" valid="valid" title="valid: True, node: 34, tag: div, level: 14" node_number="34">science robotics</div></a></div></div><div class="valid" valid="valid" title="valid: True, node: 35, tag: div, level: 11" node_number="35"><div class="valid" valid="valid" title="valid: True, node: 36, tag: div, level: 12" node_number="36"><a class="valid" valid="valid" title="valid: True, node: 37, tag: a, level: 13" node_number="37"><div class="valid" valid="valid" title="valid: True, node: 38, tag: div, level: 14" node_number="38">science signaling</div></a></div></div><div class="valid" valid="valid" title="valid: True, node: 39, tag: div, level: 11" node_number="39"><div class="valid" valid="valid" title="valid: True, node: 40, tag: div, level: 12" node_number="40"><a class="valid" valid="valid" title="valid: True, node: 41, tag: a, level: 13" node_number="41"><div class="valid" valid="valid" title="valid: True, node: 42, tag: div, level: 14" node_number="42">science translational medicine</div></a></div></div><div class="valid" valid="valid" title="valid: True, node: 43, tag: div, level: 11" node_number="43"><div class="valid" valid="valid" title="valid: True, node: 44, tag: div, level: 12" node_number="44"><a class="valid" valid="valid" title="valid: True, node: 45, tag: a, level: 13" node_number="45"><div class="valid" valid="valid" title="valid: True, node: 46, tag: div, level: 14" node_number="46">science partner journals</div></a></div></div></div></div></div></div></div> <div class="valid" valid="valid" title="valid: True, node: 47, tag: div, level: 6" node_number="47"> <div class="valid" valid="valid" title="valid: True, node: 48, tag: div, level: 7" node_number="48"> <div class="valid" valid="valid" title="valid: True, node: 49, tag: div, level: 8" node_number="49"> <div class="valid" valid="valid" title="valid: True, node: 50, tag: div, level: 9" node_number="50"> <div class="valid" valid="valid" title="valid: True, node: 51, tag: div, level: 10" node_number="51"><div class="valid" valid="valid" title="valid: True, node: 52, tag: div, level: 11" node_number="52"><div class="valid" valid="valid" title="valid: True, node: 53, tag: div, level: 12" node_number="53"><label class="valid" valid="valid" title="valid: True, node: 54, tag: label, level: 13" node_number="54">Searching:</label><div class="valid" valid="valid" title="valid: True, node: 55, tag: div, level: 13" node_number="55"><div class="valid" valid="valid" title="valid: True, node: 56, tag: div, level: 14" node_number="56"><div title="valid: False, node: 57, tag: div, level: 15" node_number="57"><a title="valid: False, node: 58, tag: a, level: 16" node_number="58">Anywhere</a><a title="valid: False, node: 59, tag: a, level: 16" node_number="59">Science</a><a title="valid: False, node: 60, tag: a, level: 16" node_number="60">Science Advances</a><a title="valid: False, node: 61, tag: a, level: 16" node_number="61">Science Immunology</a><a title="valid: False, node: 62, tag: a, level: 16" node_number="62">Science Robotics</a><a title="valid: False, node: 63, tag: a, level: 16" node_number="63">Science Signaling</a><a title="valid: False, node: 64, tag: a, level: 16" node_number="64">Science Translational Medicine</a></div></div></div></div><div class="valid" valid="valid" title="valid: True, node: 65, tag: div, level: 12" node_number="65"> <a class="valid" valid="valid" title="valid: True, node: 66, tag: a, level: 13" node_number="66"><u class="valid" valid="valid" title="valid: True, node: 67, tag: u, level: 14" node_number="67">Advanced Search</u></a> </div></div></div> </div> </div> </div> <div class="valid" valid="valid" title="valid: True, node: 68, tag: div, level: 7" node_number="68"> <div class="valid" valid="valid" title="valid: True, node: 69, tag: div, level: 8" node_number="69"> <div class="valid" valid="valid" title="valid: True, node: 70, tag: div, level: 9" node_number="70"> <h6 class="valid" valid="valid" title="valid: True, node: 71, tag: h6, level: 10" node_number="71">Trending Terms:</h6> <ul class="valid" valid="valid" title="valid: True, node: 72, tag: ul, level: 10" node_number="72"> <li class="valid" valid="valid" title="valid: True, node: 73, tag: li, level: 11" node_number="73"> <a class="valid" valid="valid" title="valid: True, node: 74, tag: a, level: 12" node_number="74">covid-19</a> </li> <li class="valid" valid="valid" title="valid: True, node: 75, tag: li, level: 11" node_number="75"> <a class="valid" valid="valid" title="valid: True, node: 76, tag: a, level: 12" node_number="76">climate</a> </li> <li class="valid" valid="valid" title="valid: True, node: 77, tag: li, level: 11" node_number="77"> <a class="valid" valid="valid" title="valid: True, node: 78, tag: a, level: 12" node_number="78">science policy</a> </li> <li class="valid" valid="valid" title="valid: True, node: 79, tag: li, level: 11" node_number="79"> <a class="valid" valid="valid" title="valid: True, node: 80, tag: a, level: 12" node_number="80">genome editing</a> </li> <li class="valid" valid="valid" title="valid: True, node: 81, tag: li, level: 11" node_number="81"> <a class="valid" valid="valid" title="valid: True, node: 82, tag: a, level: 12" node_number="82">batteries</a> </li> </ul> </div> </div> </div> </div> </header><div class="valid" valid="valid" title="valid: True, node: 83, tag: div, level: 5" node_number="83"><div class="valid" valid="valid" title="valid: True, node: 84, tag: div, level: 6" node_number="84"><div class="valid" valid="valid" title="valid: True, node: 85, tag: div, level: 7" node_number="85"> <div class="valid" valid="valid" title="valid: True, node: 86, tag: div, level: 8" node_number="86"> <div class="valid" valid="valid" title="valid: True, node: 87, tag: div, level: 9" node_number="87"> <ul class="valid" valid="valid" title="valid: True, node: 88, tag: ul, level: 10" node_number="88"> <li class="valid" valid="valid" title="valid: True, node: 89, tag: li, level: 11" node_number="89"> <a class="valid" valid="valid" title="valid: True, node: 90, tag: a, level: 12" node_number="90">Current Issue</a> </li> <li class="valid" valid="valid" title="valid: True, node: 91, tag: li, level: 11" node_number="91"> <a class="valid" valid="valid" title="valid: True, node: 92, tag: a, level: 12" node_number="92">First release papers</a> </li> <li class="valid" valid="valid" title="valid: True, node: 93, tag: li, level: 11" node_number="93"> <a class="valid" valid="valid" title="valid: True, node: 94, tag: a, level: 12" node_number="94">Archive</a> </li> <li class="valid" valid="valid" title="valid: True, node: 95, tag: li, level: 11" node_number="95"> <div class="valid" valid="valid" title="valid: True, node: 96, tag: div, level: 12" node_number="96"> <a class="valid" valid="valid" title="valid: True, node: 97, tag: a, level: 13" node_number="97">About</a> <div class="valid" valid="valid" title="valid: True, node: 98, tag: div, level: 13" node_number="98"> <a class="valid" valid="valid" title="valid: True, node: 99, tag: a, level: 14" node_number="99">About Science</a> <a class="valid" valid="valid" title="valid: True, node: 100, tag: a, level: 14" node_number="100">Mission Scope</a> <a class="valid" valid="valid" title="valid: True, node: 101, tag: a, level: 14" node_number="101">Editors Advisory Boards</a> <a class="valid" valid="valid" title="valid: True, node: 102, tag: a, level: 14" node_number="102">Editorial Policies</a> <a class="valid" valid="valid" title="valid: True, node: 103, tag: a, level: 14" node_number="103">Information for Authors</a> <a class="valid" valid="valid" title="valid: True, node: 104, tag: a, level: 14" node_number="104">Information for Reviewers</a> <a class="valid" valid="valid" title="valid: True, node: 105, tag: a, level: 14" node_number="105">Journal Metrics</a> <a class="valid" valid="valid" title="valid: True, node: 106, tag: a, level: 14" node_number="106">Staff</a> <a class="valid" valid="valid" title="valid: True, node: 107, tag: a, level: 14" node_number="107">Contact Us</a> </div> </div> </li> </ul> </div> <div class="valid" valid="valid" title="valid: True, node: 108, tag: div, level: 9" node_number="108"> <ul class="valid" valid="valid" title="valid: True, node: 109, tag: ul, level: 10" node_number="109"> <li class="valid" valid="valid" title="valid: True, node: 110, tag: li, level: 11" node_number="110"> <a class="valid" valid="valid" title="valid: True, node: 111, tag: a, level: 12" node_number="111">Submit manuscript</a> </li> <li class="valid" valid="valid" title="valid: True, node: 112, tag: li, level: 11" node_number="112"> <div class="valid" valid="valid" title="valid: True, node: 113, tag: div, level: 12" node_number="113"> <a class="valid" valid="valid" title="valid: True, node: 114, tag: a, level: 13" node_number="114">More</a> </div> </li> </ul> </div> </div> <a class="valid" valid="valid" title="valid: True, node: 115, tag: a, level: 8" node_number="115">GET OUR E-ALERTS</a> </div></div></div> <main class="valid" valid="valid" title="valid: True, node: 116, tag: main, level: 5" node_number="116"> <div class="valid" valid="valid" title="valid: True, node: 117, tag: div, level: 6" node_number="117"><div class="valid" valid="valid" title="valid: True, node: 118, tag: div, level: 7" node_number="118"><div class="valid" valid="valid" title="valid: True, node: 119, tag: div, level: 8" node_number="119"><div class="valid" valid="valid" title="valid: True, node: 120, tag: div, level: 9" node_number="120"><div class="valid" valid="valid" title="valid: True, node: 121, tag: div, level: 10" node_number="121"> <div class="valid" valid="valid" title="valid: True, node: 122, tag: div, level: 11" node_number="122"><a class="valid" valid="valid" title="valid: True, node: 123, tag: a, level: 12" node_number="123">Home</a><a class="valid" valid="valid" title="valid: True, node: 124, tag: a, level: 12" node_number="124">Science</a><a class="valid" valid="valid" title="valid: True, node: 125, tag: a, level: 12" node_number="125">First Release</a>4&#8242;-Fluorouridine is an oral antiviral that blocks respiratory syncytial virus and SARS-CoV-2 replication</div><div class="valid" valid="valid" title="valid: True, node: 126, tag: div, level: 11" node_number="126">Back To First Release</div> </div> <article class="valid" valid="valid" title="valid: True, node: 127, tag: article, level: 10" node_number="127"><section class="valid" valid="valid" title="valid: True, node: 128, tag: section, level: 11" node_number="128"><header class="valid" valid="valid" title="valid: True, node: 129, tag: header, level: 12" node_number="129"><div class="valid" valid="valid" title="valid: True, node: 130, tag: div, level: 13" node_number="130"><div class="valid" valid="valid" title="valid: True, node: 131, tag: div, level: 14" node_number="131"><div title="valid: False, node: 132, tag: div, level: 15" node_number="132"><div title="valid: False, node: 133, tag: div, level: 16" node_number="133">OPEN ACCESS</div><div title="valid: False, node: 134, tag: div, level: 16" node_number="134">Research Article</div></div><div title="valid: False, node: 135, tag: div, level: 15" node_number="135"><div title="valid: False, node: 136, tag: div, level: 16" node_number="136"> <div title="valid: False, node: 137, tag: div, level: 17" node_number="137">Share on</div> </div></div></div><h1 class="valid" valid="valid" title="valid: True, node: 138, tag: h1, level: 14" node_number="138">4&#8242;-Fluorouridine is an oral antiviral that blocks respiratory syncytial virus and SARS-CoV-2 replication</h1><div class="valid" valid="valid" title="valid: True, node: 139, tag: div, level: 14" node_number="139">Julien Sourimant https://orcid.org/0000-0002-1660-1666, Carolin M. Lieber, Megha Aggarwal, Robert M. Cox, Josef D. Wolf https://orcid.org/0000-0003-2507-6944, Jeong-Joong Yoon https://orcid.org/0000-0001-9379-0416, Mart Toots, &#8230; Show All &#8230; , Chengin Ye https://orcid.org/0000-0002-1934-9494, Zachary Sticher https://orcid.org/0000-0002-7022-1410, Alexander A. Kolykhalov, Luis Martinez-Sobrido https://orcid.org/0000-0001-7084-0804, Gregory R. Bluemling https://orcid.org/0000-0001-9138-7578, Michael G. Natchus, George R. Painter https://orcid.org/0000-0002-9803-8095, and Richard K. Plemper https://orcid.org/0000-0003-2034-2107 [email&#160;protected] Show Fewer</div><div class="valid" valid="valid" title="valid: True, node: 140, tag: div, level: 14" node_number="140">Science &#8226; 2 Dec 2021 &#8226; First Release &#8226; DOI: 10.1126/science.abj5508</div><div class="valid" valid="valid" title="valid: True, node: 141, tag: div, level: 14" node_number="141"><div title="valid: False, node: 142, tag: div, level: 15" node_number="142"> <div title="valid: False, node: 143, tag: div, level: 16" node_number="143"> <a title="valid: False, node: 144, tag: a, level: 17" node_number="144"><div title="valid: False, node: 145, tag: div, level: 18" node_number="145"><div title="valid: False, node: 146, tag: div, level: 19" node_number="146"><h6 title="valid: False, node: 147, tag: h6, level: 20" node_number="147">PREVIOUS ARTICLE</h6><div title="valid: False, node: 148, tag: div, level: 20" node_number="148">Impact of community masking on COVID-19: A cluster-randomized trial in Bangladesh</div></div></div>Previous</a><a title="valid: False, node: 149, tag: a, level: 17" node_number="149"><div title="valid: False, node: 150, tag: div, level: 18" node_number="150"><div title="valid: False, node: 151, tag: div, level: 19" node_number="151"><h6 title="valid: False, node: 152, tag: h6, level: 20" node_number="152">NEXT ARTICLE</h6><div title="valid: False, node: 153, tag: div, level: 20" node_number="153">Structural basis for continued antibody evasion by the SARS-CoV-2 receptor binding domain</div></div></div>Next</a> </div> </div></div></div></header><div class="valid" valid="valid" title="valid: True, node: 154, tag: div, level: 12" node_number="154"><div class="valid" valid="valid" title="valid: True, node: 155, tag: div, level: 13" node_number="155"><section class="valid" valid="valid" title="valid: True, node: 156, tag: section, level: 14" node_number="156"><h2 title="valid: False, node: 157, tag: h2, level: 15" node_number="157">Abstract</h2><div title="valid: False, node: 158, tag: div, level: 15" node_number="158">The COVID-19 pandemic has underscored the critical need for broad-spectrum therapeutics against respiratory viruses. Respiratory syncytial virus (RSV) is a major threat to pediatric patients and the elderly. We describe 4&#8242;-fluorouridine (4&#8242;-FlU, EIDD-2749), a ribonucleoside analog that inhibits RSV, related RNA viruses, and SARS-CoV-2 with high selectivity index in cells and human airway epithelia organoids. Polymerase inhibition within in vitro RdRP assays established for RSV and SARS-CoV-2 revealed transcriptional stalling after incorporation. Once-daily oral treatment was highly efficacious at 5 mg/kg in RSV-infected mice or 20 mg/kg in ferrets infected with different SARS-CoV-2 variants-of-concern, initiated 24 or 12 hours after infection, respectively. These properties define 4&#8242;-FlU as a broad-spectrum candidate for the treatment of RSV, SARS-CoV-2, and related RNA virus infections.</div></section></div></div></section><section class="valid" valid="valid" title="valid: True, node: 159, tag: section, level: 11" node_number="159"><div class="valid" valid="valid" title="valid: True, node: 160, tag: div, level: 12" node_number="160"><div class="valid" valid="valid" title="valid: True, node: 161, tag: div, level: 13" node_number="161">The COVID-19 experience has highlighted the need for orally-bioavailable broad-spectrum antivirals that could be quickly deployed against newly emerging viral pathogens. Remdesivir&#8212;a direct-acting broad-spectrum antiviral&#8212;is still the only small molecule therapeutic approved for use against SARS-CoV-2 infection in the United States, but it requires intravenous administration. The ensuing restriction to hospitalized patients compromises its clinical effect as treatment is initiated too late in the infection cycle (<a class="valid" valid="valid" title="valid: True, node: 162, tag: a, level: 14" node_number="162"><i title="valid: False, node: 163, tag: i, level: 15" node_number="163">1</i></a>). We have demonstrated efficacy of orally available EIDD-2801 (molnupiravir) against influenza viruses in human organoid models and ferrets (<a class="valid" valid="valid" title="valid: True, node: 164, tag: a, level: 14" node_number="164"><i title="valid: False, node: 165, tag: i, level: 15" node_number="165">2</i></a>), and subsequent animal and human data showed that antiviral efficacy of molnupiravir extends to SARS-CoV-2 in vivo (<a class="valid" valid="valid" title="valid: True, node: 166, tag: a, level: 14" node_number="166"><i title="valid: False, node: 167, tag: i, level: 15" node_number="167">3</i></a>, <a class="valid" valid="valid" title="valid: True, node: 168, tag: a, level: 14" node_number="168"><i title="valid: False, node: 169, tag: i, level: 15" node_number="169">4</i></a>). Molnupiravir acts by inducing lethal viral mutagenesis after incorporation into viral genomic RNA of influenza viruses (<a class="valid" valid="valid" title="valid: True, node: 170, tag: a, level: 14" node_number="170"><i title="valid: False, node: 171, tag: i, level: 15" node_number="171">2</i></a>) and betacoronaviruses (<a class="valid" valid="valid" title="valid: True, node: 172, tag: a, level: 14" node_number="172"><i title="valid: False, node: 173, tag: i, level: 15" node_number="173">5</i></a>). The drug was recently approved in the United Kingdom and is currently considered for emergency use authorization against COVID-19 in the United States. However, even with this accelerated development timeline, molnupiravir only became available to patients nearly two years into the pandemic. To have a substantial effect on a mounting pandemic, an antiviral must be approved for human use before a new pathogen emerges, making the case for the development of broad-spectrum antivirals.</div><div class="valid" valid="valid" title="valid: True, node: 174, tag: div, level: 13" node_number="174">We have identified RSV disease as a viable primary indication for a candidate broad-spectrum antiviral, on the basis of the unmet major health threat imposed by RSV and well-established protocols for clinical trials of anti-RSV therapeutics. RSV infections are responsible for over 58,000 hospitalizations of children below 5 years of age in the United States annually, and approximately 177,000 hospitalizations of adults above the age of 65 (<a class="valid" valid="valid" title="valid: True, node: 175, tag: a, level: 14" node_number="175"><i title="valid: False, node: 176, tag: i, level: 15" node_number="176">6</i></a>&#8211;<a class="valid" valid="valid" title="valid: True, node: 177, tag: a, level: 14" node_number="177"><i title="valid: False, node: 178, tag: i, level: 15" node_number="178">9</i></a>). Despite this major health and economic burden, no therapeutics have been licensed specifically for treatment of RSV disease (<a class="valid" valid="valid" title="valid: True, node: 179, tag: a, level: 14" node_number="179"><i title="valid: False, node: 180, tag: i, level: 15" node_number="180">10</i></a>). Anti-RSV drug discovery efforts have increasingly focused on inhibiting the viral RNA-dependent RNA polymerase (RdRP) complex (<a class="valid" valid="valid" title="valid: True, node: 181, tag: a, level: 14" node_number="181"><i title="valid: False, node: 182, tag: i, level: 15" node_number="182">11</i></a>). The core polymerase machinery comprises the large (L) polymerase protein, its obligatory cofactor, the phosphoprotein (P), and the encapsidated negative-sense RNA genome (<a class="valid" valid="valid" title="valid: True, node: 183, tag: a, level: 14" node_number="183"><i title="valid: False, node: 184, tag: i, level: 15" node_number="184">11</i></a>). Allosteric inhibitors of RSV L have potent activity as seen, for instance, with the experimental drug candidates AVG-233 (<a class="valid" valid="valid" title="valid: True, node: 185, tag: a, level: 14" node_number="185"><i title="valid: False, node: 186, tag: i, level: 15" node_number="186">12</i></a>) and inhaled PC786 (<a class="valid" valid="valid" title="valid: True, node: 187, tag: a, level: 14" node_number="187"><i title="valid: False, node: 188, tag: i, level: 15" node_number="188">13</i></a>).</div><div class="valid" valid="valid" title="valid: True, node: 189, tag: div, level: 13" node_number="189">In search of a drug that is active against RSV and SARS-CoV-2, is orally available, and acts through a distinct mechanism of activity (MOA) from molnupiravir, we explored 4&#8242;-fluorine substitutions in a series of analogs of the molnupiravir parent molecule <i class="valid" valid="valid" title="valid: True, node: 190, tag: i, level: 14" node_number="190">N</i><sup class="valid" valid="valid" title="valid: True, node: 191, tag: sup, level: 14" node_number="191">4</sup>-hydroxycytidine (NHC) (<a class="valid" valid="valid" title="valid: True, node: 192, tag: a, level: 14" node_number="192"><i title="valid: False, node: 193, tag: i, level: 15" node_number="193">14</i></a>). The focus on 4&#8242;-fluorine ribose substitutions was motivated by the small atomic radius and strong stereo-electronic effect of fluorine that can influence backbone conformation flexibility, which may lead to improved selectivity indices, increased lipophilicity, and greater metabolic stability (<a class="valid" valid="valid" title="valid: True, node: 194, tag: a, level: 14" node_number="194"><i title="valid: False, node: 195, tag: i, level: 15" node_number="195">15</i></a>). A synthetic intermediate in the approach to 4&#8242;-fluoro-<i class="valid" valid="valid" title="valid: True, node: 196, tag: i, level: 14" node_number="196">N</i><sup class="valid" valid="valid" title="valid: True, node: 197, tag: sup, level: 14" node_number="197">4</sup>-hydroxycytidine (compound 5 in fig. S1) was deprotected to provide 4&#8242;-FIU (<a class="valid" valid="valid" title="valid: True, node: 198, tag: a, level: 14" node_number="198">Fig. 1A</a>), which emerged as broadly active antiviral when biotested.</div><section class="valid" valid="valid" title="valid: True, node: 199, tag: section, level: 13" node_number="199"><h2 class="valid" valid="valid" title="valid: True, node: 200, tag: h2, level: 14" node_number="200">4&#8242;-FlU is a broad-spectrum mononegavirus inhibitor with high SI</h2><div class="valid" valid="valid" title="valid: True, node: 201, tag: div, level: 14" node_number="201">Following the approach of using RSV disease as a primary indication to advance a novel candidate broad-spectrum antiviral, we first assessed activity of 4&#8242;-FlU against a recombinant RSV A2-line19F (recRSV A2-L19F) (<a title="valid: False, node: 202, tag: a, level: 15" node_number="202"><i title="valid: False, node: 203, tag: i, level: 16" node_number="203">16</i></a>) and clinical RSV isolates on immortalized HEp-2 cells. The compound showed potent dose-dependent activity against all RSV strains tested, returning half-maximal effective concentrations (EC<sub title="valid: False, node: 204, tag: sub, level: 15" node_number="204">50</sub> values) ranging from 0.61 to 1.2 &#956;M (<a title="valid: False, node: 205, tag: a, level: 15" node_number="205">Fig. 1B</a> and table S1). This cell culture potency was on par with the previously reported anti-RSV activity of NHC (fig. S2). Global metabolic activity of established human and animal cell lines (HEp-2, MDCK, BHK-T7, and BEAS-2B) exposed to up to 500 &#956;M of 4&#8242;-FlU remained unaltered, indicating that the antiviral effect is as a result of cytotoxicity (<a title="valid: False, node: 206, tag: a, level: 15" node_number="206">Fig. 1C</a> and table S2). When glucose was replaced with galactose as a carbohydrate source to link cell metabolic activity strictly to mitochondrial oxidation (<a title="valid: False, node: 207, tag: a, level: 15" node_number="207"><i title="valid: False, node: 208, tag: i, level: 16" node_number="208">17</i></a>), we determined a half-maximal cytotoxic concentration (CC<sub title="valid: False, node: 209, tag: sub, level: 15" node_number="209">50</sub>) of 4&#8242;-FlU of 250 &#956;M (<a title="valid: False, node: 210, tag: a, level: 15" node_number="210">Fig. 1C</a> and table S2).</div><div class="valid" valid="valid" title="valid: True, node: 211, tag: div, level: 14" node_number="211">When tested on disease-relevant primary human airway epithelial cells (HAE) derived from two different donors (<a title="valid: False, node: 212, tag: a, level: 15" node_number="212">Fig. 1D</a>), 4&#8242;-FlU showed &#8805;17-fold increased anti-RSV potency relative to that on HEp-2 cells, but unchanged low cytotoxicity (CC<sub title="valid: False, node: 213, tag: sub, level: 15" node_number="213">50</sub> 169 &#956;M) (<a title="valid: False, node: 214, tag: a, level: 15" node_number="214">Fig. 1E</a>), resulting in a high selectivity index (SI = EC<sub title="valid: False, node: 215, tag: sub, level: 15" node_number="215">50</sub>/CC<sub title="valid: False, node: 216, tag: sub, level: 15" node_number="216">50</sub>) of &#8805;1877. Consistent with these findings, quantitative immunocytochemistry on HAE cells confirmed that 4&#8242;-FlU reduced steady-state levels of nuclear-(SDH-A; IC<sub title="valid: False, node: 217, tag: sub, level: 15" node_number="217">50</sub> 272.8 &#956;M) and mitochondrial-(COX-I; IC<sub title="valid: False, node: 218, tag: sub, level: 15" node_number="218">50</sub> 146.8 &#956;M) encoded proteins only at high concentrations (fig. S3).</div><div class="valid" valid="valid" title="valid: True, node: 219, tag: div, level: 14" node_number="219">We next explored the 4&#8242;-FlU indication spectrum. We assessed a panel of negative-sense RNA viruses of the paramyxovirus and rhabdovirus families, including measles virus (MeV), human parainfluenza virus type 3 (HPIV3), Sendai virus (SeV), vesicular stomatitis virus (VSV), and rabies virus (RabV) that, like RSV, belong to the mononegavirus order, and found that the compound demonstrated submicromolar active concentrations (<a title="valid: False, node: 220, tag: a, level: 15" node_number="220">Fig. 1F</a> and table S1). Testing a representative of phylogenetically distant positive-sense RNA viruses, the betacoronavirus SARS-CoV-2 was also sensitive to 4&#8242;-FlU, with EC<sub title="valid: False, node: 221, tag: sub, level: 15" node_number="221">50</sub> values ranging from 0.2 to 0.6 &#956;M against isolates of different lineages (<a title="valid: False, node: 222, tag: a, level: 15" node_number="222">Fig. 1G</a> and table S1).</div><div class="valid" valid="valid" title="valid: True, node: 223, tag: div, level: 14" node_number="223">At initial mechanistic characterization, 4&#8242;-FlU inhibited RSV and paramyxovirus RdRP complex activity in cell-based minireplicon systems (<a title="valid: False, node: 224, tag: a, level: 15" node_number="224">Fig. 1H</a> and table S1). The RdRP activity of Nipah virus (NiV)&#8212;a highly pathogenic zoonotic paramyxovirus with pandemic potential (<a title="valid: False, node: 225, tag: a, level: 15" node_number="225"><i title="valid: False, node: 226, tag: i, level: 16" node_number="226">18</i></a>)&#8212;was also efficiently inhibited by 4&#8242;-FlU in an NiV minireplicon reporter assay. The antiviral effect of 4&#8242;-FlU was dose-dependently reversed by addition of an excess of exogenous pyrimidines (cytidine and uridine) but not purines to the cultured cells, which is consistent with competitive inhibition of RdRP activity (<a title="valid: False, node: 227, tag: a, level: 15" node_number="227"><i title="valid: False, node: 228, tag: i, level: 16" node_number="228">2</i></a>, <a title="valid: False, node: 229, tag: a, level: 15" node_number="229"><i title="valid: False, node: 230, tag: i, level: 16" node_number="230">19</i></a>) (<a title="valid: False, node: 231, tag: a, level: 15" node_number="231">Fig. 1I</a>).</div></section><section class="valid" valid="valid" title="valid: True, node: 232, tag: section, level: 13" node_number="232"><h2 class="valid" valid="valid" title="valid: True, node: 233, tag: h2, level: 14" node_number="233">Incorporation of 4&#8242;-FlU by RSV and SARS-CoV-2 RdRP causes sequence-modulated transcriptional stalling</h2><div class="valid" valid="valid" title="valid: True, node: 234, tag: div, level: 14" node_number="234">To characterize the molecular MOA of 4&#8242;-FlU, we purified recombinant RSV L and P proteins expressed in insect cells (<a title="valid: False, node: 235, tag: a, level: 15" node_number="235">Fig. 2A</a>) and determined performance of the bioactive 5&#8242;-triphosphate form of 4&#8242;-FlU (4&#8242;-FlU-TP) within in vitro primer extension assays (<a title="valid: False, node: 236, tag: a, level: 15" node_number="236"><i title="valid: False, node: 237, tag: i, level: 16" node_number="237">20</i></a>) (<a title="valid: False, node: 238, tag: a, level: 15" node_number="238">Fig. 2B</a>). In the presence of radio-labeled ATP and an increasing amount of UTP, RSV RdRP complexes elongated the primer until reaching a G in third position on the template strand, and continued further upon addition of CTP (<a title="valid: False, node: 239, tag: a, level: 15" node_number="239">Fig. 2C</a>) (fig. S4 and data S1). Replacing UTP with 4&#8242;-FlU-TP resulted in efficient primer extension up to the third nucleotide, confirming that RSV RdRP recognizes and incorporates 4&#8242;-FlU in place of UTP (<a title="valid: False, node: 240, tag: a, level: 15" node_number="240">Fig. 2C</a>). Incorporation kinetics (<a title="valid: False, node: 241, tag: a, level: 15" node_number="241"><i title="valid: False, node: 242, tag: i, level: 16" node_number="242">21</i></a>) showed only a moderate reduction in substrate affinity for 4&#8242;-FlU-TP compared with UTP (<a title="valid: False, node: 243, tag: a, level: 15" node_number="243">Fig. 2D</a>). Further addition of CTP to the reaction mix resulted in limited elongation rather than the expected full-length product, which suggested delayed polymerase stalling by incorporated 4&#8242;-FlU (fig. S4 and data S1). Direct side-by-side comparison with GS-443902&#8212;the active metabolite of remdesivir and a &#8220;delayed polymerase stalling&#8221; inhibitor well-characterized for SARS-CoV-2&#8212;along with RSV and other RNA viruses (<a title="valid: False, node: 244, tag: a, level: 15" node_number="244"><i title="valid: False, node: 245, tag: i, level: 16" node_number="245">21</i></a>, <a title="valid: False, node: 246, tag: a, level: 15" node_number="246"><i title="valid: False, node: 247, tag: i, level: 16" node_number="247">22</i></a>), corroborated this antiviral effect of 4&#8242;FlU-TP (<a title="valid: False, node: 248, tag: a, level: 15" node_number="248">Fig. 2E</a> and data S1).</div><div class="valid" valid="valid" title="valid: True, node: 249, tag: div, level: 14" node_number="249">When a modified template coded for incorporation of only a single UTP (<a title="valid: False, node: 250, tag: a, level: 15" node_number="250">Fig. 2F</a> and data S1), primers elongated preferentially to position <i title="valid: False, node: 251, tag: i, level: 15" node_number="251">i</i>+3 after 4&#8242;-FlU-TP, whereas the efficiency of full elongation was strongly reduced compared with extension in the presence of UTP. However, repositioning the incorporation site further downstream in the template triggered immediate polymerase stalling at position <i title="valid: False, node: 252, tag: i, level: 15" node_number="252">i</i> (fig. S5), indicating template sequence dependence of the inhibitory effect. Transcription stalling at <i title="valid: False, node: 253, tag: i, level: 15" node_number="253">i</i> or <i title="valid: False, node: 254, tag: i, level: 15" node_number="254">i</i>+3 were also observed after multiple 4&#8242;-FlU incorporations: an AxAxxx template (<a title="valid: False, node: 255, tag: a, level: 15" node_number="255">Fig. 2G</a>) and direct tandem incorporations through an AAxxAx template (fig. S5) caused stalling at position <i title="valid: False, node: 256, tag: i, level: 15" node_number="256">i</i>, whereas increasing spacer length between the incorporated uridines shifted preferential stalling to <i title="valid: False, node: 257, tag: i, level: 15" node_number="257">i</i>+3 (fig. S5). This variable delayed polymerase stalling within one to four nucleotides of the incorporation site was equally prominent when we examined de novo initiation of RNA synthesis at the promoter with a synthetic native RSV promoter sequence rather than extension of primer-template pairs (fig. S6).</div><div class="valid" valid="valid" title="valid: True, node: 258, tag: div, level: 14" node_number="258">Purification of a core SARS-CoV-2 polymerase complex [nonstructural proteins (nsp) 7, 8, and 12] from bacterial cell lysates (<a title="valid: False, node: 259, tag: a, level: 15" node_number="259"><i title="valid: False, node: 260, tag: i, level: 16" node_number="260">23</i></a>, <a title="valid: False, node: 261, tag: a, level: 15" node_number="261"><i title="valid: False, node: 262, tag: i, level: 16" node_number="262">24</i></a>) (<a title="valid: False, node: 263, tag: a, level: 15" node_number="263">Fig. 2H</a>) and assessment of RdRP bioactivity in equivalent primer-extension in vitro polymerase assays (<a title="valid: False, node: 264, tag: a, level: 15" node_number="264">Fig. 2I</a>) again demonstrated incorporation of 4&#8242;-FlU-TP in place of UTP by the coronavirus RdRP (<a title="valid: False, node: 265, tag: a, level: 15" node_number="265">Fig. 2J</a>), but no sign of immediate polymerase stalling. However, SARS-CoV-2 polymerase stalling was triggered by multiple incorporations of 4&#8242;-FlU-TP, and was particularly prominent when a second incorporation of 4&#8242;-FlU-TP occurred at the <i title="valid: False, node: 266, tag: i, level: 15" node_number="266">i</i>+4 position (<a title="valid: False, node: 267, tag: a, level: 15" node_number="267">Fig. 2K</a> and fig. S7). Primer extension was blocked when the nsp12 subunit was omitted or an nsp12 variant carrying mutations in the catalytic site was used, confirming specificity of the reaction (fig. S7 and data S1).</div></section><section class="valid" valid="valid" title="valid: True, node: 268, tag: section, level: 13" node_number="268"><h2 class="valid" valid="valid" title="valid: True, node: 269, tag: h2, level: 14" node_number="269">4&#8242;-FlU is rapidly anabolized, metabolically stable, and potently antiviral in disease-relevant well-differentiated HAE cultures</h2><div class="valid" valid="valid" title="valid: True, node: 270, tag: div, level: 14" node_number="270">Quantitation of 4&#8242;-FlU and its anabolites in primary HAE cells (<a title="valid: False, node: 271, tag: a, level: 15" node_number="271">Fig. 3A</a>) demonstrated rapid intracellular accumulation of 4&#8242;-FlU, reaching a level of 3.42 nmol/million cells in the first hour of exposure (<a title="valid: False, node: 272, tag: a, level: 15" node_number="272">Fig. 3B</a>). Anabolism to bioactive 4&#8242;-FlU-TP was efficient, resulting in concentrations of 10.38 nmol/million cells at peak (4 hours after exposure start) and 1.31 nmol/million cells at plateau (24 hours). The anabolite was metabolically stable, remaining present in sustained concentrations of approximately 1 nmol/million cells over a 6-hour monitoring period, corresponding to an extrapolated half-life of 9.7 hours (<a title="valid: False, node: 273, tag: a, level: 15" node_number="273">Fig. 3C</a>).</div><div class="valid" valid="valid" title="valid: True, node: 274, tag: div, level: 14" node_number="274">To explore efficacy in a disease-relevant human tissue model, we cultured the HAEs at the air-liquid interface, inducing the formation of a well-differentiated 3D airway epithelium that included ciliated and mucus-producing cells (<a title="valid: False, node: 275, tag: a, level: 15" node_number="275"><i title="valid: False, node: 276, tag: i, level: 16" node_number="276">25</i></a>) (<a title="valid: False, node: 277, tag: a, level: 15" node_number="277">Fig. 3D</a>). Adding 4&#8242;-FlU to the basolateral chamber of the transwells after apical infection of the epithelium with RSV potently reduced apical virus shedding with an EC<sub title="valid: False, node: 278, tag: sub, level: 15" node_number="278">50</sub> of 55 nM (<a title="valid: False, node: 279, tag: a, level: 15" node_number="279">Fig. 3E</a>). Overall titer reduction spanned nearly four orders of magnitude, ranging from 3.86&#215;10<sup title="valid: False, node: 280, tag: sup, level: 15" node_number="280">4</sup> TCID<sub title="valid: False, node: 281, tag: sub, level: 15" node_number="281">50</sub> in control cells to 78.18 TCID<sub title="valid: False, node: 282, tag: sub, level: 15" node_number="282">50</sub> at 5 &#956;M basolateral 4&#8242;-FlU, approaching the level of detection.</div><div class="valid" valid="valid" title="valid: True, node: 283, tag: div, level: 14" node_number="283">Confocal microscopy validated formation of a pseudostratified organization of the epithelium with tight junctions in the airway epithelium tissue model (<a title="valid: False, node: 284, tag: a, level: 15" node_number="284">Fig. 3F</a>), visualized efficient RSV replication in vehicle-treated tissue models (<a title="valid: False, node: 285, tag: a, level: 15" node_number="285">Fig. 3G</a>), and confirmed near-sterilizing antiviral efficacy in the presence of 50 &#956;M basolateral 4&#8242;-FlU (<a title="valid: False, node: 286, tag: a, level: 15" node_number="286">Fig. 3H</a> and figs. S8 and S9). Under the latter conditions, positive staining for RSV antigen was rarely detected.</div></section><section class="valid" valid="valid" title="valid: True, node: 287, tag: section, level: 13" node_number="287"><h2 class="valid" valid="valid" title="valid: True, node: 288, tag: h2, level: 14" node_number="288">4&#8242;-FlU is orally efficacious in a therapeutic dosing regimen in a small-animal model of RSV infection</h2><div class="valid" valid="valid" title="valid: True, node: 289, tag: div, level: 14" node_number="289">To test 4&#8242;-FlU efficacy in vivo, we employed the mouse model of RSV infection (supplementary text), challenging animals with recRSV-A2-L19F, which efficiently replicates in mice (<a title="valid: False, node: 290, tag: a, level: 15" node_number="290"><i title="valid: False, node: 291, tag: i, level: 16" node_number="291">16</i></a>). In a dose-to-failure study, we infected BALB/cJ mice intranasally and initiated once-daily oral treatment two hours after infection at 0.2, 1, or 5 mg 4&#8242;-FlU/kg body weight. Treatment at all dose levels resulted in a statistically significant reduction in lung virus load compared with vehicle-treated animals (<a title="valid: False, node: 292, tag: a, level: 15" node_number="292">Fig. 4A</a>). The antiviral effect was dose dependent and approached nearly two orders of magnitude at the 5 mg/kg dose. Consistent with high metabolic stability in HAEs, a twice-daily dosing regimen did not significantly enhance efficacy (fig. S10). Becuase animal appearance, body weight, temperature (fig. S11), and relative lymphocyte and platelet counts (<a title="valid: False, node: 293, tag: a, level: 15" node_number="293">Fig. 4B</a> and fig. S12) were unchanged in the 5 mg/kg group compared with vehicle-treated animals, we selected this dose for further studies.</div><div class="valid" valid="valid" title="valid: True, node: 294, tag: div, level: 14" node_number="294">For a longitudinal assessment of therapeutic benefit, we employed an in vivo imaging system (IVIS) with a red-shifted luciferase (<a title="valid: False, node: 295, tag: a, level: 15" node_number="295"><i title="valid: False, node: 296, tag: i, level: 16" node_number="296">26</i></a>) expressing a RSV reporter virus generated for this study. This assay allows a noninvasive spatial appreciation of intrahost viral dissemination. Daily imaging (<a title="valid: False, node: 297, tag: a, level: 15" node_number="297">Fig. 4C</a> and fig. S13) revealed considerable reduction of bioluminescence intensity in lungs of 4&#8242;-FlU-treated animals at day 5 post-infection, corresponding to peak viral replication, independent of whether treatment was initiated 24 hours before or 1 hour after infection (<a title="valid: False, node: 298, tag: a, level: 15" node_number="298">Fig. 4D</a>). This IVIS profile is consistent with reduced viral replication and ameliorated viral pneumonia in treated animals.</div><div class="valid" valid="valid" title="valid: True, node: 299, tag: div, level: 14" node_number="299">To probe the therapeutic window of 4&#8242;-FlU, we initiated treatment at 2, 12, 24, 36, and 48 hours after infection. All treatment groups showed a statistically significant reduction of lung virus burden compared with vehicle-treated animals, but effect size was dependent on the time of treatment initiation (<a title="valid: False, node: 300, tag: a, level: 15" node_number="300">Fig. 4E</a> and fig. S14). On the basis of our experience with therapeutic intervention with related respiratory RNA viruses that cause lethal disease (<a title="valid: False, node: 301, tag: a, level: 15" node_number="301"><i title="valid: False, node: 302, tag: i, level: 16" node_number="302">25</i></a>), we require a reduction of lung virus load of at least one order of magnitude. With this constraint, the therapeutic window of 4&#8242;-FlU extended to 24 hours after infection in mice.</div></section><section class="valid" valid="valid" title="valid: True, node: 303, tag: section, level: 13" node_number="303"><h2 class="valid" valid="valid" title="valid: True, node: 304, tag: h2, level: 14" node_number="304">4&#8242;-FlU is effective against SARS-CoV-2 in HAE and the ferret model</h2><div class="valid" valid="valid" title="valid: True, node: 305, tag: div, level: 14" node_number="305">To test activity against SARS-CoV-2 in the human airway organoids, we first confirmed that the WA1 isolate replicated efficiently in HAEs of all donors tested (<a title="valid: False, node: 306, tag: a, level: 15" node_number="306">Fig. 5, A to C</a>, and fig. S15). Treatment of infected organoids with basolateral 4&#8242;-FlU dose-dependently reduced apical virus shedding, albeit with a limited maximal effect size of approximately two orders of magnitude at 50 &#956;M (<a title="valid: False, node: 307, tag: a, level: 15" node_number="307">Fig. 5D</a>). Confocal microscopy revealed that the epithelium was largely devoid of SARS-CoV-2 nucleocapsid protein under these conditions (<a title="valid: False, node: 308, tag: a, level: 15" node_number="308">Fig. 5E</a>), with only sporadic staining detectable in a small subset of ciliated cells (<a title="valid: False, node: 309, tag: a, level: 15" node_number="309">Fig. 5F</a> and fig. S15).</div><div class="valid" valid="valid" title="valid: True, node: 310, tag: div, level: 14" node_number="310">To probe for a corresponding antiviral effect in vivo, we determined efficacy of oral 4&#8242;-FlU against an early pandemic isolate (WA1) and VoC alpha, gamma, and delta in the ferret model (<a title="valid: False, node: 311, tag: a, level: 15" node_number="311"><i title="valid: False, node: 312, tag: i, level: 16" node_number="312">27</i></a>), which recapitulates hallmarks of uncomplicated human infection (<a title="valid: False, node: 313, tag: a, level: 15" node_number="313"><i title="valid: False, node: 314, tag: i, level: 16" node_number="314">3</i></a>). For dose level selection in ferrets, we determined single oral dose ferret pharmacokinetic (PK) profiles of 4&#8242;-FlU. When administered at 15 or 50 mg/kg, peak plasma concentrations (C<sub title="valid: False, node: 315, tag: sub, level: 15" node_number="315">max</sub>) of 4&#8242;-FlU reached 34.8 and 63.3 &#956;M, respectively, and overall exposure was 154 &#177; 27.6 and 413.1 &#177; 78.1 hours&#215;nmol/ml, respectively, revealing good oral dose-proportionality (<a title="valid: False, node: 316, tag: a, level: 15" node_number="316">Fig. 6A</a> and table S3). On the basis of this PK performance, we selected once-daily dosing at 20 mg/kg body weight for efficacy tests (<a title="valid: False, node: 317, tag: a, level: 15" node_number="317">Fig. 6B</a>).</div><div class="valid" valid="valid" title="valid: True, node: 318, tag: div, level: 14" node_number="318">Intranasal infection of ferrets with 1&#215;10<sup title="valid: False, node: 319, tag: sup, level: 15" node_number="319">5</sup> PFU of each isolate resulted in rapid viral shedding into the upper respiratory tract, which plateaued in vehicle-treated animals 48 to 60 hours after infection (<a title="valid: False, node: 320, tag: a, level: 15" node_number="320">Fig. 6C</a>). Therapeutic treatment with 4&#8242;-FlU initiated 12 hours after infection reduced virus burden in nasal lavages by approximately three orders of magnitude (WA1) to &lt;50 PFU/ml within 12 hours of treatment onset. All three VoC were highly sensitive to 4&#8242;-FlU, remaining below the level of detection 36 to 48 hours after onset of oral treatment. Viral titers in nasal turbinate tissue extracted 4 days after infection (<a title="valid: False, node: 321, tag: a, level: 15" node_number="321">Fig. 6D</a>) and associated viral RNA copy numbers (fig. S16) correlated with this reduction in shed virus load. Shedding of infectious particles ceased completely in all animals after 2.5 days of treatment (3 days post-infection).</div></section><section class="valid" valid="valid" title="valid: True, node: 322, tag: section, level: 13" node_number="322"><h2 class="valid" valid="valid" title="valid: True, node: 323, tag: h2, level: 14" node_number="323">Conclusions</h2><div class="valid" valid="valid" title="valid: True, node: 324, tag: div, level: 14" node_number="324">This study identifies and characterizes the ribonucleoside analog 4&#8242;-FlU, which potently inhibits pathogens of different clinically-relevant negative and positive-sense RNA virus families. The compound causes delayed stalling of RSV and SARS-CoV-2 polymerases within in vitro RdRP assays, reminiscent of the antiviral effect of remdesivir (<a title="valid: False, node: 325, tag: a, level: 15" node_number="325"><i title="valid: False, node: 326, tag: i, level: 16" node_number="326">28</i></a>, <a title="valid: False, node: 327, tag: a, level: 15" node_number="327"><i title="valid: False, node: 328, tag: i, level: 16" node_number="328">29</i></a>). However, 4&#8242;-FlU can also trigger immediate RdRP stalling depending on sequence context, suggesting steric hindrance of polymerase advance or of accommodating the next incoming nucleotide as the underlying MOA. We cannot exclude that additional effects further enhance the antiviral effect in cellula as proposed for other nucleoside analogs (<a title="valid: False, node: 329, tag: a, level: 15" node_number="329"><i title="valid: False, node: 330, tag: i, level: 16" node_number="330">30</i></a>). Slightly lower sensitivity of SARS-CoV-2 to 4&#8242;-FlU compared with RSV could be a result of the exonuclease activity of the coronavirus polymerase, which can eliminate ribonucleoside analogs (<a title="valid: False, node: 331, tag: a, level: 15" node_number="331"><i title="valid: False, node: 332, tag: i, level: 16" node_number="332">31</i></a>, <a title="valid: False, node: 333, tag: a, level: 15" node_number="333"><i title="valid: False, node: 334, tag: i, level: 16" node_number="334">32</i></a>). Alternatively, coronavirus RdRP may have a greater capacity to tolerate the compound, because SARS-CoV-2 RdRP showed a higher tendency than RSV polymerase to advance after 4&#8242;-FlU-TP incorporation in the RdRP assays, which do not contain exonuclease functionality.</div><div class="valid" valid="valid" title="valid: True, node: 335, tag: div, level: 14" node_number="335">Once-daily oral administration to mice and ferrets significantly reduced the burden of RSV and SARS-CoV-2, respectively, when treatment was initiated up to 24 (RSV) or 12 (SARS-CoV-2) hours after infection. Because RSV (<a title="valid: False, node: 336, tag: a, level: 15" node_number="336"><i title="valid: False, node: 337, tag: i, level: 16" node_number="337">33</i></a>) and SARS-CoV-2 (<a title="valid: False, node: 338, tag: a, level: 15" node_number="338"><i title="valid: False, node: 339, tag: i, level: 16" node_number="339">34</i></a>) host invasion is slower in humans, these data outline a viable therapeutic window for human treatment. Equally potent activity against SARS-CoV-2 VoC alpha, gamma, and delta demonstrated broad anti-coronavirus efficacy of 4&#8242;-FlU, building confidence that the compound will remain active against future VoC that may be increasingly less responsive to spike-targeting vaccines or antibody therapeutics. Formal tolerability studies are pending, but 4&#8242;-FlU was well tolerated by the human organoid models and efficacious in murids and mustelids. Blood analysis of treated mice uncovered no antiproliferative effect of 4&#8242;-FlU on the hematopoietic system. These results establish 4&#8242;-FlU as a broad-spectrum orally efficacious inhibitor of major RNA viruses, making it a promising therapeutic option for RSV disease and COVID-19, and a much-needed contributor to improving pandemic preparedness.</div></section><section class="valid" valid="valid" title="valid: True, node: 340, tag: section, level: 13" node_number="340"><h2 class="valid" valid="valid" title="valid: True, node: 341, tag: h2, level: 14" node_number="341">Acknowledgments</h2><div class="valid" valid="valid" title="valid: True, node: 342, tag: div, level: 14" node_number="342">We thank C. F. Basler for providing Calu-3 cells, D. Waugh for plasmid pRK792 encoding TEV protease (Addgene plasmid #8830), the Georgia State University High Containment Core and the Department for Animal Research for support, and A. L. Hammond for critical reading of the manuscript. <b title="valid: False, node: 343, tag: b, level: 15" node_number="343">Funding: </b>This work was supported, in part, by Public Health Service grants AI153400, AI071002, and AI141222 (to R.K.P.), from the NIH/NIAID. The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication. <b title="valid: False, node: 344, tag: b, level: 15" node_number="344">Author contributions:</b> Conceptualization: M.G.N., G.R.P., and R.K.P. Investigation: J.S., R.M.C., M.T., J.Y., C.M.L., M.A., J.D.W., Z.S., and R.K.P. Resources: G.R.B., A.A.K., L.M.S., and R.K.P. Visualization: G.R.B. and J.S. Validation: J.S. and R.K.P. Funding acquisition: R.K.P. Project administration: M.G.N. and R.K.P. Supervision: G.R.P. and R.K.P. Writing &#8211; original draft: J.S. and R.K.P. Writing &#8211; review and editing: J.S. and R.K.P. <b title="valid: False, node: 345, tag: b, level: 15" node_number="345">Competing interests:</b> G.R.B. and G.R.P. are coinventors on patent WO 2019/1736002 covering composition of matter and use of EIDD-2749 and its analogs as an antiviral treatment. This study could affect their personal financial status. All other authors declare that they have no competing interests. <b title="valid: False, node: 346, tag: b, level: 15" node_number="346">Data and materials availability:</b> All data are available in the main text or the supplementary materials. Materials and methods are available as supplementary materials at the Science website. Transfer of EIDD-2749 material to other institutions for research purposes is covered by MTAs from Emory University. This work is licensed under a Creative Commons Attribution 4.0 International (CC BY 4.0) license, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. To view a copy of this license, visit <a title="valid: False, node: 347, tag: a, level: 15" node_number="347">https://creativecommons.org/licenses/by/4.0/</a>. This license does not apply to figures/photos/artwork or other content included in the article that is credited to a third party; obtain authorization from the rights holder before using such material.</div></section> </div></section><section class="valid" valid="valid" title="valid: True, node: 348, tag: section, level: 11" node_number="348"><div class="valid" valid="valid" title="valid: True, node: 349, tag: div, level: 12" node_number="349"><section class="valid" valid="valid" title="valid: True, node: 350, tag: section, level: 13" node_number="350"><h2 class="valid" valid="valid" title="valid: True, node: 351, tag: h2, level: 14" node_number="351">Supplementary Material</h2><section class="valid" valid="valid" title="valid: True, node: 352, tag: section, level: 14" node_number="352"><h3 title="valid: False, node: 353, tag: h3, level: 15" node_number="353">Summary</h3><div title="valid: False, node: 354, tag: div, level: 15" node_number="354"><a title="valid: False, node: 355, tag: a, level: 16" node_number="355">science.org/doi/10.1126/science.abj5508</a></div><div title="valid: False, node: 356, tag: div, level: 15" node_number="356">Materials and Methods</div><div title="valid: False, node: 357, tag: div, level: 15" node_number="357">Supplementary Text</div><div title="valid: False, node: 358, tag: div, level: 15" node_number="358">Figs. S1 to S18</div><div title="valid: False, node: 359, tag: div, level: 15" node_number="359">Tables S1 to S3 </div><div title="valid: False, node: 360, tag: div, level: 15" node_number="360">References (<a title="valid: False, node: 361, tag: a, level: 16" node_number="361"><i title="valid: False, node: 362, tag: i, level: 17" node_number="362">35</i></a>, <a title="valid: False, node: 363, tag: a, level: 16" node_number="363"><i title="valid: False, node: 364, tag: i, level: 17" node_number="364">36</i></a>)</div><div title="valid: False, node: 365, tag: div, level: 15" node_number="365">MDAR Reproducibility Checklist</div><div title="valid: False, node: 366, tag: div, level: 15" node_number="366">Data S1 and S2</div></section><section class="valid" valid="valid" title="valid: True, node: 367, tag: section, level: 14" node_number="367"><h3 title="valid: False, node: 368, tag: h3, level: 15" node_number="368">Resources</h3><div title="valid: False, node: 369, tag: div, level: 15" node_number="369"><div title="valid: False, node: 370, tag: div, level: 16" node_number="370"><div title="valid: False, node: 371, tag: div, level: 17" node_number="371">File (science.abj5508-sm.pdf)</div><div title="valid: False, node: 372, tag: div, level: 17" node_number="372">Download</div></div><div title="valid: False, node: 373, tag: div, level: 16" node_number="373"><div title="valid: False, node: 374, tag: div, level: 17" node_number="374">File (science.abj5508_data_s1_and_s2.zip)</div><div title="valid: False, node: 375, tag: div, level: 17" node_number="375">Download</div></div><div title="valid: False, node: 376, tag: div, level: 16" node_number="376"><div title="valid: False, node: 377, tag: div, level: 17" node_number="377">File (science.abj5508_mdar_reproducibility_checklist.pdf)</div><div title="valid: False, node: 378, tag: div, level: 17" node_number="378">Download</div></div></div></section></section><section class="valid" valid="valid" title="valid: True, node: 379, tag: section, level: 13" node_number="379"><h2 class="valid" valid="valid" title="valid: True, node: 380, tag: h2, level: 14" node_number="380">References and Notes</h2><div class="valid" valid="valid" title="valid: True, node: 381, tag: div, level: 14" node_number="381"><div title="valid: False, node: 382, tag: div, level: 15" node_number="382">1</div><div title="valid: False, node: 383, tag: div, level: 15" node_number="383"><div title="valid: False, node: 384, tag: div, level: 16" node_number="384"><div title="valid: False, node: 385, tag: div, level: 17" node_number="385">J. H. Beigel, K. M. Tomashek, L. E. Dodd, A. K. Mehta, B. S. Zingman, A. C. Kalil, E. Hohmann, H. Y. Chu, A. Luetkemeyer, S. Kline, D. Lopez de Castilla, R. W. Finberg, K. Dierberg, V. Tapson, L. Hsieh, T. F. Patterson, R. Paredes, D. A. Sweeney, W. R. Short, G. Touloumi, D. C. Lye, N. Ohmagari, M. D. Oh, G. M. Ruiz-Palacios, T. Benfield, G. F&#228;tkenheuer, M. G. Kortepeter, R. L. Atmar, C. B. Creech, J. Lundgren, A. G. Babiker, S. Pett, J. D. Neaton, T. H. Burgess, T. Bonnett, M. Green, M. Makowski, A. Osinusi, S. Nayak, H. C. Lane; ACTT-1 Study Group Members, Remdesivir for the Treatment of Covid-19 - Final Report. N. Engl. J. Med. <b title="valid: False, node: 386, tag: b, level: 18" node_number="386">383</b>, 1813&#8211;1826 (2020).</div><div title="valid: False, node: 387, tag: div, level: 17" node_number="387"><div title="valid: False, node: 388, tag: div, level: 18" node_number="388">Crossref</div><div title="valid: False, node: 389, tag: div, level: 18" node_number="389"><a title="valid: False, node: 390, tag: a, level: 19" node_number="390">PubMed</a></div><div title="valid: False, node: 391, tag: div, level: 18" node_number="391"><a title="valid: False, node: 392, tag: a, level: 19" node_number="392">Google Scholar</a></div></div></div></div></div><div class="valid" valid="valid" title="valid: True, node: 393, tag: div, level: 14" node_number="393"><div title="valid: False, node: 394, tag: div, level: 15" node_number="394">2</div><div title="valid: False, node: 395, tag: div, level: 15" node_number="395"><div title="valid: False, node: 396, tag: div, level: 16" node_number="396"><div title="valid: False, node: 397, tag: div, level: 17" node_number="397">M. Toots, J.-J. Yoon, R. M. Cox, M. Hart, Z. M. Sticher, N. Makhsous, R. Plesker, A. H. Barrena, P. G. Reddy, D. G. Mitchell, R. C. Shean, G. R. Bluemling, A. A. Kolykhalov, A. L. Greninger, M. G. Natchus, G. R. Painter, R. K. Plemper, Characterization of orally efficacious influenza drug with high resistance barrier in ferrets and human airway epithelia. Sci. Transl. Med. <b title="valid: False, node: 398, tag: b, level: 18" node_number="398">11</b>, eaax5866 (2019).</div><div title="valid: False, node: 399, tag: div, level: 17" node_number="399"><div title="valid: False, node: 400, tag: div, level: 18" node_number="400"><a title="valid: False, node: 401, tag: a, level: 19" node_number="401">Crossref</a></div><div title="valid: False, node: 402, tag: div, level: 18" node_number="402"><a title="valid: False, node: 403, tag: a, level: 19" node_number="403">PubMed</a></div><div title="valid: False, node: 404, tag: div, level: 18" node_number="404"><a title="valid: False, node: 405, tag: a, level: 19" node_number="405">Google Scholar</a></div></div></div></div></div><div class="valid" valid="valid" title="valid: True, node: 406, tag: div, level: 14" node_number="406"><div title="valid: False, node: 407, tag: div, level: 15" node_number="407">3</div><div title="valid: False, node: 408, tag: div, level: 15" node_number="408"><div title="valid: False, node: 409, tag: div, level: 16" node_number="409"><div title="valid: False, node: 410, tag: div, level: 17" node_number="410">R. M. Cox, J. D. Wolf, R. K. Plemper, Therapeutically administered ribonucleoside analogue MK-4482/EIDD-2801 blocks SARS-CoV-2 transmission in ferrets. Nat. Microbiol. <b title="valid: False, node: 411, tag: b, level: 18" node_number="411">6</b>, 11&#8211;18 (2021).</div><div title="valid: False, node: 412, tag: div, level: 17" node_number="412"><div title="valid: False, node: 413, tag: div, level: 18" node_number="413"><a title="valid: False, node: 414, tag: a, level: 19" node_number="414">Crossref</a></div><div title="valid: False, node: 415, tag: div, level: 18" node_number="415"><a title="valid: False, node: 416, tag: a, level: 19" node_number="416">PubMed</a></div><div title="valid: False, node: 417, tag: div, level: 18" node_number="417"><a title="valid: False, node: 418, tag: a, level: 19" node_number="418">Google Scholar</a></div></div></div></div></div><div class="valid" valid="valid" title="valid: True, node: 419, tag: div, level: 14" node_number="419"><div title="valid: False, node: 420, tag: div, level: 15" node_number="420">4</div><div title="valid: False, node: 421, tag: div, level: 15" node_number="421"><div title="valid: False, node: 422, tag: div, level: 16" node_number="422"><div title="valid: False, node: 423, tag: div, level: 17" node_number="423">G. R. Painter, R. A. Bowen, G. R. Bluemling, J. DeBergh, V. Edpuganti, P. R. Gruddanti, D. B. Guthrie, M. Hager, D. L. Kuiper, M. A. Lockwood, D. G. Mitchell, M. G. Natchus, Z. M. Sticher, A. A. Kolykhalov, The prophylactic and therapeutic activity of a broadly active ribonucleoside analog in a murine model of intranasal venezuelan equine encephalitis virus infection. Antiviral Res. <b title="valid: False, node: 424, tag: b, level: 18" node_number="424">171</b>, 104597 (2019).</div><div title="valid: False, node: 425, tag: div, level: 17" node_number="425"><div title="valid: False, node: 426, tag: div, level: 18" node_number="426"><a title="valid: False, node: 427, tag: a, level: 19" node_number="427">Crossref</a></div><div title="valid: False, node: 428, tag: div, level: 18" node_number="428"><a title="valid: False, node: 429, tag: a, level: 19" node_number="429">PubMed</a></div><div title="valid: False, node: 430, tag: div, level: 18" node_number="430"><a title="valid: False, node: 431, tag: a, level: 19" node_number="431">Google Scholar</a></div></div></div></div></div><div class="valid" valid="valid" title="valid: True, node: 432, tag: div, level: 14" node_number="432"><div title="valid: False, node: 433, tag: div, level: 15" node_number="433">5</div><div title="valid: False, node: 434, tag: div, level: 15" node_number="434"><div title="valid: False, node: 435, tag: div, level: 16" node_number="435"><div title="valid: False, node: 436, tag: div, level: 17" node_number="436">T. P. Sheahan, A. C. Sims, S. Zhou, R. L. Graham, A. J. Pruijssers, M. L. Agostini, S. R. Leist, A. Sch&#228;fer, K. H. Dinnon 3rd, L. J. Stevens, J. D. Chappell, X. Lu, T. M. Hughes, A. S. George, C. S. Hill, S. A. Montgomery, A. J. Brown, G. R. Bluemling, M. G. Natchus, M. Saindane, A. A. Kolykhalov, G. Painter, J. Harcourt, A. Tamin, N. J. Thornburg, R. Swanstrom, M. R. Denison, R. S. Baric, An orally bioavailable broad-spectrum antiviral inhibits SARS-CoV-2 in human airway epithelial cell cultures and multiple coronaviruses in mice. Sci. Transl. Med. <b title="valid: False, node: 437, tag: b, level: 18" node_number="437">12</b>, eabb5883 (2020).</div><div title="valid: False, node: 438, tag: div, level: 17" node_number="438"><div title="valid: False, node: 439, tag: div, level: 18" node_number="439"><a title="valid: False, node: 440, tag: a, level: 19" node_number="440">Crossref</a></div><div title="valid: False, node: 441, tag: div, level: 18" node_number="441"><a title="valid: False, node: 442, tag: a, level: 19" node_number="442">PubMed</a></div><div title="valid: False, node: 443, tag: div, level: 18" node_number="443"><a title="valid: False, node: 444, tag: a, level: 19" node_number="444">Google Scholar</a></div></div></div></div></div><div class="valid" valid="valid" title="valid: True, node: 445, tag: div, level: 14" node_number="445"><div title="valid: False, node: 446, tag: div, level: 15" node_number="446">6</div><div title="valid: False, node: 447, tag: div, level: 15" node_number="447"><div title="valid: False, node: 448, tag: div, level: 16" node_number="448"><div title="valid: False, node: 449, tag: div, level: 17" node_number="449">A. R. Falsey, P. A. Hennessey, M. A. Formica, C. Cox, E. E. Walsh, Respiratory syncytial virus infection in elderly and high-risk adults. N. Engl. J. Med. <b title="valid: False, node: 450, tag: b, level: 18" node_number="450">352</b>, 1749&#8211;1759 (2005).</div><div title="valid: False, node: 451, tag: div, level: 17" node_number="451"><div title="valid: False, node: 452, tag: div, level: 18" node_number="452"><a title="valid: False, node: 453, tag: a, level: 19" node_number="453">Crossref</a></div><div title="valid: False, node: 454, tag: div, level: 18" node_number="454"><a title="valid: False, node: 455, tag: a, level: 19" node_number="455">PubMed</a></div><div title="valid: False, node: 456, tag: div, level: 18" node_number="456"><a title="valid: False, node: 457, tag: a, level: 19" node_number="457">Google Scholar</a></div></div></div></div></div><div class="valid" valid="valid" title="valid: True, node: 458, tag: div, level: 14" node_number="458"><div title="valid: False, node: 459, tag: div, level: 15" node_number="459">7</div><div title="valid: False, node: 460, tag: div, level: 15" node_number="460"><div title="valid: False, node: 461, tag: div, level: 16" node_number="461"><div title="valid: False, node: 462, tag: div, level: 17" node_number="462">B. Rha, A. T. Curns, J. Y. Lively, A. P. Campbell, J. A. Englund, J. A. Boom, P. H. Azimi, G. A. Weinberg, M. A. Staat, R. Selvarangan, N. B. Halasa, M. M. McNeal, E. J. Klein, C. J. Harrison, J. V. Williams, P. G. Szilagyi, M. N. Singer, L. C. Sahni, D. Figueroa-Downing, D. McDaniel, M. M. Prill, B. L. Whitaker, L. S. Stewart, J. E. Schuster, B. A. Pahud, G. Weddle, V. Avadhanula, F. M. Munoz, P. A. Piedra, D. C. Payne, G. Langley, S. I. Gerber, Respiratory Syncytial Virus-Associated Hospitalizations Among Young Children: 2015-2016. Pediatrics <b title="valid: False, node: 463, tag: b, level: 18" node_number="463">146</b>, e20193611 (2020).</div><div title="valid: False, node: 464, tag: div, level: 17" node_number="464"><div title="valid: False, node: 465, tag: div, level: 18" node_number="465"><a title="valid: False, node: 466, tag: a, level: 19" node_number="466">Crossref</a></div><div title="valid: False, node: 467, tag: div, level: 18" node_number="467"><a title="valid: False, node: 468, tag: a, level: 19" node_number="468">PubMed</a></div><div title="valid: False, node: 469, tag: div, level: 18" node_number="469"><a title="valid: False, node: 470, tag: a, level: 19" node_number="470">Google Scholar</a></div></div></div></div></div><div class="valid" valid="valid" title="valid: True, node: 471, tag: div, level: 14" node_number="471"><div title="valid: False, node: 472, tag: div, level: 15" node_number="472">8</div><div title="valid: False, node: 473, tag: div, level: 15" node_number="473"><div title="valid: False, node: 474, tag: div, level: 16" node_number="474"><div title="valid: False, node: 475, tag: div, level: 17" node_number="475">T. Shi, A. Denouel, A. K. Tietjen, I. Campbell, E. Moran, X. Li, H. Campbell, C. Demont, B. O. Nyawanda, H. Y. Chu, S. K. Stoszek, A. Krishnan, P. Openshaw, A. R. Falsey, H. Nair, H. Nair, H. Campbell, T. Shi, S. Zhang, Y. Li, P. Openshaw, J. Wedzicha, A. Falsey, M. Miller, P. Beutels, L. Bont, A. Pollard, E. Molero, F. Martinon-Torres, T. Heikkinen, A. Meijer, T. K. Fischer, M. van den Berge, C. Giaquinto, R. Mikolajczyk, J. Hackett, B. Cai, C. Knirsch, A. Leach, S. K. Stoszek, S. Gallichan, A. Kieffer, C. Demont, A. Denouel, A. Cheret, S. Gavart, J. Aerssens, R. Fuentes, B. Rosen, H. Nair, H. Campbell, T. Shi, S. Zhang, Y. Li, P. Openshaw, J. Wedzicha, A. Falsey, M. Miller, P. Beutels, L. Bont, A. Pollard, E. Molero, F. Martinon-Torres, T. Heikkinen, A. Meijer, T. K. Fischer, M. van den Berge, C. Giaquinto, R. Mikolajczyk, J. Hackett, B. Cai, C. Knirsch, A. Leach, S. K. Stoszek, S. Gallichan, A. Kieffer, C. Demont, A. Denouel, A. Cheret, S. Gavart, J. Aerssens, R. Fuentes, B. Rosen; RESCEU Investigators, Global Disease Burden Estimates of Respiratory Syncytial Virus-Associated Acute Respiratory Infection in Older Adults in 2015: A Systematic Review and Meta-Analysis. J. Infect. Dis. <b title="valid: False, node: 476, tag: b, level: 18" node_number="476">222</b> (Suppl 7), S577&#8211;S583 (2020).</div><div title="valid: False, node: 477, tag: div, level: 17" node_number="477"><div title="valid: False, node: 478, tag: div, level: 18" node_number="478"><a title="valid: False, node: 479, tag: a, level: 19" node_number="479">Crossref</a></div><div title="valid: False, node: 480, tag: div, level: 18" node_number="480"><a title="valid: False, node: 481, tag: a, level: 19" node_number="481">PubMed</a></div><div title="valid: False, node: 482, tag: div, level: 18" node_number="482"><a title="valid: False, node: 483, tag: a, level: 19" node_number="483">Google Scholar</a></div></div></div></div></div><div class="valid" valid="valid" title="valid: True, node: 484, tag: div, level: 14" node_number="484"><div title="valid: False, node: 485, tag: div, level: 15" node_number="485">9</div><div title="valid: False, node: 486, tag: div, level: 15" node_number="486"><div title="valid: False, node: 487, tag: div, level: 16" node_number="487"><div title="valid: False, node: 488, tag: div, level: 17" node_number="488">T. Shi, D. A. McAllister, K. L. O&#8217;Brien, E. A. F. Simoes, S. A. Madhi, B. D. Gessner, F. P. Polack, E. Balsells, S. Acacio, C. Aguayo, I. Alassani, A. Ali, M. Antonio, S. Awasthi, J. O. Awori, E. Azziz-Baumgartner, H. C. Baggett, V. L. Baillie, A. Balmaseda, A. Barahona, S. Basnet, Q. Bassat, W. Basualdo, G. Bigogo, L. Bont, R. F. Breiman, W. A. Brooks, S. Broor, N. Bruce, D. Bruden, P. Buchy, S. Campbell, P. Carosone-Link, M. Chadha, J. Chipeta, M. Chou, W. Clara, C. Cohen, E. de Cuellar, D.-A. Dang, B. Dash-Yandag, M. Deloria-Knoll, M. Dherani, T. Eap, B. E. Ebruke, M. Echavarria, C. C. de Freitas L&#225;zaro Emediato, R. A. Fasce, D. R. Feikin, L. Feng, A. Gentile, A. Gordon, D. Goswami, S. Goyet, M. Groome, N. Halasa, S. Hirve, N. Homaira, S. R. C. Howie, J. Jara, I. Jroundi, C. B. Kartasasmita, N. Khuri-Bulos, K. L. Kotloff, A. Krishnan, R. Libster, O. Lopez, M. G. Lucero, F. Lucion, S. P. Lupisan, D. N. Marcone, J. P. McCracken, M. Mejia, J. C. Moisi, J. M. Montgomery, D. P. Moore, C. Moraleda, J. Moyes, P. Munywoki, K. Mutyara, M. P. Nicol, D. J. Nokes, P. Nymadawa, M. T. da Costa Oliveira, H. Oshitani, N. Pandey, G. Paranhos-Baccal&#224;, L. N. Phillips, V. S. Picot, M. Rahman, M. Rakoto-Andrianarivelo, Z. A. Rasmussen, B. A. Rath, A. Robinson, C. Romero, G. Russomando, V. Salimi, P. Sawatwong, N. Scheltema, B. Schweiger, J. A. G. Scott, P. Seidenberg, K. Shen, R. Singleton, V. Sotomayor, T. A. Strand, A. Sutanto, M. Sylla, M. D. Tapia, S. Thamthitiwat, E. D. Thomas, R. Tokarz, C. Turner, M. Venter, S. Waicharoen, J. Wang, W. Watthanaworawit, L.-M. Yoshida, H. Yu, H. J. Zar, H. Campbell, H. Nair; RSV Global Epidemiology Network, Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in young children in 2015: A systematic review and modelling study. Lancet <b title="valid: False, node: 489, tag: b, level: 18" node_number="489">390</b>, 946&#8211;958 (2017).</div><div title="valid: False, node: 490, tag: div, level: 17" node_number="490"><div title="valid: False, node: 491, tag: div, level: 18" node_number="491"><a title="valid: False, node: 492, tag: a, level: 19" node_number="492">Crossref</a></div><div title="valid: False, node: 493, tag: div, level: 18" node_number="493"><a title="valid: False, node: 494, tag: a, level: 19" node_number="494">PubMed</a></div><div title="valid: False, node: 495, tag: div, level: 18" node_number="495"><a title="valid: False, node: 496, tag: a, level: 19" node_number="496">Google Scholar</a></div></div></div></div></div><div class="valid" valid="valid" title="valid: True, node: 497, tag: div, level: 14" node_number="497"><div title="valid: False, node: 498, tag: div, level: 15" node_number="498">10</div><div title="valid: False, node: 499, tag: div, level: 15" node_number="499"><div title="valid: False, node: 500, tag: div, level: 16" node_number="500"><div title="valid: False, node: 501, tag: div, level: 17" node_number="501">G. S. Cockerill, J. A. D. Good, N. Mathews, State of the Art in Respiratory Syncytial Virus Drug Discovery and Development. J. Med. Chem. <b title="valid: False, node: 502, tag: b, level: 18" node_number="502">62</b>, 3206&#8211;3227 (2019).</div><div title="valid: False, node: 503, tag: div, level: 17" node_number="503"><div title="valid: False, node: 504, tag: div, level: 18" node_number="504"><a title="valid: False, node: 505, tag: a, level: 19" node_number="505">Crossref</a></div><div title="valid: False, node: 506, tag: div, level: 18" node_number="506"><a title="valid: False, node: 507, tag: a, level: 19" node_number="507">PubMed</a></div><div title="valid: False, node: 508, tag: div, level: 18" node_number="508"><a title="valid: False, node: 509, tag: a, level: 19" node_number="509">Google Scholar</a></div></div></div></div></div><div class="valid" valid="valid" title="valid: True, node: 510, tag: div, level: 14" node_number="510"><div title="valid: False, node: 511, tag: div, level: 15" node_number="511">11</div><div title="valid: False, node: 512, tag: div, level: 15" node_number="512"><div title="valid: False, node: 513, tag: div, level: 16" node_number="513"><div title="valid: False, node: 514, tag: div, level: 17" node_number="514">R. Fearns, R. K. Plemper, Polymerases of paramyxoviruses and pneumoviruses. Virus Res. <b title="valid: False, node: 515, tag: b, level: 18" node_number="515">234</b>, 87&#8211;102 (2017).</div><div title="valid: False, node: 516, tag: div, level: 17" node_number="516"><div title="valid: False, node: 517, tag: div, level: 18" node_number="517"><a title="valid: False, node: 518, tag: a, level: 19" node_number="518">Crossref</a></div><div title="valid: False, node: 519, tag: div, level: 18" node_number="519"><a title="valid: False, node: 520, tag: a, level: 19" node_number="520">PubMed</a></div><div title="valid: False, node: 521, tag: div, level: 18" node_number="521"><a title="valid: False, node: 522, tag: a, level: 19" node_number="522">Google Scholar</a></div></div></div></div></div><div class="valid" valid="valid" title="valid: True, node: 523, tag: div, level: 14" node_number="523"><div title="valid: False, node: 524, tag: div, level: 15" node_number="524">12</div><div title="valid: False, node: 525, tag: div, level: 15" node_number="525"><div title="valid: False, node: 526, tag: div, level: 16" node_number="526"><div title="valid: False, node: 527, tag: div, level: 17" node_number="527">R. M. Cox, M. Toots, J.-J. Yoon, J. Sourimant, B. Ludeke, R. Fearns, E. Bourque, J. Patti, E. Lee, J. Vernachio, R. K. Plemper, Development of an allosteric inhibitor class blocking RNA elongation by the respiratory syncytial virus polymerase complex. J. Biol. Chem. <b title="valid: False, node: 528, tag: b, level: 18" node_number="528">293</b>, 16761&#8211;16777 (2018).</div><div title="valid: False, node: 529, tag: div, level: 17" node_number="529"><div title="valid: False, node: 530, tag: div, level: 18" node_number="530"><a title="valid: False, node: 531, tag: a, level: 19" node_number="531">Crossref</a></div><div title="valid: False, node: 532, tag: div, level: 18" node_number="532"><a title="valid: False, node: 533, tag: a, level: 19" node_number="533">PubMed</a></div><div title="valid: False, node: 534, tag: div, level: 18" node_number="534"><a title="valid: False, node: 535, tag: a, level: 19" node_number="535">Google Scholar</a></div></div></div></div></div><div class="valid" valid="valid" title="valid: True, node: 536, tag: div, level: 14" node_number="536"><div title="valid: False, node: 537, tag: div, level: 15" node_number="537">13</div><div title="valid: False, node: 538, tag: div, level: 15" node_number="538"><div title="valid: False, node: 539, tag: div, level: 16" node_number="539"><div title="valid: False, node: 540, tag: div, level: 17" node_number="540">J. DeVincenzo, L. Cass, A. Murray, K. Woodward, E. Meals, M. Coates, L. Daly, V. Wheeler, J. Mori, C. Brindley, A. Davis, M. McCurdy, K. Ito, B. Murray, P. Strong, G. Rapeport, Safety and Anti-viral Effects of Nebulized PC786 in a Respiratory Syncytial Virus Challenge Study. J. Infect. Dis. jiaa716 (2020).</div><div title="valid: False, node: 541, tag: div, level: 17" node_number="541"><div title="valid: False, node: 542, tag: div, level: 18" node_number="542"><a title="valid: False, node: 543, tag: a, level: 19" node_number="543">Crossref</a></div><div title="valid: False, node: 544, tag: div, level: 18" node_number="544"><a title="valid: False, node: 545, tag: a, level: 19" node_number="545">PubMed</a></div><div title="valid: False, node: 546, tag: div, level: 18" node_number="546"><a title="valid: False, node: 547, tag: a, level: 19" node_number="547">Google Scholar</a></div></div></div></div></div><div class="valid" valid="valid" title="valid: True, node: 548, tag: div, level: 14" node_number="548"><div title="valid: False, node: 549, tag: div, level: 15" node_number="549">14</div><div title="valid: False, node: 550, tag: div, level: 15" node_number="550"><div title="valid: False, node: 551, tag: div, level: 16" node_number="551"><div title="valid: False, node: 552, tag: div, level: 17" node_number="552">J. J. Yoon, M. Toots, S. Lee, M.-E. Lee, B. Ludeke, J. M. Luczo, K. Ganti, R. M. Cox, Z. M. Sticher, V. Edpuganti, D. G. Mitchell, M. A. Lockwood, A. A. Kolykhalov, A. L. Greninger, M. L. Moore, G. R. Painter, A. C. Lowen, S. M. Tompkins, R. Fearns, M. G. Natchus, R. K. Plemper, Orally Efficacious Broad-Spectrum Ribonucleoside Analog Inhibitor of Influenza and Respiratory Syncytial Viruses. Antimicrob. Agents Chemother. <b title="valid: False, node: 553, tag: b, level: 18" node_number="553">62</b>, &#8226;&#8226;&#8226; (2018).</div><div title="valid: False, node: 554, tag: div, level: 17" node_number="554"><div title="valid: False, node: 555, tag: div, level: 18" node_number="555"><a title="valid: False, node: 556, tag: a, level: 19" node_number="556">Crossref</a></div><div title="valid: False, node: 557, tag: div, level: 18" node_number="557"><a title="valid: False, node: 558, tag: a, level: 19" node_number="558">PubMed</a></div><div title="valid: False, node: 559, tag: div, level: 18" node_number="559"><a title="valid: False, node: 560, tag: a, level: 19" node_number="560">Google Scholar</a></div></div></div></div></div><div class="valid" valid="valid" title="valid: True, node: 561, tag: div, level: 14" node_number="561"><div title="valid: False, node: 562, tag: div, level: 15" node_number="562">15</div><div title="valid: False, node: 563, tag: div, level: 15" node_number="563"><div title="valid: False, node: 564, tag: div, level: 16" node_number="564"><div title="valid: False, node: 565, tag: div, level: 17" node_number="565">P. Richardson, Applications of fluorine to the construction of bioisosteric elements for the purposes of novel drug discovery. Expert Opin. Drug Discov. <b title="valid: False, node: 566, tag: b, level: 18" node_number="566">16</b>, 1261&#8211;1286 (2021).</div><div title="valid: False, node: 567, tag: div, level: 17" node_number="567"><div title="valid: False, node: 568, tag: div, level: 18" node_number="568"><a title="valid: False, node: 569, tag: a, level: 19" node_number="569">Crossref</a></div><div title="valid: False, node: 570, tag: div, level: 18" node_number="570"><a title="valid: False, node: 571, tag: a, level: 19" node_number="571">PubMed</a></div><div title="valid: False, node: 572, tag: div, level: 18" node_number="572"><a title="valid: False, node: 573, tag: a, level: 19" node_number="573">Google Scholar</a></div></div></div></div></div><div class="valid" valid="valid" title="valid: True, node: 574, tag: div, level: 14" node_number="574"><div title="valid: False, node: 575, tag: div, level: 15" node_number="575">16</div><div title="valid: False, node: 576, tag: div, level: 15" node_number="576"><div title="valid: False, node: 577, tag: div, level: 16" node_number="577"><div title="valid: False, node: 578, tag: div, level: 17" node_number="578">M. L. Moore, M. H. Chi, C. Luongo, N. W. Lukacs, V. V. Polosukhin, M. M. Huckabee, D. C. Newcomb, U. J. Buchholz, J. E. Crowe Jr., K. Goleniewska, J. V. Williams, P. L. Collins, R. S. Peebles Jr., A chimeric A2 strain of respiratory syncytial virus (RSV) with the fusion protein of RSV strain line 19 exhibits enhanced viral load, mucus, and airway dysfunction. J. Virol. <b title="valid: False, node: 579, tag: b, level: 18" node_number="579">83</b>, 4185&#8211;4194 (2009).</div><div title="valid: False, node: 580, tag: div, level: 17" node_number="580"><div title="valid: False, node: 581, tag: div, level: 18" node_number="581"><a title="valid: False, node: 582, tag: a, level: 19" node_number="582">Crossref</a></div><div title="valid: False, node: 583, tag: div, level: 18" node_number="583"><a title="valid: False, node: 584, tag: a, level: 19" node_number="584">PubMed</a></div><div title="valid: False, node: 585, tag: div, level: 18" node_number="585"><a title="valid: False, node: 586, tag: a, level: 19" node_number="586">Google Scholar</a></div></div></div></div></div><div class="valid" valid="valid" title="valid: True, node: 587, tag: div, level: 14" node_number="587"><div title="valid: False, node: 588, tag: div, level: 15" node_number="588">17</div><div title="valid: False, node: 589, tag: div, level: 15" node_number="589"><div title="valid: False, node: 590, tag: div, level: 16" node_number="590"><div title="valid: False, node: 591, tag: div, level: 17" node_number="591">L. D. Marroquin, J. Hynes, J. A. Dykens, J. D. Jamieson, Y. Will, Circumventing the Crabtree effect: Replacing media glucose with galactose increases susceptibility of HepG2 cells to mitochondrial toxicants. Toxicol. Sci. <b title="valid: False, node: 592, tag: b, level: 18" node_number="592">97</b>, 539&#8211;547 (2007).</div><div title="valid: False, node: 593, tag: div, level: 17" node_number="593"><div title="valid: False, node: 594, tag: div, level: 18" node_number="594"><a title="valid: False, node: 595, tag: a, level: 19" node_number="595">Crossref</a></div><div title="valid: False, node: 596, tag: div, level: 18" node_number="596"><a title="valid: False, node: 597, tag: a, level: 19" node_number="597">PubMed</a></div><div title="valid: False, node: 598, tag: div, level: 18" node_number="598"><a title="valid: False, node: 599, tag: a, level: 19" node_number="599">Google Scholar</a></div></div></div></div></div><div class="valid" valid="valid" title="valid: True, node: 600, tag: div, level: 14" node_number="600"><div title="valid: False, node: 601, tag: div, level: 15" node_number="601">18</div><div title="valid: False, node: 602, tag: div, level: 15" node_number="602"><div title="valid: False, node: 603, tag: div, level: 16" node_number="603"><div title="valid: False, node: 604, tag: div, level: 17" node_number="604">S. P. Luby, The pandemic potential of Nipah virus. Antiviral Res. <b title="valid: False, node: 605, tag: b, level: 18" node_number="605">100</b>, 38&#8211;43 (2013).</div><div title="valid: False, node: 606, tag: div, level: 17" node_number="606"><div title="valid: False, node: 607, tag: div, level: 18" node_number="607"><a title="valid: False, node: 608, tag: a, level: 19" node_number="608">Crossref</a></div><div title="valid: False, node: 609, tag: div, level: 18" node_number="609"><a title="valid: False, node: 610, tag: a, level: 19" node_number="610">PubMed</a></div><div title="valid: False, node: 611, tag: div, level: 18" node_number="611"><a title="valid: False, node: 612, tag: a, level: 19" node_number="612">Google Scholar</a></div></div></div></div></div><div class="valid" valid="valid" title="valid: True, node: 613, tag: div, level: 14" node_number="613"><div title="valid: False, node: 614, tag: div, level: 15" node_number="614">19</div><div title="valid: False, node: 615, tag: div, level: 15" node_number="615"><div title="valid: False, node: 616, tag: div, level: 16" node_number="616"><div title="valid: False, node: 617, tag: div, level: 17" node_number="617">Note: Based on the current knowledge of the pyrimidine salvage pathway, it must be assumed that the large excess of extracellular cytidine leads to conversion of CTP to UTP via cytidine deaminase (CDA), competing with 4&#8242;-FlU.</div></div></div></div><div class="valid" valid="valid" title="valid: True, node: 618, tag: div, level: 14" node_number="618"><div title="valid: False, node: 619, tag: div, level: 15" node_number="619">20</div><div title="valid: False, node: 620, tag: div, level: 15" node_number="620"><div title="valid: False, node: 621, tag: div, level: 16" node_number="621"><div title="valid: False, node: 622, tag: div, level: 17" node_number="622">B. Ludeke, R. Fearns, The respiratory syncytial virus polymerase can perform RNA synthesis with modified primers and nucleotide analogs. Virology <b title="valid: False, node: 623, tag: b, level: 18" node_number="623">540</b>, 66&#8211;74 (2020).</div><div title="valid: False, node: 624, tag: div, level: 17" node_number="624"><div title="valid: False, node: 625, tag: div, level: 18" node_number="625"><a title="valid: False, node: 626, tag: a, level: 19" node_number="626">Crossref</a></div><div title="valid: False, node: 627, tag: div, level: 18" node_number="627"><a title="valid: False, node: 628, tag: a, level: 19" node_number="628">PubMed</a></div><div title="valid: False, node: 629, tag: div, level: 18" node_number="629"><a title="valid: False, node: 630, tag: a, level: 19" node_number="630">Google Scholar</a></div></div></div></div></div><div class="valid" valid="valid" title="valid: True, node: 631, tag: div, level: 14" node_number="631"><div title="valid: False, node: 632, tag: div, level: 15" node_number="632">21</div><div title="valid: False, node: 633, tag: div, level: 15" node_number="633"><div title="valid: False, node: 634, tag: div, level: 16" node_number="634"><div title="valid: False, node: 635, tag: div, level: 17" node_number="635">E. P. Tchesnokov, J. Y. Feng, D. P. Porter, M. G&#246;tte, Mechanism of Inhibition of Ebola Virus RNA-Dependent RNA Polymerase by Remdesivir. Viruses <b title="valid: False, node: 636, tag: b, level: 18" node_number="636">11</b>, 326 (2019).</div><div title="valid: False, node: 637, tag: div, level: 17" node_number="637"><div title="valid: False, node: 638, tag: div, level: 18" node_number="638"><a title="valid: False, node: 639, tag: a, level: 19" node_number="639">Crossref</a></div><div title="valid: False, node: 640, tag: div, level: 18" node_number="640"><a title="valid: False, node: 641, tag: a, level: 19" node_number="641">PubMed</a></div><div title="valid: False, node: 642, tag: div, level: 18" node_number="642"><a title="valid: False, node: 643, tag: a, level: 19" node_number="643">Google Scholar</a></div></div></div></div></div><div class="valid" valid="valid" title="valid: True, node: 644, tag: div, level: 14" node_number="644"><div title="valid: False, node: 645, tag: div, level: 15" node_number="645">22</div><div title="valid: False, node: 646, tag: div, level: 15" node_number="646"><div title="valid: False, node: 647, tag: div, level: 16" node_number="647"><div title="valid: False, node: 648, tag: div, level: 17" node_number="648">C. J. Gordon, E. P. Tchesnokov, E. Woolner, J. K. Perry, J. Y. Feng, D. P. Porter, M. G&#246;tte, Remdesivir is a direct-acting antiviral that inhibits RNA-dependent RNA polymerase from severe acute respiratory syndrome coronavirus 2 with high potency. J. Biol. Chem. <b title="valid: False, node: 649, tag: b, level: 18" node_number="649">295</b>, 6785&#8211;6797 (2020).</div><div title="valid: False, node: 650, tag: div, level: 17" node_number="650"><div title="valid: False, node: 651, tag: div, level: 18" node_number="651"><a title="valid: False, node: 652, tag: a, level: 19" node_number="652">Crossref</a></div><div title="valid: False, node: 653, tag: div, level: 18" node_number="653"><a title="valid: False, node: 654, tag: a, level: 19" node_number="654">PubMed</a></div><div title="valid: False, node: 655, tag: div, level: 18" node_number="655"><a title="valid: False, node: 656, tag: a, level: 19" node_number="656">Google Scholar</a></div></div></div></div></div><div class="valid" valid="valid" title="valid: True, node: 657, tag: div, level: 14" node_number="657"><div title="valid: False, node: 658, tag: div, level: 15" node_number="658">23</div><div title="valid: False, node: 659, tag: div, level: 15" node_number="659"><div title="valid: False, node: 660, tag: div, level: 16" node_number="660"><div title="valid: False, node: 661, tag: div, level: 17" node_number="661">T. L. Dangerfield, N. Z. Huang, K. A. Johnson, Expression and purification of tag-free SARS-CoV-2 RNA-dependent RNA polymerase in <i title="valid: False, node: 662, tag: i, level: 18" node_number="662">Escherichia coli</i>. STAR Protoc <b title="valid: False, node: 663, tag: b, level: 18" node_number="663">2</b>, 100357 (2021).</div><div title="valid: False, node: 664, tag: div, level: 17" node_number="664"><div title="valid: False, node: 665, tag: div, level: 18" node_number="665"><a title="valid: False, node: 666, tag: a, level: 19" node_number="666">Crossref</a></div><div title="valid: False, node: 667, tag: div, level: 18" node_number="667"><a title="valid: False, node: 668, tag: a, level: 19" node_number="668">PubMed</a></div><div title="valid: False, node: 669, tag: div, level: 18" node_number="669"><a title="valid: False, node: 670, tag: a, level: 19" node_number="670">Google Scholar</a></div></div></div></div></div><div class="valid" valid="valid" title="valid: True, node: 671, tag: div, level: 14" node_number="671"><div title="valid: False, node: 672, tag: div, level: 15" node_number="672">24</div><div title="valid: False, node: 673, tag: div, level: 15" node_number="673"><div title="valid: False, node: 674, tag: div, level: 16" node_number="674"><div title="valid: False, node: 675, tag: div, level: 17" node_number="675">Note: Our nsp12 preparations contain a mixture of &#8216;GroEL&#8217; and &#8216;tf&#8217;, and nsp12 as described before, the latter representing 19% and 18% of the protein content of the preparations containing catalytically active and inactive nsp12, respectively.</div></div></div></div><div class="valid" valid="valid" title="valid: True, node: 676, tag: div, level: 14" node_number="676"><div title="valid: False, node: 677, tag: div, level: 15" node_number="677">25</div><div title="valid: False, node: 678, tag: div, level: 15" node_number="678"><div title="valid: False, node: 679, tag: div, level: 16" node_number="679"><div title="valid: False, node: 680, tag: div, level: 17" node_number="680">M. Toots, J.-J. Yoon, M. Hart, M. G. Natchus, G. R. Painter, R. K. Plemper, Quantitative efficacy paradigms of the influenza clinical drug candidate EIDD-2801 in the ferret model. Transl. Res. <b title="valid: False, node: 681, tag: b, level: 18" node_number="681">218</b>, 16&#8211;28 (2020).</div><div title="valid: False, node: 682, tag: div, level: 17" node_number="682"><div title="valid: False, node: 683, tag: div, level: 18" node_number="683"><a title="valid: False, node: 684, tag: a, level: 19" node_number="684">Crossref</a></div><div title="valid: False, node: 685, tag: div, level: 18" node_number="685"><a title="valid: False, node: 686, tag: a, level: 19" node_number="686">PubMed</a></div><div title="valid: False, node: 687, tag: div, level: 18" node_number="687"><a title="valid: False, node: 688, tag: a, level: 19" node_number="688">Google Scholar</a></div></div></div></div></div><div class="valid" valid="valid" title="valid: True, node: 689, tag: div, level: 14" node_number="689"><div title="valid: False, node: 690, tag: div, level: 15" node_number="690">26</div><div title="valid: False, node: 691, tag: div, level: 15" node_number="691"><div title="valid: False, node: 692, tag: div, level: 16" node_number="692"><div title="valid: False, node: 693, tag: div, level: 17" node_number="693">S. M. Coleman, A. McGregor, A bright future for bioluminescent imaging in viral research. Future Virol. <b title="valid: False, node: 694, tag: b, level: 18" node_number="694">10</b>, 169&#8211;183 (2015).</div><div title="valid: False, node: 695, tag: div, level: 17" node_number="695"><div title="valid: False, node: 696, tag: div, level: 18" node_number="696"><a title="valid: False, node: 697, tag: a, level: 19" node_number="697">Crossref</a></div><div title="valid: False, node: 698, tag: div, level: 18" node_number="698"><a title="valid: False, node: 699, tag: a, level: 19" node_number="699">PubMed</a></div><div title="valid: False, node: 700, tag: div, level: 18" node_number="700"><a title="valid: False, node: 701, tag: a, level: 19" node_number="701">Google Scholar</a></div></div></div></div></div><div class="valid" valid="valid" title="valid: True, node: 702, tag: div, level: 14" node_number="702"><div title="valid: False, node: 703, tag: div, level: 15" node_number="703">27</div><div title="valid: False, node: 704, tag: div, level: 15" node_number="704"><div title="valid: False, node: 705, tag: div, level: 16" node_number="705"><div title="valid: False, node: 706, tag: div, level: 17" node_number="706">Note: Male ferrets were not included in this study for practical reasons as they are territorial and available ABSL3 space cannot accommodate the number of cages that this study would require to achieve meaningful statistical power.</div></div></div></div><div class="valid" valid="valid" title="valid: True, node: 707, tag: div, level: 14" node_number="707"><div title="valid: False, node: 708, tag: div, level: 15" node_number="708">28</div><div title="valid: False, node: 709, tag: div, level: 15" node_number="709"><div title="valid: False, node: 710, tag: div, level: 16" node_number="710"><div title="valid: False, node: 711, tag: div, level: 17" node_number="711">G. Kokic, H. S. Hillen, D. Tegunov, C. Dienemann, F. Seitz, J. Schmitzova, L. Farnung, A. Siewert, C. H&#246;bartner, P. Cramer, Mechanism of SARS-CoV-2 polymerase stalling by remdesivir. Nat. Commun. <b title="valid: False, node: 712, tag: b, level: 18" node_number="712">12</b>, 279 (2021).</div><div title="valid: False, node: 713, tag: div, level: 17" node_number="713"><div title="valid: False, node: 714, tag: div, level: 18" node_number="714"><a title="valid: False, node: 715, tag: a, level: 19" node_number="715">Crossref</a></div><div title="valid: False, node: 716, tag: div, level: 18" node_number="716"><a title="valid: False, node: 717, tag: a, level: 19" node_number="717">PubMed</a></div><div title="valid: False, node: 718, tag: div, level: 18" node_number="718"><a title="valid: False, node: 719, tag: a, level: 19" node_number="719">Google Scholar</a></div></div></div></div></div><div class="valid" valid="valid" title="valid: True, node: 720, tag: div, level: 14" node_number="720"><div title="valid: False, node: 721, tag: div, level: 15" node_number="721">29</div><div title="valid: False, node: 722, tag: div, level: 15" node_number="722"><div title="valid: False, node: 723, tag: div, level: 16" node_number="723"><div title="valid: False, node: 724, tag: div, level: 17" node_number="724">E. P. Tchesnokov, C. J. Gordon, E. Woolner, D. Kocinkova, J. K. Perry, J. Y. Feng, D. P. Porter, M. G&#246;tte, Template-dependent inhibition of coronavirus RNA-dependent RNA polymerase by remdesivir reveals a second mechanism of action. J. Biol. Chem. <b title="valid: False, node: 725, tag: b, level: 18" node_number="725">295</b>, 16156&#8211;16165 (2020).</div><div title="valid: False, node: 726, tag: div, level: 17" node_number="726"><div title="valid: False, node: 727, tag: div, level: 18" node_number="727"><a title="valid: False, node: 728, tag: a, level: 19" node_number="728">Crossref</a></div><div title="valid: False, node: 729, tag: div, level: 18" node_number="729"><a title="valid: False, node: 730, tag: a, level: 19" node_number="730">PubMed</a></div><div title="valid: False, node: 731, tag: div, level: 18" node_number="731"><a title="valid: False, node: 732, tag: a, level: 19" node_number="732">Google Scholar</a></div></div></div></div></div><div class="valid" valid="valid" title="valid: True, node: 733, tag: div, level: 14" node_number="733"><div title="valid: False, node: 734, tag: div, level: 15" node_number="734">30</div><div title="valid: False, node: 735, tag: div, level: 15" node_number="735"><div title="valid: False, node: 736, tag: div, level: 16" node_number="736"><div title="valid: False, node: 737, tag: div, level: 17" node_number="737">J. J. Feld, J. H. Hoofnagle, Mechanism of action of interferon and ribavirin in treatment of hepatitis C. Nature <b title="valid: False, node: 738, tag: b, level: 18" node_number="738">436</b>, 967&#8211;972 (2005).</div><div title="valid: False, node: 739, tag: div, level: 17" node_number="739"><div title="valid: False, node: 740, tag: div, level: 18" node_number="740"><a title="valid: False, node: 741, tag: a, level: 19" node_number="741">Crossref</a></div><div title="valid: False, node: 742, tag: div, level: 18" node_number="742"><a title="valid: False, node: 743, tag: a, level: 19" node_number="743">PubMed</a></div><div title="valid: False, node: 744, tag: div, level: 18" node_number="744"><a title="valid: False, node: 745, tag: a, level: 19" node_number="745">Google Scholar</a></div></div></div></div></div><div class="valid" valid="valid" title="valid: True, node: 746, tag: div, level: 14" node_number="746"><div title="valid: False, node: 747, tag: div, level: 15" node_number="747">31</div><div title="valid: False, node: 748, tag: div, level: 15" node_number="748"><div title="valid: False, node: 749, tag: div, level: 16" node_number="749"><div title="valid: False, node: 750, tag: div, level: 17" node_number="750">E. C. Smith, H. Blanc, M. C. Surdel, M. Vignuzzi, M. R. Denison, Coronaviruses lacking exoribonuclease activity are susceptible to lethal mutagenesis: Evidence for proofreading and potential therapeutics. PLOS Pathog. <b title="valid: False, node: 751, tag: b, level: 18" node_number="751">9</b>, e1003565 (2013).</div><div title="valid: False, node: 752, tag: div, level: 17" node_number="752"><div title="valid: False, node: 753, tag: div, level: 18" node_number="753"><a title="valid: False, node: 754, tag: a, level: 19" node_number="754">Crossref</a></div><div title="valid: False, node: 755, tag: div, level: 18" node_number="755"><a title="valid: False, node: 756, tag: a, level: 19" node_number="756">PubMed</a></div><div title="valid: False, node: 757, tag: div, level: 18" node_number="757"><a title="valid: False, node: 758, tag: a, level: 19" node_number="758">Google Scholar</a></div></div></div></div></div><div class="valid" valid="valid" title="valid: True, node: 759, tag: div, level: 14" node_number="759"><div title="valid: False, node: 760, tag: div, level: 15" node_number="760">32</div><div title="valid: False, node: 761, tag: div, level: 15" node_number="761"><div title="valid: False, node: 762, tag: div, level: 16" node_number="762"><div title="valid: False, node: 763, tag: div, level: 17" node_number="763">E. Minskaia, T. Hertzig, A. E. Gorbalenya, V. Campanacci, C. Cambillau, B. Canard, J. Ziebuhr, Discovery of an RNA virus 3&#8242;-&gt;5&#8242; exoribonuclease that is critically involved in coronavirus RNA synthesis. Proc. Natl. Acad. Sci. U.S.A. <b title="valid: False, node: 764, tag: b, level: 18" node_number="764">103</b>, 5108&#8211;5113 (2006).</div><div title="valid: False, node: 765, tag: div, level: 17" node_number="765"><div title="valid: False, node: 766, tag: div, level: 18" node_number="766"><a title="valid: False, node: 767, tag: a, level: 19" node_number="767">Crossref</a></div><div title="valid: False, node: 768, tag: div, level: 18" node_number="768"><a title="valid: False, node: 769, tag: a, level: 19" node_number="769">PubMed</a></div><div title="valid: False, node: 770, tag: div, level: 18" node_number="770"><a title="valid: False, node: 771, tag: a, level: 19" node_number="771">Google Scholar</a></div></div></div></div></div><div class="valid" valid="valid" title="valid: True, node: 772, tag: div, level: 14" node_number="772"><div title="valid: False, node: 773, tag: div, level: 15" node_number="773">33</div><div title="valid: False, node: 774, tag: div, level: 15" node_number="774"><div title="valid: False, node: 775, tag: div, level: 16" node_number="775"><div title="valid: False, node: 776, tag: div, level: 17" node_number="776">C. M. El Saleeby, A. J. Bush, L. M. Harrison, J. A. Aitken, J. P. Devincenzo, Respiratory syncytial virus load, viral dynamics, and disease severity in previously healthy naturally infected children. J. Infect. Dis. <b title="valid: False, node: 777, tag: b, level: 18" node_number="777">204</b>, 996&#8211;1002 (2011).</div><div title="valid: False, node: 778, tag: div, level: 17" node_number="778"><div title="valid: False, node: 779, tag: div, level: 18" node_number="779"><a title="valid: False, node: 780, tag: a, level: 19" node_number="780">Crossref</a></div><div title="valid: False, node: 781, tag: div, level: 18" node_number="781"><a title="valid: False, node: 782, tag: a, level: 19" node_number="782">PubMed</a></div><div title="valid: False, node: 783, tag: div, level: 18" node_number="783"><a title="valid: False, node: 784, tag: a, level: 19" node_number="784">Google Scholar</a></div></div></div></div></div><div class="valid" valid="valid" title="valid: True, node: 785, tag: div, level: 14" node_number="785"><div title="valid: False, node: 786, tag: div, level: 15" node_number="786">34</div><div title="valid: False, node: 787, tag: div, level: 15" node_number="787"><div title="valid: False, node: 788, tag: div, level: 16" node_number="788"><div title="valid: False, node: 789, tag: div, level: 17" node_number="789">B. Oberfeld, A. Achanta, K. Carpenter, P. Chen, N. M. Gilette, P. Langat, J. T. Said, A. E. Schiff, A. S. Zhou, A. K. Barczak, S. Pillai, SnapShot: COVID-19. Cell <b title="valid: False, node: 790, tag: b, level: 18" node_number="790">181</b>, 954&#8211;954.e1 (2020).</div><div title="valid: False, node: 791, tag: div, level: 17" node_number="791"><div title="valid: False, node: 792, tag: div, level: 18" node_number="792"><a title="valid: False, node: 793, tag: a, level: 19" node_number="793">Crossref</a></div><div title="valid: False, node: 794, tag: div, level: 18" node_number="794"><a title="valid: False, node: 795, tag: a, level: 19" node_number="795">PubMed</a></div><div title="valid: False, node: 796, tag: div, level: 18" node_number="796"><a title="valid: False, node: 797, tag: a, level: 19" node_number="797">Google Scholar</a></div></div></div></div></div><div class="valid" valid="valid" title="valid: True, node: 798, tag: div, level: 14" node_number="798"><div title="valid: False, node: 799, tag: div, level: 15" node_number="799">35</div><div title="valid: False, node: 800, tag: div, level: 15" node_number="800"><div title="valid: False, node: 801, tag: div, level: 16" node_number="801"><div title="valid: False, node: 802, tag: div, level: 17" node_number="802">C. Ye, K. Chiem, J.-G. Park, J. A. Silvas, D. Morales Vasquez, J. Sourimant, M. J. Lin, A. L. Greninger, R. K. Plemper, J. B. Torrelles, J. J. Kobie, M. R. Walter, J. C. de la Torre, L. Martinez-Sobrido, Analysis of SARS-CoV-2 infection dynamic in vivo using reporter-expressing viruses. Proc. Natl. Acad. Sci. U.S.A. <b title="valid: False, node: 803, tag: b, level: 18" node_number="803">118</b>, e2111593118 (2021).</div><div title="valid: False, node: 804, tag: div, level: 17" node_number="804"><div title="valid: False, node: 805, tag: div, level: 18" node_number="805"><a title="valid: False, node: 806, tag: a, level: 19" node_number="806">Crossref</a></div><div title="valid: False, node: 807, tag: div, level: 18" node_number="807"><a title="valid: False, node: 808, tag: a, level: 19" node_number="808">PubMed</a></div><div title="valid: False, node: 809, tag: div, level: 18" node_number="809"><a title="valid: False, node: 810, tag: a, level: 19" node_number="810">Google Scholar</a></div></div></div></div></div><div class="valid" valid="valid" title="valid: True, node: 811, tag: div, level: 14" node_number="811"><div title="valid: False, node: 812, tag: div, level: 15" node_number="812">36</div><div title="valid: False, node: 813, tag: div, level: 15" node_number="813"><div title="valid: False, node: 814, tag: div, level: 16" node_number="814"><div title="valid: False, node: 815, tag: div, level: 17" node_number="815">M. A. Rameix-Welti, R. Le Goffic, P.-L. Herv&#233;, J. Sourimant, A. R&#233;mot, S. Riffault, Q. Yu, M. Galloux, E. Gault, J.-F. El&#233;ou&#235;t, Visualizing the replication of respiratory syncytial virus in cells and in living mice. Nat. Commun. <b title="valid: False, node: 816, tag: b, level: 18" node_number="816">5</b>, 5104 (2014).</div><div title="valid: False, node: 817, tag: div, level: 17" node_number="817"><div title="valid: False, node: 818, tag: div, level: 18" node_number="818"><a title="valid: False, node: 819, tag: a, level: 19" node_number="819">Crossref</a></div><div title="valid: False, node: 820, tag: div, level: 18" node_number="820"><a title="valid: False, node: 821, tag: a, level: 19" node_number="821">PubMed</a></div><div title="valid: False, node: 822, tag: div, level: 18" node_number="822"><a title="valid: False, node: 823, tag: a, level: 19" node_number="823">Google Scholar</a></div></div></div></div></div></section></div></section><div class="valid" valid="valid" title="valid: True, node: 824, tag: div, level: 11" node_number="824"><div class="valid" valid="valid" title="valid: True, node: 825, tag: div, level: 12" node_number="825"><header class="valid" valid="valid" title="valid: True, node: 826, tag: header, level: 13" node_number="826"><h2 class="valid" valid="valid" title="valid: True, node: 827, tag: h2, level: 14" node_number="827">Information Authors</h2></header><section class="valid" valid="valid" title="valid: True, node: 828, tag: section, level: 13" node_number="828"><h3 class="valid" valid="valid" title="valid: True, node: 829, tag: h3, level: 14" node_number="829">Information</h3><section class="valid" valid="valid" title="valid: True, node: 830, tag: section, level: 14" node_number="830"><h4 title="valid: False, node: 831, tag: h4, level: 15" node_number="831">Published In</h4><div title="valid: False, node: 832, tag: div, level: 15" node_number="832"> <div title="valid: False, node: 833, tag: div, level: 16" node_number="833"><div title="valid: False, node: 834, tag: div, level: 17" node_number="834">Science</div><div title="valid: False, node: 835, tag: div, level: 17" node_number="835">First Release</div></div></div></section><section class="valid" valid="valid" title="valid: True, node: 836, tag: section, level: 14" node_number="836"><h4 title="valid: False, node: 837, tag: h4, level: 15" node_number="837">Copyright</h4><div title="valid: False, node: 838, tag: div, level: 15" node_number="838"> Copyright &#169; 2021 The Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. No claim to original U.S. Government Works. Distributed under a Creative Commons Attribution License 4.0 (CC BY).</div><div title="valid: False, node: 839, tag: div, level: 15" node_number="839">https://creativecommons.org/licenses/by/4.0/</div><div title="valid: False, node: 840, tag: div, level: 15" node_number="840">This is an open-access article distributed under the terms of the <a title="valid: False, node: 841, tag: a, level: 16" node_number="841">Creative Commons Attribution license</a>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</div></section><section class="valid" valid="valid" title="valid: True, node: 842, tag: section, level: 14" node_number="842"><h4 title="valid: False, node: 843, tag: h4, level: 15" node_number="843">Submission history</h4><div title="valid: False, node: 844, tag: div, level: 15" node_number="844"><b title="valid: False, node: 845, tag: b, level: 16" node_number="845">Received</b>: 19 May 2021</div><div title="valid: False, node: 846, tag: div, level: 15" node_number="846"><b title="valid: False, node: 847, tag: b, level: 16" node_number="847">Accepted</b>: 29 November 2021</div></section><section class="valid" valid="valid" title="valid: True, node: 848, tag: section, level: 14" node_number="848"><h4 title="valid: False, node: 849, tag: h4, level: 15" node_number="849">Permissions</h4><div title="valid: False, node: 850, tag: div, level: 15" node_number="850">Request permissions for this article.</div><div title="valid: False, node: 851, tag: div, level: 15" node_number="851"><a title="valid: False, node: 852, tag: a, level: 16" node_number="852">Request Permissions</a></div></section><section class="valid" valid="valid" title="valid: True, node: 853, tag: section, level: 14" node_number="853"><h4 title="valid: False, node: 854, tag: h4, level: 15" node_number="854">Acknowledgments</h4><div title="valid: False, node: 855, tag: div, level: 15" node_number="855">We thank C. F. Basler for providing Calu-3 cells, D. Waugh for plasmid pRK792 encoding TEV protease (Addgene plasmid #8830), the Georgia State University High Containment Core and the Department for Animal Research for support, and A. L. Hammond for critical reading of the manuscript. <b title="valid: False, node: 856, tag: b, level: 16" node_number="856">Funding: </b>This work was supported, in part, by Public Health Service grants AI153400, AI071002, and AI141222 (to R.K.P.), from the NIH/NIAID. The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication. <b title="valid: False, node: 857, tag: b, level: 16" node_number="857">Author contributions:</b> Conceptualization: M.G.N., G.R.P., and R.K.P. Investigation: J.S., R.M.C., M.T., J.Y., C.M.L., M.A., J.D.W., Z.S., and R.K.P. Resources: G.R.B., A.A.K., L.M.S., and R.K.P. Visualization: G.R.B. and J.S. Validation: J.S. and R.K.P. Funding acquisition: R.K.P. Project administration: M.G.N. and R.K.P. Supervision: G.R.P. and R.K.P. Writing &#8211; original draft: J.S. and R.K.P. Writing &#8211; review and editing: J.S. and R.K.P. <b title="valid: False, node: 858, tag: b, level: 16" node_number="858">Competing interests:</b> G.R.B. and G.R.P. are coinventors on patent WO 2019/1736002 covering composition of matter and use of EIDD-2749 and its analogs as an antiviral treatment. This study could affect their personal financial status. All other authors declare that they have no competing interests. <b title="valid: False, node: 859, tag: b, level: 16" node_number="859">Data and materials availability:</b> All data are available in the main text or the supplementary materials. Materials and methods are available as supplementary materials at the Science website. Transfer of EIDD-2749 material to other institutions for research purposes is covered by MTAs from Emory University. This work is licensed under a Creative Commons Attribution 4.0 International (CC BY 4.0) license, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. To view a copy of this license, visit <a title="valid: False, node: 860, tag: a, level: 16" node_number="860">https://creativecommons.org/licenses/by/4.0/</a>. This license does not apply to figures/photos/artwork or other content included in the article that is credited to a third party; obtain authorization from the rights holder before using such material.</div></section></section><section class="valid" valid="valid" title="valid: True, node: 861, tag: section, level: 13" node_number="861"><h3 class="valid" valid="valid" title="valid: True, node: 862, tag: h3, level: 14" node_number="862">Authors</h3><section class="valid" valid="valid" title="valid: True, node: 863, tag: section, level: 14" node_number="863"><h4 title="valid: False, node: 864, tag: h4, level: 15" node_number="864">Affiliations</h4><div title="valid: False, node: 865, tag: div, level: 15" node_number="865"><div title="valid: False, node: 866, tag: div, level: 16" node_number="866">Julien Sourimant https://orcid.org/0000-0002-1660-1666</div><div title="valid: False, node: 867, tag: div, level: 16" node_number="867"><div title="valid: False, node: 868, tag: div, level: 17" node_number="868"><div title="valid: False, node: 869, tag: div, level: 18" node_number="869">Center for Translational Antiviral Research, Georgia State University, Atlanta, GA 30303, USA.</div></div><div title="valid: False, node: 870, tag: div, level: 17" node_number="870">View all articles by this author</div></div></div><div title="valid: False, node: 871, tag: div, level: 15" node_number="871"><div title="valid: False, node: 872, tag: div, level: 16" node_number="872">Carolin M. Lieber</div><div title="valid: False, node: 873, tag: div, level: 16" node_number="873"><div title="valid: False, node: 874, tag: div, level: 17" node_number="874"><div title="valid: False, node: 875, tag: div, level: 18" node_number="875">Center for Translational Antiviral Research, Georgia State University, Atlanta, GA 30303, USA.</div></div><div title="valid: False, node: 876, tag: div, level: 17" node_number="876">View all articles by this author</div></div></div><div title="valid: False, node: 877, tag: div, level: 15" node_number="877"><div title="valid: False, node: 878, tag: div, level: 16" node_number="878">Megha Aggarwal</div><div title="valid: False, node: 879, tag: div, level: 16" node_number="879"><div title="valid: False, node: 880, tag: div, level: 17" node_number="880"><div title="valid: False, node: 881, tag: div, level: 18" node_number="881">Center for Translational Antiviral Research, Georgia State University, Atlanta, GA 30303, USA.</div></div><div title="valid: False, node: 882, tag: div, level: 17" node_number="882">View all articles by this author</div></div></div><div title="valid: False, node: 883, tag: div, level: 15" node_number="883"><div title="valid: False, node: 884, tag: div, level: 16" node_number="884">Robert M. Cox</div><div title="valid: False, node: 885, tag: div, level: 16" node_number="885"><div title="valid: False, node: 886, tag: div, level: 17" node_number="886"><div title="valid: False, node: 887, tag: div, level: 18" node_number="887">Center for Translational Antiviral Research, Georgia State University, Atlanta, GA 30303, USA.</div></div><div title="valid: False, node: 888, tag: div, level: 17" node_number="888">View all articles by this author</div></div></div><div title="valid: False, node: 889, tag: div, level: 15" node_number="889"><div title="valid: False, node: 890, tag: div, level: 16" node_number="890">Josef D. Wolf https://orcid.org/0000-0003-2507-6944</div><div title="valid: False, node: 891, tag: div, level: 16" node_number="891"><div title="valid: False, node: 892, tag: div, level: 17" node_number="892"><div title="valid: False, node: 893, tag: div, level: 18" node_number="893">Center for Translational Antiviral Research, Georgia State University, Atlanta, GA 30303, USA.</div></div><div title="valid: False, node: 894, tag: div, level: 17" node_number="894">View all articles by this author</div></div></div><div title="valid: False, node: 895, tag: div, level: 15" node_number="895"><div title="valid: False, node: 896, tag: div, level: 16" node_number="896">Jeong-Joong Yoon https://orcid.org/0000-0001-9379-0416</div><div title="valid: False, node: 897, tag: div, level: 16" node_number="897"><div title="valid: False, node: 898, tag: div, level: 17" node_number="898"><div title="valid: False, node: 899, tag: div, level: 18" node_number="899">Center for Translational Antiviral Research, Georgia State University, Atlanta, GA 30303, USA.</div></div><div title="valid: False, node: 900, tag: div, level: 17" node_number="900">View all articles by this author</div></div></div><div title="valid: False, node: 901, tag: div, level: 15" node_number="901"><div title="valid: False, node: 902, tag: div, level: 16" node_number="902">Mart Toots</div><div title="valid: False, node: 903, tag: div, level: 16" node_number="903"><div title="valid: False, node: 904, tag: div, level: 17" node_number="904"><div title="valid: False, node: 905, tag: div, level: 18" node_number="905">Center for Translational Antiviral Research, Georgia State University, Atlanta, GA 30303, USA.</div></div><div title="valid: False, node: 906, tag: div, level: 17" node_number="906">View all articles by this author</div></div></div><div title="valid: False, node: 907, tag: div, level: 15" node_number="907"><div title="valid: False, node: 908, tag: div, level: 16" node_number="908">Chengin Ye https://orcid.org/0000-0002-1934-9494</div><div title="valid: False, node: 909, tag: div, level: 16" node_number="909"><div title="valid: False, node: 910, tag: div, level: 17" node_number="910"><div title="valid: False, node: 911, tag: div, level: 18" node_number="911">Texas Biomedical Research Institute, San Antonio, TX 78227, USA.</div></div><div title="valid: False, node: 912, tag: div, level: 17" node_number="912">View all articles by this author</div></div></div><div title="valid: False, node: 913, tag: div, level: 15" node_number="913"><div title="valid: False, node: 914, tag: div, level: 16" node_number="914">Zachary Sticher https://orcid.org/0000-0002-7022-1410</div><div title="valid: False, node: 915, tag: div, level: 16" node_number="915"><div title="valid: False, node: 916, tag: div, level: 17" node_number="916"><div title="valid: False, node: 917, tag: div, level: 18" node_number="917">Emory Institute for Drug Development, Emory University, Atlanta, GA 30322, USA.</div></div><div title="valid: False, node: 918, tag: div, level: 17" node_number="918">View all articles by this author</div></div></div><div title="valid: False, node: 919, tag: div, level: 15" node_number="919"><div title="valid: False, node: 920, tag: div, level: 16" node_number="920">Alexander A. Kolykhalov</div><div title="valid: False, node: 921, tag: div, level: 16" node_number="921"><div title="valid: False, node: 922, tag: div, level: 17" node_number="922"><div title="valid: False, node: 923, tag: div, level: 18" node_number="923">Emory Institute for Drug Development, Emory University, Atlanta, GA 30322, USA.</div><div title="valid: False, node: 924, tag: div, level: 18" node_number="924">Drug Innovation Ventures at Emory (DRIVE), Atlanta, GA 30322, USA.</div></div><div title="valid: False, node: 925, tag: div, level: 17" node_number="925">View all articles by this author</div></div></div><div title="valid: False, node: 926, tag: div, level: 15" node_number="926"><div title="valid: False, node: 927, tag: div, level: 16" node_number="927">Luis Martinez-Sobrido https://orcid.org/0000-0001-7084-0804</div><div title="valid: False, node: 928, tag: div, level: 16" node_number="928"><div title="valid: False, node: 929, tag: div, level: 17" node_number="929"><div title="valid: False, node: 930, tag: div, level: 18" node_number="930">Texas Biomedical Research Institute, San Antonio, TX 78227, USA.</div></div><div title="valid: False, node: 931, tag: div, level: 17" node_number="931">View all articles by this author</div></div></div><div title="valid: False, node: 932, tag: div, level: 15" node_number="932"><div title="valid: False, node: 933, tag: div, level: 16" node_number="933">Gregory R. Bluemling https://orcid.org/0000-0001-9138-7578</div><div title="valid: False, node: 934, tag: div, level: 16" node_number="934"><div title="valid: False, node: 935, tag: div, level: 17" node_number="935"><div title="valid: False, node: 936, tag: div, level: 18" node_number="936">Emory Institute for Drug Development, Emory University, Atlanta, GA 30322, USA.</div><div title="valid: False, node: 937, tag: div, level: 18" node_number="937">Drug Innovation Ventures at Emory (DRIVE), Atlanta, GA 30322, USA.</div></div><div title="valid: False, node: 938, tag: div, level: 17" node_number="938">View all articles by this author</div></div></div><div title="valid: False, node: 939, tag: div, level: 15" node_number="939"><div title="valid: False, node: 940, tag: div, level: 16" node_number="940">Michael G. Natchus</div><div title="valid: False, node: 941, tag: div, level: 16" node_number="941"><div title="valid: False, node: 942, tag: div, level: 17" node_number="942"><div title="valid: False, node: 943, tag: div, level: 18" node_number="943">Emory Institute for Drug Development, Emory University, Atlanta, GA 30322, USA.</div></div><div title="valid: False, node: 944, tag: div, level: 17" node_number="944">View all articles by this author</div></div></div><div title="valid: False, node: 945, tag: div, level: 15" node_number="945"><div title="valid: False, node: 946, tag: div, level: 16" node_number="946">George R. Painter https://orcid.org/0000-0002-9803-8095</div><div title="valid: False, node: 947, tag: div, level: 16" node_number="947"><div title="valid: False, node: 948, tag: div, level: 17" node_number="948"><div title="valid: False, node: 949, tag: div, level: 18" node_number="949">Emory Institute for Drug Development, Emory University, Atlanta, GA 30322, USA.</div><div title="valid: False, node: 950, tag: div, level: 18" node_number="950">Drug Innovation Ventures at Emory (DRIVE), Atlanta, GA 30322, USA.</div><div title="valid: False, node: 951, tag: div, level: 18" node_number="951">Department of Pharmacology, Emory University School of Medicine, Atlanta, GA 30322, USA.</div></div><div title="valid: False, node: 952, tag: div, level: 17" node_number="952">View all articles by this author</div></div></div><div title="valid: False, node: 953, tag: div, level: 15" node_number="953"><div title="valid: False, node: 954, tag: div, level: 16" node_number="954">Richard K. Plemper<sup title="valid: False, node: 955, tag: sup, level: 17" node_number="955">*</sup> https://orcid.org/0000-0003-2034-2107 [email&#160;protected]</div><div title="valid: False, node: 956, tag: div, level: 16" node_number="956"><div title="valid: False, node: 957, tag: div, level: 17" node_number="957"><div title="valid: False, node: 958, tag: div, level: 18" node_number="958">Center for Translational Antiviral Research, Georgia State University, Atlanta, GA 30303, USA.</div><div title="valid: False, node: 959, tag: div, level: 18" node_number="959">Department of Pediatrics, Emory University School of Medicine, Atlanta, GA 30322, USA.</div></div><div title="valid: False, node: 960, tag: div, level: 17" node_number="960">View all articles by this author</div></div></div></section><section class="valid" valid="valid" title="valid: True, node: 961, tag: section, level: 14" node_number="961"><h4 title="valid: False, node: 962, tag: h4, level: 15" node_number="962">Funding Information</h4><div title="valid: False, node: 963, tag: div, level: 15" node_number="963">National Institute of Allergy and Infectious Diseases: AI153400</div><div title="valid: False, node: 964, tag: div, level: 15" node_number="964">National Institute of Allergy and Infectious Diseases: AI071002</div><div title="valid: False, node: 965, tag: div, level: 15" node_number="965"><a title="valid: False, node: 966, tag: a, level: 16" node_number="966">National Institute of Allergy and Infectious Diseases</a>: AI141222</div></section><section class="valid" valid="valid" title="valid: True, node: 967, tag: section, level: 14" node_number="967"><h4 title="valid: False, node: 968, tag: h4, level: 15" node_number="968">Notes</h4><div title="valid: False, node: 969, tag: div, level: 15" node_number="969">*Corresponding author. Email: <a title="valid: False, node: 970, tag: a, level: 16" node_number="970">[email&#160;protected]</a></div></section></section></div><div class="valid" valid="valid" title="valid: True, node: 971, tag: div, level: 12" node_number="971"><header class="valid" valid="valid" title="valid: True, node: 972, tag: header, level: 13" node_number="972"><h2 class="valid" valid="valid" title="valid: True, node: 973, tag: h2, level: 14" node_number="973">Metrics Citations</h2></header><section class="valid" valid="valid" title="valid: True, node: 974, tag: section, level: 13" node_number="974"><h3 class="valid" valid="valid" title="valid: True, node: 975, tag: h3, level: 14" node_number="975">Metrics</h3><section class="valid" valid="valid" title="valid: True, node: 976, tag: section, level: 14" node_number="976"> <h5 title="valid: False, node: 977, tag: h5, level: 15" node_number="977"> Article Usage </h5> </section><section class="valid" valid="valid" title="valid: True, node: 978, tag: section, level: 14" node_number="978"> <h5 title="valid: False, node: 979, tag: h5, level: 15" node_number="979"> Altmetrics </h5> </section></section><section class="valid" valid="valid" title="valid: True, node: 980, tag: section, level: 13" node_number="980"><h3 class="valid" valid="valid" title="valid: True, node: 981, tag: h3, level: 14" node_number="981">Citations</h3><section class="valid" valid="valid" title="valid: True, node: 982, tag: section, level: 14" node_number="982"> <div title="valid: False, node: 983, tag: div, level: 15" node_number="983"> <h5 title="valid: False, node: 984, tag: h5, level: 16" node_number="984">Export citation</h5> <p title="valid: False, node: 985, tag: p, level: 16" node_number="985">Select the format you want to export the citation of this publication.</p> </div> </section></section></div><div class="valid" valid="valid" title="valid: True, node: 986, tag: div, level: 12" node_number="986"><header class="valid" valid="valid" title="valid: True, node: 987, tag: header, level: 13" node_number="987"><h2 class="valid" valid="valid" title="valid: True, node: 988, tag: h2, level: 14" node_number="988">View Options</h2></header><div class="valid" valid="valid" title="valid: True, node: 989, tag: div, level: 13" node_number="989"><h3 class="valid" valid="valid" title="valid: True, node: 990, tag: h3, level: 14" node_number="990">View options</h3><section class="valid" valid="valid" title="valid: True, node: 991, tag: section, level: 14" node_number="991"><h4 title="valid: False, node: 992, tag: h4, level: 15" node_number="992">PDF format</h4><p title="valid: False, node: 993, tag: p, level: 15" node_number="993">Download this article as a PDF file</p><a title="valid: False, node: 994, tag: a, level: 15" node_number="994">Download PDF</a></section></div><div class="valid" valid="valid" title="valid: True, node: 995, tag: div, level: 13" node_number="995"><h3 class="valid" valid="valid" title="valid: True, node: 996, tag: h3, level: 14" node_number="996">Get Access</h3><section class="valid" valid="valid" title="valid: True, node: 997, tag: section, level: 14" node_number="997"> <div title="valid: False, node: 998, tag: div, level: 15" node_number="998"><h5 title="valid: False, node: 999, tag: h5, level: 16" node_number="999">Log in to view the full text</h5> <p title="valid: False, node: 1000, tag: p, level: 16" node_number="1000"><a title="valid: False, node: 1001, tag: a, level: 17" node_number="1001">AAAS Log in</a></p> <p title="valid: False, node: 1002, tag: p, level: 16" node_number="1002">AAAS login provides access to Science for AAAS members, and access to other journals in the Science family to users who have purchased individual subscriptions.</p> <ul title="valid: False, node: 1003, tag: ul, level: 16" node_number="1003"> <li title="valid: False, node: 1004, tag: li, level: 17" node_number="1004">Become a AAAS Member</li> <li title="valid: False, node: 1005, tag: li, level: 17" node_number="1005"><a title="valid: False, node: 1006, tag: a, level: 18" node_number="1006">Activate your Account</a></li> <li title="valid: False, node: 1007, tag: li, level: 17" node_number="1007"><a title="valid: False, node: 1008, tag: a, level: 18" node_number="1008">Purchase Access to Other Journals in the Science Family</a></li> <li title="valid: False, node: 1009, tag: li, level: 17" node_number="1009"><a title="valid: False, node: 1010, tag: a, level: 18" node_number="1010">Account Help</a></li> </ul> <div title="valid: False, node: 1011, tag: div, level: 16" node_number="1011"> <div title="valid: False, node: 1012, tag: div, level: 17" node_number="1012">Log in via OpenAthens. <div title="valid: False, node: 1013, tag: div, level: 18" node_number="1013"><a title="valid: False, node: 1014, tag: a, level: 19" node_number="1014">via OpenAthens</a></div> </div> <div title="valid: False, node: 1015, tag: div, level: 17" node_number="1015">Log in via Shibboleth. <div title="valid: False, node: 1016, tag: div, level: 18" node_number="1016"><a title="valid: False, node: 1017, tag: a, level: 19" node_number="1017">via Shibboleth</a></div> </div> </div> </div> <div title="valid: False, node: 1018, tag: div, level: 15" node_number="1018"><h5 title="valid: False, node: 1019, tag: h5, level: 16" node_number="1019">More options</h5><p title="valid: False, node: 1020, tag: p, level: 16" node_number="1020"><a title="valid: False, node: 1021, tag: a, level: 17" node_number="1021">Purchase digital access to this article</a></p><p title="valid: False, node: 1022, tag: p, level: 16" node_number="1022">Download and print this article for your personal scholarly, research, and educational use.</p><p title="valid: False, node: 1023, tag: p, level: 16" node_number="1023"><a title="valid: False, node: 1024, tag: a, level: 17" node_number="1024">Purchase this issue in print</a></p><p title="valid: False, node: 1025, tag: p, level: 16" node_number="1025">Buy a single issue of Science for just $15 USD.</p></div> </section></div></div><div class="valid" valid="valid" title="valid: True, node: 1026, tag: div, level: 12" node_number="1026"><header class="valid" valid="valid" title="valid: True, node: 1027, tag: header, level: 13" node_number="1027"><h2 class="valid" valid="valid" title="valid: True, node: 1028, tag: h2, level: 14" node_number="1028">Media</h2></header><section class="valid" valid="valid" title="valid: True, node: 1029, tag: section, level: 13" node_number="1029"><h3 class="valid" valid="valid" title="valid: True, node: 1030, tag: h3, level: 14" node_number="1030">Figures</h3></section><section class="valid" valid="valid" title="valid: True, node: 1031, tag: section, level: 13" node_number="1031"><h3 class="valid" valid="valid" title="valid: True, node: 1032, tag: h3, level: 14" node_number="1032">Multimedia</h3></section></div><div class="valid" valid="valid" title="valid: True, node: 1033, tag: div, level: 12" node_number="1033"><header class="valid" valid="valid" title="valid: True, node: 1034, tag: header, level: 13" node_number="1034"><h2 class="valid" valid="valid" title="valid: True, node: 1035, tag: h2, level: 14" node_number="1035">Tables</h2></header></div><div class="valid" valid="valid" title="valid: True, node: 1036, tag: div, level: 12" node_number="1036"><header class="valid" valid="valid" title="valid: True, node: 1037, tag: header, level: 13" node_number="1037"><h2 class="valid" valid="valid" title="valid: True, node: 1038, tag: h2, level: 14" node_number="1038">Share</h2></header><h3 class="valid" valid="valid" title="valid: True, node: 1039, tag: h3, level: 13" node_number="1039">Share</h3><div class="valid" valid="valid" title="valid: True, node: 1040, tag: div, level: 13" node_number="1040"><section class="valid" valid="valid" title="valid: True, node: 1041, tag: section, level: 14" node_number="1041"><h4 title="valid: False, node: 1042, tag: h4, level: 15" node_number="1042">Share article link</h4><div title="valid: False, node: 1043, tag: div, level: 15" node_number="1043"><a title="valid: False, node: 1044, tag: a, level: 16" node_number="1044">Copy Link</a><div title="valid: False, node: 1045, tag: div, level: 16" node_number="1045"><p title="valid: False, node: 1046, tag: p, level: 17" node_number="1046">Copied!</p><p title="valid: False, node: 1047, tag: p, level: 17" node_number="1047">Copying failed.</p></div></div></section><section class="valid" valid="valid" title="valid: True, node: 1048, tag: section, level: 14" node_number="1048"><h4 title="valid: False, node: 1049, tag: h4, level: 15" node_number="1049">Share on social media</h4><div title="valid: False, node: 1050, tag: div, level: 15" node_number="1050">facebook<a title="valid: False, node: 1051, tag: a, level: 16" node_number="1051">twitter</a><a title="valid: False, node: 1052, tag: a, level: 16" node_number="1052">linkedin</a><a title="valid: False, node: 1053, tag: a, level: 16" node_number="1053">email</a></div></section></div></div></div></article><section class="valid" valid="valid" title="valid: True, node: 1054, tag: section, level: 10" node_number="1054"><div class="valid" valid="valid" title="valid: True, node: 1055, tag: div, level: 11" node_number="1055"><div class="valid" valid="valid" title="valid: True, node: 1056, tag: div, level: 12" node_number="1056"><div class="valid" valid="valid" title="valid: True, node: 1057, tag: div, level: 13" node_number="1057"><div class="valid" valid="valid" title="valid: True, node: 1058, tag: div, level: 14" node_number="1058"><h3 title="valid: False, node: 1059, tag: h3, level: 15" node_number="1059">Submit a Response to This Article</h3></div></div></div></div> <div class="valid" valid="valid" title="valid: True, node: 1060, tag: div, level: 11" node_number="1060"> <div class="valid" valid="valid" title="valid: True, node: 1061, tag: div, level: 12" node_number="1061"> <h2 class="valid" valid="valid" title="valid: True, node: 1062, tag: h2, level: 13" node_number="1062">(0)eLetters</h2> </div> <p class="valid" valid="valid" title="valid: True, node: 1063, tag: p, level: 12" node_number="1063">eLetters is an online forum for ongoing peer review. Submission of eLetters are open to all. eLetters are not edited, proofread, or indexed. Please read our Terms of Service before submitting your own eLetter.</p> <a class="valid" valid="valid" title="valid: True, node: 1064, tag: a, level: 12" node_number="1064">Log In to Submit a Response</a> <p class="valid" valid="valid" title="valid: True, node: 1065, tag: p, level: 12" node_number="1065">No eLetters have been published for this article yet.</p> </div> </section> <div class="valid" valid="valid" title="valid: True, node: 1066, tag: div, level: 10" node_number="1066"><a class="valid" valid="valid" title="valid: True, node: 1067, tag: a, level: 11" node_number="1067">View Full Text</a><a class="valid" valid="valid" title="valid: True, node: 1068, tag: a, level: 11" node_number="1068">Download PDF</a></div> </div></div></div></div><div class="valid" valid="valid" title="valid: True, node: 1069, tag: div, level: 6" node_number="1069"><div class="valid" valid="valid" title="valid: True, node: 1070, tag: div, level: 7" node_number="1070"><div class="valid" valid="valid" title="valid: True, node: 1071, tag: div, level: 8" node_number="1071"><div class="valid" valid="valid" title="valid: True, node: 1072, tag: div, level: 9" node_number="1072"><section class="valid" valid="valid" title="valid: True, node: 1073, tag: section, level: 10" node_number="1073"><div class="valid" valid="valid" title="valid: True, node: 1074, tag: div, level: 11" node_number="1074"><h4 class="valid" valid="valid" title="valid: True, node: 1075, tag: h4, level: 12" node_number="1075"> Current Issue </h4><div class="valid" valid="valid" title="valid: True, node: 1076, tag: div, level: 12" node_number="1076"><div class="valid" valid="valid" title="valid: True, node: 1077, tag: div, level: 13" node_number="1077"> <div class="valid" valid="valid" title="valid: True, node: 1078, tag: div, level: 14" node_number="1078"><div title="valid: False, node: 1079, tag: div, level: 15" node_number="1079"><article title="valid: False, node: 1080, tag: article, level: 16" node_number="1080"><div title="valid: False, node: 1081, tag: div, level: 17" node_number="1081"><div title="valid: False, node: 1082, tag: div, level: 18" node_number="1082"><h3 title="valid: False, node: 1083, tag: h3, level: 19" node_number="1083"><a title="valid: False, node: 1084, tag: a, level: 20" node_number="1084">Cell-by-cell dissection of phloem development links a maturation gradient to cell specialization</a></h3><ul title="valid: False, node: 1085, tag: ul, level: 19" node_number="1085"><li title="valid: False, node: 1086, tag: li, level: 20" node_number="1086">By<ul title="valid: False, node: 1087, tag: ul, level: 21" node_number="1087"> <li title="valid: False, node: 1088, tag: li, level: 22" node_number="1088">Pawel Roszak</li> <li title="valid: False, node: 1089, tag: li, level: 22" node_number="1089">Jung-ok Heo</li> <li title="valid: False, node: 1090, tag: li, level: 22" node_number="1090">et al.</li> </ul> </li></ul></div></div></article><article title="valid: False, node: 1091, tag: article, level: 16" node_number="1091"><div title="valid: False, node: 1092, tag: div, level: 17" node_number="1092"><div title="valid: False, node: 1093, tag: div, level: 18" node_number="1093"><h3 title="valid: False, node: 1094, tag: h3, level: 19" node_number="1094">The energetics of uniquely human subsistence strategies</h3><ul title="valid: False, node: 1095, tag: ul, level: 19" node_number="1095"><li title="valid: False, node: 1096, tag: li, level: 20" node_number="1096">By<ul title="valid: False, node: 1097, tag: ul, level: 21" node_number="1097"> <li title="valid: False, node: 1098, tag: li, level: 22" node_number="1098">Thomas S. Kraft</li> <li title="valid: False, node: 1099, tag: li, level: 22" node_number="1099">Vivek V. Venkataraman</li> <li title="valid: False, node: 1100, tag: li, level: 22" node_number="1100">et al.</li> </ul> </li></ul></div></div></article><article title="valid: False, node: 1101, tag: article, level: 16" node_number="1101"><div title="valid: False, node: 1102, tag: div, level: 17" node_number="1102"><div title="valid: False, node: 1103, tag: div, level: 18" node_number="1103"><h3 title="valid: False, node: 1104, tag: h3, level: 19" node_number="1104">Early giant reveals faster evolution of large body size in ichthyosaurs than in cetaceans</h3><ul title="valid: False, node: 1105, tag: ul, level: 19" node_number="1105"><li title="valid: False, node: 1106, tag: li, level: 20" node_number="1106">By<ul title="valid: False, node: 1107, tag: ul, level: 21" node_number="1107"> <li title="valid: False, node: 1108, tag: li, level: 22" node_number="1108">P. Martin Sander</li> <li title="valid: False, node: 1109, tag: li, level: 22" node_number="1109">Eva Maria Griebeler</li> <li title="valid: False, node: 1110, tag: li, level: 22" node_number="1110">et al.</li> </ul> </li></ul></div></div></article></div><div title="valid: False, node: 1111, tag: div, level: 15" node_number="1111"><a title="valid: False, node: 1112, tag: a, level: 16" node_number="1112">Table of Contents</a></div></div> </div></div></div></section><section class="valid" valid="valid" title="valid: True, node: 1113, tag: section, level: 10" node_number="1113"> <h4 class="valid" valid="valid" title="valid: True, node: 1114, tag: h4, level: 11" node_number="1114">LATEST NEWS</h4> <div class="valid" valid="valid" title="valid: True, node: 1115, tag: div, level: 11" node_number="1115"> <div class="valid" valid="valid" title="valid: True, node: 1116, tag: div, level: 12" node_number="1116"><div class="valid" valid="valid" title="valid: True, node: 1117, tag: div, level: 13" node_number="1117"> <article class="valid" valid="valid" title="valid: True, node: 1118, tag: article, level: 14" node_number="1118"> <div title="valid: False, node: 1119, tag: div, level: 15" node_number="1119"> <div title="valid: False, node: 1120, tag: div, level: 16" node_number="1120"> News<time title="valid: False, node: 1121, tag: time, level: 17" node_number="1121">30 Dec 2021</time> </div> <div title="valid: False, node: 1122, tag: div, level: 16" node_number="1122"> Airborne DNA from plants could reveal invasive species, impact of climate change </div> </div> </article> <article class="valid" valid="valid" title="valid: True, node: 1123, tag: article, level: 14" node_number="1123"> <div title="valid: False, node: 1124, tag: div, level: 15" node_number="1124"> <div title="valid: False, node: 1125, tag: div, level: 16" node_number="1125"> ScienceInsider<time title="valid: False, node: 1126, tag: time, level: 17" node_number="1126">29 Dec 2021</time> </div> <div title="valid: False, node: 1127, tag: div, level: 16" node_number="1127"> Once a &#8216;crazy idea,&#8217; patent-pooling nonprofit will help bring COVID-19 pills to world&#8217;s poor </div> </div> </article> <article class="valid" valid="valid" title="valid: True, node: 1128, tag: article, level: 14" node_number="1128"> <div title="valid: False, node: 1129, tag: div, level: 15" node_number="1129"> <div title="valid: False, node: 1130, tag: div, level: 16" node_number="1130"> ScienceInsider<time title="valid: False, node: 1131, tag: time, level: 17" node_number="1131">28 Dec 2021</time> </div> <div title="valid: False, node: 1132, tag: div, level: 16" node_number="1132"> The natural world loses two of its biggest advocates </div> </div> </article> <article class="valid" valid="valid" title="valid: True, node: 1133, tag: article, level: 14" node_number="1133"> <div title="valid: False, node: 1134, tag: div, level: 15" node_number="1134"> <div title="valid: False, node: 1135, tag: div, level: 16" node_number="1135"> ScienceInsider<time title="valid: False, node: 1136, tag: time, level: 17" node_number="1136">28 Dec 2021</time> </div> <div title="valid: False, node: 1137, tag: div, level: 16" node_number="1137"> <a title="valid: False, node: 1138, tag: a, level: 17" node_number="1138"> What the Charles Lieber verdict says about U.S. China Initiative </a> </div> </div> </article> <article class="valid" valid="valid" title="valid: True, node: 1139, tag: article, level: 14" node_number="1139"> <div title="valid: False, node: 1140, tag: div, level: 15" node_number="1140"> <div title="valid: False, node: 1141, tag: div, level: 16" node_number="1141"> ScienceInsider<time title="valid: False, node: 1142, tag: time, level: 17" node_number="1142">25 Dec 2021</time> </div> <div title="valid: False, node: 1143, tag: div, level: 16" node_number="1143"> NASA&#8217;s Webb telescope takes flight&#8212;a Christmas gift to astronomers everywhere </div> </div> </article> <article class="valid" valid="valid" title="valid: True, node: 1144, tag: article, level: 14" node_number="1144"> <div title="valid: False, node: 1145, tag: div, level: 15" node_number="1145"> <div title="valid: False, node: 1146, tag: div, level: 16" node_number="1146"> News<time title="valid: False, node: 1147, tag: time, level: 17" node_number="1147">23 Dec 2021</time> </div> <div title="valid: False, node: 1148, tag: div, level: 16" node_number="1148"> <a title="valid: False, node: 1149, tag: a, level: 17" node_number="1149"> More than a virus: Science&#8217;s areas to watch in 2022 </a> </div> </div> </article> </div></div> </div></section></div></div></div></div> </main> </div> </div> </div> </body>
        <style tyle='text/css'>
body{
    position: relative;
    padding-left: 30px;
    top: 60px;
}
* {
    border: 1px solid #eee;
    padding: 5px 12px;
    margin: 3px 0;
    box-sizing: content-box;
    background-color: #fff;
    cursor: no-drop;
}
main:hover > *, section:hover > *, header:hover > *, nav:hover > *, a:hover > *, div:hover > *, p:hover > *, ul:hover > *, h1:hover > *, h2:hover > *, h3:hover > *, li:hover > *, span:hover > *{
    border: 2px solid green;
    background-color: #fffeee;
    padding: 5px 23px !important;
    margin: 1px 0;
    color: green;
}
main:hover, section:hover, header:hover, nav:hover, a:hover, div:hover, p:hover, ul:hover, h1:hover, h2:hover, h3:hover, li:hover, span:hover{
    border: 1px solid #fff;
    background-color: #eee;
}
a, span {
    display: block;
}
.selected {
    border: 2px solid orchid !important;
    opacity: 0.8;
    color: orchid !important;
}
.selected * {
    padding: 2px !important;
    color: orchid !important;
}
.valid {
  cursor: pointer;
}
.btn{
  cursor: pointer;
  font-weight: bolder;
  padding: 8px;
}
</style> 
        <script>function OpenOriginalLink($event){
    $event.stopPropagation();
    console.log(url);
}

function removeItem($event){
    $event.stopPropagation();
    console.log('Remove item: ', url)
    localStorage.removeItem(url)
}

function exportData($event){
    $event.stopPropagation();

    result = []
    for(let i=0; i<localStorage.length; i++) {
        let key = localStorage.key(i);
        result.push(localStorage.getItem(key))
    }
    const _url = URL.createObjectURL(new Blob([result.join("\n")], {type: 'text/plain'}))
    $event.target.href = _url;
    localStorage.clear()
}

var removeItemBtn = document.createElement("BUTTON");   // Create a <button> element
removeItemBtn.innerHTML = "Remove Item";
removeItemBtn.classList.add('btn');
removeItemBtn.style.position = "fixed";
removeItemBtn.style.left = '5px';
removeItemBtn.style.top = 0;
removeItemBtn.style.border = "1px solid";
removeItemBtn.style.boxShadow = "3px 3px #888";
removeItemBtn.onclick = removeItem;
document.body.appendChild(removeItemBtn);

var goToOriginLink = document.createElement("A");   // Create a <button> element
goToOriginLink.innerHTML = "GoToOrigin";
goToOriginLink.classList.add('btn');
goToOriginLink.style.position = "fixed"
goToOriginLink.style.left = '115px'
goToOriginLink.style.top = 0;
goToOriginLink.onclick = OpenOriginalLink;
goToOriginLink.setAttribute('href', decodeURIComponent(url));
goToOriginLink.target = '_blank';
document.body.appendChild(goToOriginLink);

var current = new Date
var exportDataLink = document.createElement("A");   // Create a <button> element
exportDataLink.innerHTML = "Export data";
exportDataLink.classList.add('btn');
exportDataLink.download = current.toISOString() + '.exported.txt';
exportDataLink.style.position = "fixed";
exportDataLink.style.right = '5px';
exportDataLink.style.top = 0;
exportDataLink.style.border = "1px solid #888";
exportDataLink.style.boxShadow = "3px 3px #888";
exportDataLink.onclick = exportData;
document.body.appendChild(exportDataLink);

data = {
    'title': null ,
    'article': null
}

var body = document.getElementsByTagName("body")[0];

body.onclick = function($e){
    var num = $e.target.getAttribute('node_number')
    var valid = $e.target.getAttribute('valid')

    if(!valid){
        console.log("Element is invalid")
        return
    }

    if(data.length > 2){
        data = data.splice(0, 2)
    }

    console.log("node:", $e.target)

    if(!data.title && !data.article){
        data.title = num;
        console.log("data:", data)
        $e.target.classList.add('selected')
    }else if (data.title && !data.article){
        data.article = num;
        console.log("data:", data)
        $e.target.classList.add('selected')
    }else{
        selected = Array.from(document.getElementsByClassName("selected"))
        selected.forEach(function(el){
            el.classList.remove('selected')
        })

        data.title = num;
        data.article = null;
        $e.target.classList.add('selected')

    }

    if(data.title && data.article){
        var obj = {
            url: url,
            text: body_html,
            title: data.title,
            article: data.article,
        }

        var datasetItem = JSON.stringify(obj)
        localStorage.setItem(url, datasetItem)
    }
}
</script> 
      </html>